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The prevalence of cardiometabolic diseases, which include chronic 
cardiovascular disease and diabetes, increases worldwide each year due 
largely to today's living habits, sedentary lifestyle, stress and 
consumption of high-calorie, high-fat foods with an elevated content of 
sugar and salt and poor concentration in micronutrients. The occurrence 
of this cardiometabolic disorders has dramatically increased the number 
of cardiovascular accidents, placing cardiovascular disease (CVD) as the 
leading cause of death worldwide1. 
Traditionally, these diseases have been diagnosed by analysing the 
risk factors presented by patients, such as smoking, high cholesterol and 
high blood pressure, as well as obesity, sedentary lifestyle or type 2 
diabetes. However, current medicine has been demonstrated to be 
incapable of accurately diagnosing individuals at risk of cardiovascular 
accidents or complications, since today there is still a high incidence of 
unexpected ischemic events, both in patients with known 
arteriosclerosis and in subjects classified as healthy. 
Cardiovascular (CV) risk functions, such as REGICOR and Framingham 
Coronary Heart Disease Risk Score, are the usual methods for assessing 
CV risk in asymptomatic patients. They are multifactorial functions that 
give a score according to classic CV risk factors which include, among 
others, a basic lipid profile. A high concentration of cholesterol 
transported by LDL, a low concentration of cholesterol transported by 
HDL and/or a high concentration of triglycerides are associated with an 
increased risk of suffering a CV accident2,3. However, most early CV 
events occur in people not included in high-risk categories. This reflects 
the poor discriminatory capacity of classical CV risk factors.  
Chapter 1 
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In recent years, one of the factors considered to be predictive of CV 
events in asymptomatic populations is the presence of subclinical 
atherosclerosis (atherosclerotic plaque)4,5. In relation to classic CV risk 
factors, it is known that patients who meet the therapeutic objectives of 
LDL cholesterol, blood pressure and blood glucose have CV events. 
According to a recent study6, up to the 50% of CV accidents occur in 
individuals with normal levels of LDL-c. The CV risk of these subjects is 
known as residual risk. Possible causes of residual risk contributing to a 
subjacent atherosclerotic disease include lipid fractions other than LDL-
c, such as HDL-c and non-HDL cholesterol7.  
The latter includes all atherogenic particles in addition to LDL-c, and 
several prospective studies show that it is a better predictor of CVD than 
LDL concentrations especially in populations with cardiometabolic 
disorders, which are more vulnerable to suffering CV accidents. In these 
individuals, LDL-c concentrations are usually normal or slightly elevated, 
while the amount of LDL particles is clearly increased due to the 
presence of smaller type of particles, lower in cholesterol and more 
atherogenic7,8.  
The presence of this small LDL particles dramatically increases the 
risk of CVD and goes unnoticed by the traditional scales of risk 
estimation9,10. That is why there are already clinical guidelines that 
recommend the determination of the size and number of LDL 
lipoprotein particles, beyond their lipid load, to evaluate a patient's CV 
risk11. 
The European ESC/EAS 2016 guidelines12 for the management of 
dyslipidaemia in section 3.3.8 recognize the role of the size of the LDL-p 
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particles in the correct evaluation of cardiovascular risk, although the 
recommendation on its use cannot be generalized yet for lack of 
standardization and universal access to the technique. The European 
ESC 2016 Guidelines on cardiovascular prevention in clinical practice13, 
in their point 3a.7.5, associate a specific pattern of small LDL-p 
lipoprotein particles with patients with type 2 diabetes mellitus (DM2) 
along with moderately elevated triglycerides, reduced HDL-c fractions, 
obesity, and insulin resistance.  
Regarding high-density lipoprotein (HDL), HDL particle (HDL-p) 
concentration or number has shown to perform better than their 
respective major lipid components, i.e. HDL-c, for assessing CVD risk14,15. 
These clinical studies suggest that HDL-p concentration can provide 
information on the CV status of an individual that is independent of 
HDL-c.  In the MESA study, taking into account 5,598 men and women, 
HDL-c was not associated with two measures of cardiovascular disease 
status after adjusting for LDL-c and the concentration of LDL-p16. In 
contrast, HDL-p remained strongly and independently associated with 
cardiovascular disease status. In addition, in the JUPITER study, Mora et 
al. reported that the concentration of HDL-p under pharmacological 
treatment is a better marker of residual cardiovascular risk than HDL-c 
or apolipoprotein A1 (ApoA1) concentrations17.  
Diabetes mellitus and atherosclerosis 
DM is considered an independent risk factor for CVD18. People with 
type 2 DM (DM2) have a 2-fold greater risk of death from myocardial 
infarction or ictus than people without DM18. In patients with type 1 DM 
(DM1), there is also an increase in CV mortality between 2 and 4 times 
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higher, especially in women and patients with poor glycemic control19. 
In addition, patients with DM present a worse evolutionary course after 
the acute CV event than those without DM20. Despite the different 
etiology, DM1 and DM2 are associated with an accelerated 
development of atherosclerotic lesions. In DM patients, atherosclerosis 
is a complex multifactorial disease characterized by being more 
extensive (more plaques and territories affected) and progressing more 
rapidly than atheromatous disease without DM21. In addition, none of 
the CV risk functions (Framingham, SCORE and DECODE) accurately 
estimates the CV risk for these patients22. The mechanisms of high 
atherogenicity of DM are incompletely understood. Although diabetic 
arteriosclerosis has a common base with non-DM, undoubtedly 
hyperglycemia is a determining factor in the acceleration and severity of 
the atherogenic process18.  
Differences in the size of different lipoprotein subfractions have 
been demonstrated in patients with DM1, especially in women, 
although these have not been correlated with parameters of subclinical 
atherosclerosis23. Regarding the predictive capacity of CVD of different 
lipoproteins in DM1, the number of VLDL and large and medium HDL 
particles independently predict the risk of future CV events24. On the 
other hand, a typical feature of DM2 – as well as obesity, insulin 
resistance and the metabolic syndrome – is atherogenic dyslipidemia 
(AD), which has emerged as an important risk factor for CVD25,26. AD 
consists of a triad of increased blood concentrations of small and 
cholesterol-depleted LDL particles, decreased HDL-c levels and 
increased total triglycerides. In these patients, with DM2 and AD, 
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advanced lipoprotein analysis can definitely contribute to identify the 
patients with an increased risk attributable to the presence of 
lipoprotein abnormalities, such as a shift between large and small LDL 
and HDL lipoprotein subclasses: DM2 patients with AD have a lower 
number of medium and large LDL and HDL particles than patients 
without AD. Patients with DM2 and AD also have a higher total number 
of LDL-p and, particularly, the small LDL subclass27.  
Despite the advances, there are still important gaps in the 
knowledge of diabetic atherosclerosis. The specific contribution of 
hyperglycemia per se to lipid metabolism disorders potentially 
implicated in atherogenesis is only partially known, and new markers of 
atherosclerosis are needed to improve the risk stratification, the 
patients treatment and the prevention strategies. 
Modifiable Factors  
Reduction in LDL-c levels has been shown to reduce the risk of 
coronary artery disease (CAD) and death. Currently, statins are the 
agents primarily used to lower LDL-c. Statin efficacy has been proven 
both in patients with cardiovascular (CV) and cerebrovascular disease in 
secondary prevention, and in high CV risk patients in primary 
prevention28,29. In the presence of additional CV risk factors, achieving 
low density lipoprotein (LDL) concentration below 70 mg/dl is 
recommended30. Despite the widespread use of statin therapy, alone or 
in combination with other agents, many individuals do not achieve LDL-c 
goals and the rates of CV events and mortality remain high31. Therefore, 
a number of new therapies have been developed which rely on novel 
mechanisms to further lower LDL-c in patients with high risk for CAD, 
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including mipomersen, inhibitors of PCSK9, inhibitors of cholesteryl 
ester transfer protein (CETP) and lomitapide 32. Additional therapies, 
such as nicotinic acid, fenofibrate and ezetimibe, which also lower LDL-
c, often serve as adjunctive therapies. The role of nicotinic acid and 
fenofibrates for the primary and secondary prevention of CVD is limited 
although these agents can improve a patient’s lipid profile, their effects 
on clinical outcomes are often neutral or restricted to subgroups of 
subjects33,34. 
However, even if the LDL-c target is achieved, an important residual 
risk remains. A portion of this residual risk has been attributed to lipid 
and lipoprotein profile alterations. Evidence suggests that coronary 
heart disease risk is increased by larger very-low-density lipoprotein 
(VLDL) particle sizes, smaller HDL and LDL particle sizes, and increased 
concentration of small LDL and large VLDL particles; although the ideal 
lipoprotein profiles for the prevention of coronary heart disease may 
vary according to age, gender and health status10,35.  
A variety of non-pharmacological factors can also modulate the 
lipoprotein profile, including dietary habits36,37 and physical exercise38. A 
diet rich in fatty acids such as palmitic acid is associated, in comparison 
with a diet rich in oleic acid, to a higher concentration in blood and 
muscle of ceramides (metabolites of sphingomyelin), lipid species 
related to insulin resistance39. In addition, a complex carbohydrate-rich 
intake supplemented with long-chain polyunsaturated fatty acids is 
associated with a decrease in triglycerides and free fatty acids in blood; 
in the same way, several experimental studies have found omega 3 fatty 
acids to act as a pleiotropic agent which beneficially influences a 
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number of cardiometabolic risk factors including anti-arrhythmic 
effects40, blood pressure41, thrombosis, inflammation42, vascular 
reactivity and lipids43,44, although their contribution on the CV risk 
reduction remains unclear.  
The proper evaluation of the cardiometabolic status of the patients, 
as well as the evaluation of pharmacological and nutritional 
interventions, could guide clinicians to design and achieve better 
preventive strategies. However, atherosclerosis develops in an 
underlying way and early diagnosis and effective prediction are difficult. 
For this reason, one of the great challenges of cardiovascular medicine 
is to find a way to predict individual's risk of suffering a cardiovascular 
accident and to detect the presence of subclinical atherosclerosis.  
Conventional lipid analysis only provides information on the total 
amount of cholesterol in each of the lipid fractions. However, they do 
not report on individual characteristics of lipid-carrying lipoproteins. As 
the lipoprotein profile reflects part of the complexity of the metabolism, 
it is necessary to learn beyond the lipid content. Advanced lipoprotein 
test adds information about the etiology of lipoprotein metabolism and 
function, helps to proper characterize the patient’s dyslipidemic 
phenotype, aids clinical decisions and can guide appropriate therapy15.  
Nuclear magnetic resonance (NMR) spectroscopy is a technique that 
allows the characterization of complete lipoprotein profile (VLDL, LDL 
and HDL), including the particle number, size and lipidic content, in a 
high throughput way, necessary to be used in clinics15.  
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Therefore the exhaustive analysis of the profile of lipoproteins by 
NMR, an advanced lipoprotein test, results in a promising tool for early 
diagnosis of these diseases. 
Different scientific publications support this fact: recent cost-
effectiveness studies conducted in the clinical practice in the USA have 
concluded that the inclusion of these tests for the risk evaluation and 
the LDL-lowering therapy guidance by using the LDL-P parameter (and 
not the LDL-C) have demonstrated to be cost effective, with greater 
clinical and economic benefit seen over longer time horizons and with 
increased use of generic statins45,46. 
Recently, the research group in which the present thesis has been 
developed has patented and validated the Liposcale test, an advanced 
lipoprotein test based on diffusion ordered NMR spectroscopy (DOSY-
NMR) that measures the size, the lipid content and the number of the 
particles of the main types of lipoprotein (VLDL, LDL and HDL) and the 
concentration of particles of nine subtypes (large, medium and small of 
each main type). The Liposcale test is technologically innovative because 
it is based on the physical sizes of the particles thanks to 2D nuclear 
magnetic resonance spectroscopy. This approach allows to directly 
measure the size of the lipoproteins providing more accurate results 
than the commercial alternatives27. 
 
 
  
 
 
 
 
 
 
 
1.2 Motivation 
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The doctoral thesis presented in this document is the result of the 
research conducted in the Department of Electronic, Electrical and 
Automation Engineering at the Rovira i Virgili University (URV) in 
collaboration with the Metabolomics Platform of the same university, 
the Research Unit of Lipids and Atherosclerosis (URLA) of Sant Joan 
University Hospital from Reus (HUSJR), the CIBER of Diabetes and 
Metabolic Diseases (CIBERDEM), the Institut d'Investigació Sanitària 
Pere Virgili (IISPV) and the Spin-off company Biosfer Teslab, co-founded 
and lead (since 2015) by the PhD candidate. Complementary, part of the 
research presented in this document was conducted in the 
Cardiovascular Disease Unit of the Division of Preventive Medicine of 
the Brigham and Women’s Hospital, a Harvard Medical School Affiliate. 
Thanks to this collaboration it was possible to develop and 
consolidate a methodology to get insight the lipoprotein metabolism 
through the whole and fractioned human plasma analysis by using NMR. 
In particular, the study of the metabolism by the Liposcale test, an 
advanced lipoprotein test based on NMR spectroscopy patented and 
developed by our research group. The use of NMR for the human 
plasma analysis is aimed at obtaining a better characterization of plasma 
lipoproteins, i.e. lipid content, size, particle number and particle 
distribution, in order to improve cardiometabolic characterization for 
cardiovascular risk assessment.  
As a consequence of developing the Liposcale test, opportunity 
and need of constituting a company arise to, firstly, finish the 
industrialization process of the test; secondly, to construct the 
regulatory and quality environment in order to make it available to 
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society through the commercialization and; finally, to collaborate with 
other research institutions to generate scientific evidences to facilitate 
the incorporation of the advanced lipoprotein test for clinical 
applications. Thus, Biosfer Teslab S.L., a spin-off of the Rovira i Virgili 
University (URV) and the Pere Virgili Health Research Institute (IISPV) 
was founded in December 2013 in Reus (Tarragona). Its creation comes 
from the results obtained during the research of Dr. Roger Mallol Parera 
and part of the results presented in this thesis in relation of the 
lipoprotein characterization by NMR.   
It is remarkable how far the company has come since created. In 
three years, the Biosfer team has achieved industrial development of 
the first test (Liposcale) created in a pure research framework. It has 
also overcome regulatory barriers to achieve CE certification for the 
current Liposcale lipoprotein test and the approval by the Spanish 
Agency of Medicine and Medical Devices (AEMPS) for manufacture of 
medical software for in-vitro diagnostic applications. Finally, Biosfer has 
establish solid research collaborations which have generated different 
research articles summarized in this doctoral thesis.  
Despite being a newly created company, Biosfer Teslab has 
obtained a good evaluation in four competitive tenders for its projects 
in Innovation and Development:  
· Two Torres Quevedo grants from the Ministry for recruitment of 
Doctors in private enterprise (2014 and 2017). 
· ENISA loan guaranteeing the company's structural capacity 
(December 2015).  
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· Aid for development of a project at the territorial level by the 
Government of Catalonia (NUCLIS, financed by Acció10, 
Generalitat de Catalunya, January 2016).  
· Neotec-CDTI Aid, financed by CDTI (Ministry of Economy, Spain) 
for development of new in-vitro diagnostic tests based on NMR 
for early detection of cardiometabolic disease (February 2017). 
Biosfer Teslab has also been awarded by an international 
business acceleration program, The Big Booster, during which the PhD 
candidate took part in a prestigious MassChallenge program in the R&D 
capital of the health sector in USA (Boston).  
Reinforcing the innovative value of the company, since August 
2014, Products and Technology (P&T) (a subsidiary of the Catalan 
pharmaceutical company Laboratorios Rubió) had become part of 
Biosfer's capital stock, enabling the industrial development and the 
introduction of new diagnostic tests in the clinic through a more 
consolidated business infrastructure, knowledge of the market and an 
extensive commercial network. 
Biosfer Teslab signed also different agreements of clinical and 
scientific collaboration. Biosfer collaborates with the Spanish 
Nephrology Society, with the Spanish Arteriosclerosis Society and with 
the Institute of Health Research (INCLIVA) of Valencia, with the will to 
continue innovating and allowing the NMR to be a clinical tool of value 
for the improvement of personalized medicine. 
This thesis has generated different scientific publications which 
will be detailed in the next sections regarding to lipoprotein profiling 
and monitoring by using, mainly, the NMR technology complemented by 
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other biophysical techniques -Atomic Force Microscopy (AFM) and 
spectroflourimetry- as well as two patents that have been filled in 2014 
to the European Patent Office (EPO) and, recently, to Patent 
Cooperation Treaty (PCT). 
 
  
 
 
 
 
 
 
 
1.3 Hypothesis and objectives  
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The constant growth of analytical techniques applied in the 
medical field over the last years is an undeniable fact that indicates the 
importance of collaborating between interdisciplinary projects, as an 
ideal environment to provide clinicians with better tools for clinical 
diagnostics. In particular, determination of lipoprotein particle size and 
number using advanced lipoprotein tests (ALTs) is of particular 
importance to improve cardiovascular risk prediction and evaluation of 
the metabolic state.  
The research presented in this thesis is based, mainly, on the 
lipoprotein characterization by NMR spectroscopy for cardiometabolic 
risk evaluation and monitoring.  
The application of the NMR lipoprotein profile characterization 
has allowed to explore lipoprotein properties beyond lipid content from 
complementary perspectives: NMR allows advancement of knowledge 
of the molecular lipoprotein structure favoring to understand their 
functionality in processes that deal with metabolic disorders; makes 
possible the evaluation of different types of interventions, both 
pharmacological and nutritional; and, finally, provides analysis of large 
sets of samples enabling epidemiological study of the lipoprotein profile 
associated with concrete life habits. 
In this context, the objectives of this thesis have been:  
1. Mastering of the use of Nuclear magnetic field (NMR) for 
lipoprotein characterization beyond lipid content and its application in 
the characterization of cardiometabolic risk.  
2. Approaching the Lipoprotein structure and lipid composition. 
Application of biophysical techniques to explore abnormal lipoprotein 
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subclasses altered in diseases, such as size, particle lipid distribution and 
surface properties.  
3. Evaluating pharmacological and nutritional interventions 
through the lipoprotein profile and assessment of changes in 
metabolism.  
  
 
 
 
 
 
 
 
1.4 Organization of the document  
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This chapter has provided a general overview of the background 
and motivation for the realization of this thesis. The need for better 
predictors of cardiovascular disease is increasing due to the pandemic 
levels which metabolic disorders are achieving. One of the main areas 
where new biomarkers can be looked for is the area of lipids and 
lipoproteins. For this purpose, NMR spectroscopy appears to be a 
suitable analytical tool to develop novel methodologies, which will aid in 
the assessment and management of cardiovascular events. 
Chapter 2 presents a state of the art of the lipoprotein 
characterization by NMR, from a research framework to the clinical 
practice. In the first section of the chapter, the lipoprotein classification 
and metabolism are described as well as the standard methods for 
lipoprotein quantification. In the second section, different strategies for 
the lipoprotein characterization by using 1 and 2-dimensional NMR 
methodologies are briefly explained. The third section includes the 
patent of the Liposcale lipoprotein characterization. Finally, the final 
two sections include the industrial development that the company 
Biosfer has carried out for the implementation of the Liposcale test into 
the clinical practice and the main studies in which the PhD candidate 
has participated since the creation of the company. 
Chapter 3 focuses on the use of lipoproteins as biomarkers 
beyond their lipidic content for the evaluation and monitoring of the 
HDL subclass in the diabetic dyslipemia. By using NMR and 
complementary biophysical techniques -such as AFM and 
spectrofluorimetry- a new mathematical model for HDL structure is 
stated accordingly to the NMR derived parameters and biochemical 
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composition. The HDL size determines the structure which modulates 
the final function of lipoproteins particles.  
Chapter 4 describes how nutrition and, in particular, the fish 
consumption and total n-3, and the main n-3 subtypes: 
eicosapentaenoic (EPA), docosahexaenoic (DHA) and alpha-linolenic 
(ALA) fatty acids, modulates the lipoprotein profile in an epidemiological 
association study and two nutritional interventions.  
Chapter 5 discusses the current use of the DOSY 1H-NMR based 
on lipoprotein characterization for clinical applications and the 
perspectives for its use in the near future in different contexts and, 
particularly, for the study of the structure and composition of the HDL 
subfraction. Finally, the chapter summarizes the main results and 
conclusions derived from the NMR experiments for the study of 
metabolism presented in this thesis. 
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Lipoproteins are important constituents of the lipid fraction of 
the human body, which function as carriers for water-insoluble lipids 
through the aqueous bloodstream. Lipoproteins vehicles provide the 
active mobilization of endogenous and exogenous (dietary) lipids 
through the aqueous compartments within the cells, as well as in the 
blood and body tissues where lipid molecules can be either stored (i.e. 
adipose tissue) or used as energy source1.  
The general structure of lipoprotein molecules is spherical and 
they are synthesized within the liver and intestines. Non-polar lipids 
(triacylglycerols and cholesterol esters) are mainly found within the 
core, while polar lipids (phospholipids and free cholesterol) are 
distributed through a surface monolayer together with the protein 
component (named as apolipoproteins or apoproteins), a group of 
proteins of immense structural diversity, that define the structure, 
metabolism and functionality of a given lipoprotein class, as well as  its 
interaction with receptor molecules or different enzymes in the liver 
and peripheral tissues1. 
Based on their buoyant densities, lipoproteins can be classified in 
five major groups: Chylomicrons (CM), Very Low Density Lipoproteins 
(VLDL), Intermediate Density Lipoproteins (IDL), Low Density 
Lipoproteins (LDL), and High Density Lipoprotein (HDL) with CM being 
the biggest and least dense lipoproteins particle. 
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Figure 1. Lipoprotein subclasses2. 
Each of these lipoprotein classes can be further divided into 
several subclasses, but the number and nomenclature is method-
dependent, since the density of lipoproteins is really a continuum, not 
discrete values corresponding to a finite number of classes.  
Chylomicrons transport triglycerides and esterified cholesterol 
formed by dietary lipids (such as free fatty acids, monoglycerides and 
free cholesterol) being processed. In addition to cholesterol absorbed 
from the diet, they may also receive new cholesterol synthesized in the 
gut and cholesterol transferred from other lipoproteins. Chylomicrons 
are rich in triglycerides. However, while tissues take up fatty acids and 
glycerol from released and hydrolyzed core triglycerides, as the 
circulating chylomicrons become progressively smaller, their triglyceride 
content decreases and they become relatively richer in cholesterol and 
protein. They become what is known as a chylomicron remnant. VLDLs 
are secreted by the liver to supply triglycerides to tissues in the fasting 
or postprandial state. VLDL particles are slightly smaller than 
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chylomicrons and they undergo exactly the same lipid release process 
described for chylomicrons. The loss of triglycerides converts some VLDL 
into IDL and LDL, which are the main cholesterol transporters2. 
 HDL are the most diverse lipoproteins. They are synthesized in 
the liver and small intestine as protein-rich, disc-shaped particles 
containing ApoA1 and phospholipids. These particles mature by the 
acquisition of cholesterol from peripheral tissues and the action of 
several sterifying enzymes (LCAT)3.  
The HDL particles make it possible for cholesterol to flow out of 
the cells, esterify in plasma, transfer to other lipoproteins and return to 
the liver for excretion, a process known as reverse cholesterol transport. 
The HDL mediation of the transfer of lipids and apolipoproteins 
between lipoprotein classes also plays a key role in the overall 
lipoprotein metabolism.  
 
  
Table 1: List of the origin, function and composition of the main lipoproteins2. 
    Percentage %  
 Origin Density APO  Chol TG Prot PL Function 
CM Intestine <0.950 A, B, C, E 4 90 1 5 Exogenous lipids transport 
(from intestine to cells) 
VLDL Liver 0.950-1.006 B, C, E 25 55 8 12 Endogenous lipids transport 
(from liver to cells) 
LDL VLDL via IDL 1.019-1.063 B 55 5 20 20 Cholesterol transport to 
cells 
HDL Intestine, 
liver  
1.063-1,210 A, C, E, 
J… 
20 5 50 25 Cholesterol transport from 
cells to liver 
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Lipoproteins fractionation and quantification is a matter of 
primary interest in the field of clinical medicine since elevated 
concentrations of cholesterol and triglycerides, in specific lipoproteins, 
have been associated with significantly increased occurrence of 
cardiovascular diseases (CVDs)4. 
Studies on lipoprotein metabolism have shown a highly 
consistent and direct correlation between plasma LDL and the 
development of atherosclerosis4. Even though such epidemiological 
investigations have shown a positive correlation between total 
cholesterol concentrations in LDL and Coronary Heart Disease (CHD) 
mortality, total LDL cholesterol does not accurately predict the risk of 
CHD in many patients5. The LDL/HDL cholesterol ratios, the LDL particle 
number or the Non-HDL cholesterol are nowadays considered risk 
indicators with greater predictive value than single parameters, such as 
LDL6 cholesterol. Due to their role on reverse cholesterol transport, HDL 
prevent the formation of atherosclerotic plaques that may derive from 
LDL metabolism and thus represent a non-casual integrative marker of 
CVDs7. Moreover, it has been proven that individuals with 
predominantly small LDL particles experience greater CHD risk than 
those with large-size LDL8, making accurate quantification of the 
lipoproteins subfractions an essential screening tool for CVDs 
prevention and diagnosis. 
Several analytical approaches can be used for accurately 
measuring blood lipoproteins, such as gel electrophoresis and Gel-
Permeation High Performance Liquid Chromatography (GP-HPLC), but 
density gradient Ultra-Centrifugation (UC) represents the “gold standard 
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method” for lipoproteins isolation and quantification. A brief description 
of standard quantification methods is detailed below:  
Ultracentrifugation. The UC technique is often described as the 
benchmark method for lipoproteins measurement which has become a 
routine method for lipoproteins separation9. Separation of CM, VLDL, 
LDL, and HDL is obtained by adjusting the density of the medium at each 
centrifugation step in order to allow sequential floatation of the 
individual lipoprotein fractions. A discontinuous gradient is then created 
and layers of solvents with different densities will cause the lipoproteins 
of different densities to be isolated in a cumulative fashion. The main 
disadvantage is that, due to long spin times, complete separation of all 
lipoprotein fractions may require from 2 to 5 days of centrifugation time 
which seriously limits the applicability of the method as a rapid 
individualized monitoring tool and naturally in large epidemiological 
studies10. 
In order to reduce the experiment time, several improvements in 
the UC equipment have been introduced. Amongst these, the Vertical 
Auto Profiling (VAP) method allows lipoproteins to be separated in a 
single spin by using high centrifugal speeds (65,000 rpm, 1 hour)11. This 
is achieved by using a vertical rotor in which the centrifuge tube remains 
perpendicular to the x-axis (ground) during centrifugation. This set-up 
will allow the lipoproteins separation across the shorter horizontal axis 
of the centrifuge. After centrifugation, all five lipoprotein fractions are 
analyzed for cholesterol content using the continuous flow VAP 
analyzer: every lipoprotein layer is mixed with a specific reagent for 
cholesterol connected to a spectrophotometric cholesterol detector. 
Chapter 2 
44 
 Gel-Permeation High Performance Liquid Chromatography. GP-
HPLC is used to separate lipoproteins on the basis of the particle 
diameter, with small particles exhibiting a longer elution time than the 
big ones. The particle diameter of the lipoproteins is calibrated using 
stained lipoprotein standards with a known diameter whose size can be 
determined by gel gradient electrophoresis, dynamic light scattering or 
electron microscopy12. The elution position of the lipoproteins is derived 
from the relationship of calibration standards and its retention time. GP-
HPLC can be coupled with enzymatic assays for lipid quantification12. 
Gel Electrophoresis. Gel electrophoresis is a method for 
macromolecules separation and analysis based on their size and charge. 
The lipid concentrations per main lipoprotein class are calculated using 
peak integration. Gradient GE using nondenaturing conditions is 
commonly used to characterize the distribution of particles with very 
small differences in size13. 
Nevertheless, lipoproteins analysis by the previous standard 
techniques are time consuming and labour intensive as they require 
numerous sample handlings, and specific enzymatic assays are needed 
to further estimate their composition10.  
High-field proton Nuclear Magnetic Resonance (1H-NMR)-based 
lipoprotein profiling has proven to be a valuable alternative to the 
standard lipoprotein quantification methods. 1H-NMR, which is normally 
used for structure elucidation and chemical mixture quantifications, has 
one more advantage, namely that it is sensitive to the size (rotational 
diffusion), density of macromolecules and supramolecular aggregates as 
well as the lipid concentration14. This makes NMR a unique platform for 
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investigating lipoprotein particle profiles because different lipoproteins 
fractions and subfractions have different magnetic susceptibilities which 
will broadcast different signals whose amplitude reflects particles 
concentration. On the other hand, minimum sample handling, non-
destructive, fast and automatable features make 1H-NMR spectroscopy 
a preferable/valuable screening tool for clinical practice as well as for 
large scale epidemiological investigation.  
 
 
  
  
 
 
 
 
 
 
 
2.2 Serum/Plasma lipoprotein analysis by 
1H-NMR spectroscopy  
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1H-NMR spectroscopy has become an indispensable technique 
for characterization of complex biological samples such as tissues and 
body fluids15. In particular, due to the possibility of conducting phase 
transitional studies, the use of 1H-NMR spectroscopy has emerged as a 
valuable screening tool for lipoproteins in plasma and serum samples16–
18. The lipids inside the lipoproteins exist as liquid crystals of 
triglycerides and cholesterol esters whose limited mobility gives rise to 
the broadening of the NMR signals of the methyl (-CH3) and methylene 
(-CH2-) groups centered around 0.8 and 1.2 ppm, respectively.  
 
Figure 1. Methyl and methylene regions of the NMR plasma spectrum19. 
The previous figure illustrate the broadening of the pure isolated 
methyl and methylene signal CH2-CH3 (black line), pure fat with 
conformational freedom (blue line) and from the interior of the 
lipoproteins in a blood plasma sample (red line)19. 
The main advantage of using NMR spectroscopy for the 
identification and quantification of lipoproteins is due to the fact that 
different lipoprotein fractions and subfractions have different chemical 
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compositions and sizes and therefore experience slightly different 
magnetic susceptibilities. This gives rise then to distinctive NMR signals 
whose chemical shift is mainly determined by the local electron density, 
and rotational diffusion of the lipoprotein vehicles. In particular, the 
methyl (-CH3) signals arising from large and less dense lipoproteins 
particles (i.e. VLDL and LDL) are different in shape and resonate at lower 
field strength (higher frequency) than the lipid signals emitted by 
smaller lipoproteins (i.e. HDL)20.  
 
Figure 2. Size depending chemical shift. Adapted from: Spectroscopic 
Approach to Lipoprotein Subclass Analysis. J. Otvos et al., JCLA, 1996. 
 
A typical NMR spectrum of plasma/serum is characterized by the 
presence of numerous metabolites (i.e. amino acids, organic acids), 
macromolecules (i.e. proteins) and lipoproteins whose signals are 
heavily overlapped. The entire up-field signal from about 0.6 to 1.4 ppm 
can be used for lipoprotein quantifications, but in many cases only the 
methyl signal envelope at approximately 0.8 ppm is used21,22. The latter 
band contains the distinctive signals emitted by the terminal methyl 
group protons of phospholipids, cholesterol, cholesterol esters and 
triglycerides from the different lipoprotein main fractions and all the 
subfractions. The individual amplitudes of the NMR signals are directly 
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proportional to the concentration of the lipoprotein particles giving 
NMR spectroscopy the unique capability of identifying and quantifying 
blood lipoproteins.  
Several 1H-NMR based protocols for lipoproteins fractions and 
subfractions identification and measurement have been developed. 
Amongst these, the commercial assays NMR LipoProfile® (LipoScience 
Inc., now Labcorp)21, AXINON® lipoFIT® (Numares AG, Regensburg, 
Germany)23, Brainshake-Nightingale Ltd.24 and the Liposcale test (Biosfer 
Teslab SL)25 are  considered the pioneers for driving “the lipoprotein 
analysis by NMR” interest of the clinical and epidemiological 
community19. 
 
2.2.1 Sample Handling procedures 
Lipoproteins are heterogeneous particles whose distribution in 
the blood depends on genotype-specific properties and reflects the 
dynamic response of the human body to changes in the external 
conditions (e.g. diet, lifestyle and environment)26. The sample handling 
and preparation steps required before lipoprotein quantification, such as 
sample collection, storage and sample preparation, can alter the 
lipoprotein structure by destroying the natural equilibrium of the sample. 
For this reason, high-throughput protocols and Standard Operating 
Procedures (SOPs) and Quality Control (QC) criteria have been developed 
for minimizing as such as possible the inherent variability.  
Measurement matrix: serum vs plasma  
Serum and plasma samples are routinely used for lipoprotein 
measurements. Both fractions derive from blood samples that have 
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undergone different biochemical treatments after collection. In the 
serum case, coagulation factors (i.e. fibrinogen) along with blood cells 
are removed by centrifugation, while plasma is typically obtained from 
blood samples to which an anticoagulant agent (i.e. heparin, citrate or 
EDTA) is added before the removal of blood cells. The choice of the 
most appropriate matrix and anticoagulant agent is a crucial point in 
lipoprotein studies. If the analysis contemplates the use of automated 
robots for the sample preparation step, the serum samples are the 
preferred specimens, as its use improves the reliability of the 
production process eliminating undesired stoppages (as the presence of 
fibrinogen increases the probability of clogging the robot’s injection 
syringe).   
Sample handling and storage  
Standardized sample handling and storage conditions are highly 
important in order to obtain blood samples with stable physical 
lipoprotein characteristics (i.e. density and size). Due to the rapid 
increase in the number of studies aimed at biomarker discovery by 
profiling technologies (i.e. HPLC and NMR spectroscopy) detailed 
standardized procedures for sample handling and storage have been 
developed whose analytical and experimental bias have been carefully 
assessed27,28. In particular, in the case of NMR spectroscopy, storage 
conditions have been shown to be critical and special attention has 
been paid to address the effect of common sources of analytical bias on 
serum and plasma profiles in terms of reproducibility and reliability of 
the obtained results29. According to the most recently developed SOPs, 
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blood serum and plasma samples can be stored for 9 months at -80 ⁰C 
without leading to any significant differences when analyzed28. 
 
2.2.2 Serum/plasma lipoprotein analysis by 1D 1H-NMR 
spectroscopy 
As it was mentioned before, lipoprotein analysis with NMR 
spectroscopy is based on the depending magnetic susceptibility of the 
molecules to the particle size: the methyl groups of the lipids traveling 
within the lipoprotein resonate at a slightly different frequency 
according to the lipoprotein size, being the lipids carried in smaller 
particles resonating at lower frequencies as from the internal space (in 
which the lipids are distributed unstructured) to the particle membrane 
(in which the lipids are arranged in a radial order) and, therefore, it 
manifests itself in a general directional dependency of the 
magnetizability existing a size-depending shield. For larger particles, this 
results in a lower shielding and consequently a higher chemical shift 
than for smaller particles. This magnitude is different enough and, 
therefore, lipoproteins can be quantified through the signal 
decomposition of the methyl group from the 1-D NMR spectrum into 
individual signals using basically two different strategies:  
The Curve Fitting method and multivariant Partial Least Squares 
(PLS) regressions30. In curve fitting methods, two different approaches 
have been applied: in the first one, the NMR spectra are fitted with 
individual lorentzian line shapes while, in the second one, the NMR 
spectra are fitted with pure line profiles from predetermined lipoprotein 
subclass spectra. Alternatively, in the case of multivariate PLS 
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regression, it has been applied either in the full spectral version -
normally restricted to be from 0.6 to 1.4 ppm- or in the interval based 
version (iPLS) -where the same region is divided into a number of small 
intervals- which are to be regressed towards the response values of 
triglycerides and cholesterol, respectively31.  
The above mentioned methods are outlined in the following figure: 
 
 
Figure 3. Strategies for lipoprotein quantification from 1-D 1H-NMR 
Spectra a) Curve fitting using lorentzian functions; b) Curve fitting using 
isolated lipoprotein subfractions functions c) PLS regression models. 
Adapted from Aru et al.19 
The most relevant groups that have developed and applied 
successfully the previous mentioned strategies to introduce the current 
commercially available advanced lipoprotein tests will be described 
below:    
The NMR LipoProfile test 
Since the beginning of the 1990s the group led by Professor 
James Otvos created and perfected the LipoProfile® test, which was 
made commercially available in 1997 by Liposcience Inc (from 2014, 
acquired by Labcorp). In the first studies reported by Otvos and 
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colleagues, they described a curve fitting method using isolated 
lipoprotein subfractions functions for quantifying the particle 
concentration and mean particle size of different lipoprotein subclasses. 
First, the main lipoprotein fractions (chylomicrons, VLDL, IDL, LDL and 
HDL) obtained by sequential ultracentrifugation32 were used to obtain 
highly purified lipoprotein subfractions with a range of particle 
diameters as homogeneous as possible. Agarose gel filtration 
chromatography was used in combination with ultracentrifugation. The 
lipid content (cholesterol and triglycerides) of lipoprotein subfractions 
was measured by standard biochemistry methods and the particle size 
for the purified VLDL and LDL subclasses were assessed by Transmission 
Electron Microscopy (TEM). Additionally, non-denaturing gradient gel 
electrophoresis33  was used to measure the particle sizes of the LDL34,35 
and HDL36–38 subfractions. Then, 1H-NMR spectra were acquired of all 
plasma and isolated lipoprotein samples on a 400 MHz NMR 
spectrometer equipped with a flow probe and a sample volume of 120 
μl. All NMR measurements for lipoprotein analyses were performed at 
47 °C, a temperature at which the molecules in the core of the particles 
have an NMR-isotropic behavior. The basic principle of the method is 
the specific magnetic behavior of lipoproteins: i.e. lipids in smaller 
lipoproteins broadcast signals at lower frequencies than lipids in larger 
ones resulting from the different compositions of the lipoproteins39,40. 
Particle concentrations are obtained by fitting the methyl envelope 
arising at around 0.8 ppm of the 1H-NMR spectra of plasma samples. 
The adjusted curve is calculated using a linear combination of 1H-NMR 
spectra from individual lipoprotein subfractions taken from a reference 
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library20,40 in a linear least squares process41. This spectral library of 
lipoprotein subfractions, measured by 1H-NMR, is representative of the 
different subfractions which can be found in human plasma samples of 
patients with either normolipidemia or dyslipidemia. It is worth 
mentioning that the area of the methyl envelope is proportional to the 
number of protons (3) for every methyl termination of the core lipids 
(i.e. 3 for TG and CE). This means that the amplitude is insensitive to 
compositional variability in subclasses (cholesterol ester–triglyceride 
exchange mediated by cholesterol ester transport protein, CETP)42. 
The mean particle sizes estimated by LipoProfile® have been 
compared with those measured by TEM (VLDL and LDL fractions)43 and 
GGE (LDL and HDL fractions)34–38. Agreement with GGE was excellent, 
although some offset differences in mass estimation were found 
between LDL sizes measured by NMR and TEM. Nowadays, the 
LipoProfile® test is the most commercially spread method which can 
quickly and accurately give information about the size and particle 
number of several lipoprotein fractions in plasma (or serum) 
samples20,40 . The NMR LipoProfile® test44 has been available in United 
States hospitals since 1997 for clinical analysis. Since then, millions of 
analyses have been performed in the LipoScience laboratory in North 
Carolina, and more than 250 clinical studies have been completed. 
The Mika Ala-Korpela methodologies 
During the first half of the 1990s, Ala-Korpela and colleagues set 
up a curve fitting model by using lorentzian functions for deconvoluting 
the overlapping information in the methyl and methylene peaks of 1H-
NMR spectra of plasma samples45–47, measured at the physiological 
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temperature of 37 °C. In these studies, VLDL, LDL and HDL fractions 
were modeled by adding three lorentzian components for VLDL and LDL 
fractions and one for HDL. The approach used for this curve fitting 
analysis was an in-house algorithm, named as FITPLAC, that 
mathematically optimized the half-line width, the resonance frequency 
and the intensity for each lorentzian function, in order to characterize 
the lipoprotein profile. The model also included background resonances 
related to residual water, and albumin-bound immobile fatty acids or 
proteins46,48.  
The curve fitting analysis of the methyl peak using the FITPLAC 
algorithm confirmed that the parameters of the lorentzians functions 
for every fraction were very similar for all the individuals, so the half 
linewidth and position of every lorentzian was set at a constant value. 
This indicated that the main variable in the 1H-NMR spectra of the 
lipoprotein fractions of different people was the intensity for each 
lorentzian function (i.e. the fraction concentration). The linear 
correlation between the fraction areas found by NMR and the 
concentration values of triglycerides, phospholipids, total cholesterol, 
free cholesterol, esterified cholesterol, total proteins and total masses 
of the VLDL, LDL and HDL fractions by biochemistry methods made it 
possible to estimate their concentration using statistical methods. In 
particular, correlation coefficients were found to be high (e.g. 0.98, 
0.88, and 0.93) in the VLDL triglycerides, LDL cholesterol, and HDL 
cholesterol, respectively, in plasma samples.  
However, curve fitting with multiple lorentzians is an ill-posed 
problem which is easily influenced by the shapes of the spectra, strongly 
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overlapping peaks and the number of curves to be fitted. In recent 
applications, the same group solved this problem by applying a Bayesian 
approach for lipoproteins quantification from 1H-NMR spectra39,49. By 
using this methodology, the total concentration of TG and C in serum, as 
well as VLDL-TG, IDL-C, LDL-C and HDL-C can be quantified. They also 
reported that they were able to quantify total lipid content, and particle 
concentrations and size in 14 lipoprotein subclasses, distributed in 
chylomicrons, 5 VLDL, 1 IDL, 3 LDL and 4 HDL. The lipoprotein size of 
these subclasses was calibrated with High Performance Liquid 
Chromatography50, although no details about the calibration process 
were given.  
From 2014, the Finnish company Brainshake (since 2017 known 
as Nightingale Health Ltd.) was established as a serum NMR 
metabolomics platform that measures more than 200 metabolic 
measures in a highly automated way. Among their products, they 
commercialize the lipoprotein profile characterization developed by Ala-
Korpela and colleagues. 
PLS regression models 
PLS regression represents an effective alternative to curve fitting 
and was first applied to quantification of lipoproteins by Bathen et al. 
(2000) where PLS and Neuronal Network (NN) analysis were 
combined51. In this approach, a PLS regression model is built to find the 
best linear association between the NMR spectra and the measured 
data from a reference method (i.e. UC). In contrast to the curve fitting 
approach, overlapping signals do not need to be deconvoluted directly 
since the PLS models focus on the relation between the NMR spectra 
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and the reference UC data. PLS regression is an effective method for 
quantification, and most modern lipoprotein quantifications are based 
on this method. Since PLS models are based on correlation (or 
covariance in the unscaled version), special care has to be taken to 
interpret the models in order to limit the effect of the so-called cage of 
covariance52. 
Interval PLS. In order to develop a more parsimonious regression 
model, iPLS has been proposed for lipoproteins quantification. iPLS 
allows localization of relevant spectral regions that are correlated with 
the response variable (i.e. cholesterol and/or triglycerides 
concentrations as measured by a reference method) in the regression 
equation. This approach, which combines PLS with regional/interval 
variable selection, has proven to be successful for the prediction of 
postprandial chylomicrons53 as well as for the determination of 
cholesterol in rodent plasma lipoprotein fractions54. However, in 
principle many other variable selection methods could be used for 
improving the parsimony, interpretability and performance of the 
prediction methods. 
 
2.2.3 Serum/plasma lipoprotein analysis by 2D 1H-NMR 
spectroscopy   
Despite of the great technological advances and efforts made by 
the pioneers in the field of advanced lipoprotein testing (ALT) by NMR, 
there is still some controversy about the introduction of NMR-based 
ALTs into clinical practice, partly because current methods do not 
provide a direct measure of lipoprotein sizes. As an alternative to 
current NMR methods, there has been increasing interest in 2D 
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diffusion-edited 1H NMR spectroscopy for the analysis of plasma 
samples18. Briefly, by applying a gradient strength iteratively, different 
NMR spectra are acquired while their intensities are attenuated. 
Changes in the NMR intensity of a given peak depend not only on the 
strength of the gradient applied, but also on the diffusion coefficient of 
the metabolite from which such resonance originates. Thus, using 
diffusion NMR experiments it is possible to obtain estimated diffusion 
coefficients of the lipoproteins within a plasma sample. Once the 
diffusion coefficients have been derived, they can be entered into the 
Stokes–Einstein equation to assess the hydrodynamic radius.  
Several prior works have used diffusion experiments:  
Liu et al. mathematically55 deconvoluted the methyl and 
methylene peaks in the diffusion-edited 1H-NMR spectra of one plasma 
sample into six lorentzian functions, each one of which was 
characterized by amplitude, position, width and a diffusion coefficient. 
They demonstrated that the hydrodynamic radii estimated from the 
diffusion coefficients for every function has a good correlation with the 
radii of the conventional subfractions. The measurements were made at 
25 ºC, a temperature at which some lipid fractions have reduced 
visibility in the NMR spectra. The same group shown that the use of 
diffusion-edited experiments improved their assessments of 
hepatotoxicity in rat blood serum compared to assessments derived 
from traditional 1H-NMR spectra55.  
Dyrby et al.56 applied multi-way calibration by N-PLS and multi-
way curve resolution using PARAFAC to 2D diffusion-edited 1H-NMR 
spectra of human blood samples. The application of PARAFAC with four 
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components extracted from the methylene peak revealed that these 
components correspond well with the four main lipoprotein groups 
(VLDL, IDL, LDL and HDL) because the diffusion coefficients (and hence 
their derived radii) that represent the extracted coefficients correspond 
quite well with the size characteristics of each fraction. However, the 
correlation between them and the concentration of the fractions was 
poor, probably because of the limited number of samples (n = 17). N-PLS 
calibration led to better lipoprotein lipid correlations for the four main 
fractions, and the 11 subfractions considered (the correlation coefficient 
r had values between 0.75 and 0.98)56.  
Numares, a German company (http://www.numares-
health.com/quicklinks-oben-health/home.html -consulted 15.08.2017-), 
has described a procedure for determining the concentration and size of 
lipoprotein subclass particles, and a patent application for the invention. 
The serum/plasma samples are measured at different temperatures 
(typically 278 K, 298 K, 308 K and 318 K). As the temperature rises, the 
relaxation times T1 and T2 increase and the lineshape narrows. These 
measuring conditions, combined with three Diffusion weighted 1H-NMR 
measurements carried out with a modified STE–LED (stimulated echo 
and longitudinal eddy-current delay) pulse sequence, produce a range 
of different spectra, which depend on the attenuation of the lipoprotein 
fractions under each of the measuring conditions. Previously, the 
different lipoprotein classes were characterized individually and their 
characteristic parameters (chemical shift, shape of NMR signal 
intensities, signal width and line form) extracted for each temperature 
and gradient strength. Then, the simulated NMR spectrum is calculated 
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and adjusted to the experimental spectrum by means of 
multidimensional optimization processes. The lipoprotein size limits of 
the different fractions are calculated once the particle density is known 
through their lipid contents. This method makes it possible to determine 
15 different fractions – including CM, VLDL, IDL, LDL, HDL fractions – and 
Lp(a) proteins. The determination of the latter is clinically very relevant 
because of the high health risk associated with this lipoprotein57.  
In our research group, Mallol et al.58 used a mathematical 
deconvolution of the 2D diffusion edited spectra of plasma samples into 
8 lorentzian functions to demonstrate that the extracted areas and 
diffusion coefficients in a set of 26 plasma samples separate the 
different lipoprotein profiles (normal, high triglycerides, low HDL/LDL 
ratio, and both risk factors) in a PCA score plot much better than the 
original spectra. They also showed that the relationship between the 
shift position of the lorentzian functions and the lipoprotein radii 
calculated from the experimental diffusion coefficient agrees with 
results found by other authors39,40, particularly in normolipidemic 
samples. 
The latter study, established the bases for the development and 
refinement of the advanced lipoprotein test, named Liposcale test. The 
Liposcale test is a novel method for characterizing lipoprotein particles 
based on 2D diffusion-ordered 1H-NMR spectroscopy (DOSY). DOSY 
allows measuring the diffusion coefficients and directly calculating 
lipoprotein sizes through the Stokes-Einstein equation59. It should be 
noted that the direct measurement of lipoprotein size is of particular 
importance since it is used to calculate the number of lipoprotein 
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particles by dividing the spatial volume of the total lipid molecules by 
the mean volume (i.e. size) of the lipoprotein particles. Thus, the 
development of the Liposcale test, based on DOSY NMR experiments, 
enables direct measurement of lipoprotein sizes producing more 
accurate determinations of lipoprotein particle concentrations than 1D 
NMR-based methods, and has originated a patent application and 
several research application studies that will be presented in the next 
section as part of the research of the PhD candidate.  
 
 
  
 
  
 
 
 
 
 
 
 
2.3 The Liposcale test 
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As a Metabolomic Platform, the research group in which the 
present thesis has been conducted, has closely collaborate with several 
research clinical teams to provide NMR-based on technologies and 
software development solutions for biomarker research discovery and 
disease assessment, including the DOSY-NMR-based on Liposcale test.  
The analysis of plasma by means of DOSY-NMR generates a 
complex resonance spectrum from which a superior degree of 
information compared to that obtained in the traditional analyses. 
 
 
Figure 1. DOSY-NMR experimental spectrum, mathematical 
reconstruction with lorentzian function. Mallol R. et al., Journal of Lipid 
Research, 2015. 
The DOSY-NMR plasma spectrum is characterized by the 
appearance of peaks in different areas, the intensity of which is 
proportional to the concentration of molecular families that resonate at 
characteristic frequencies. The complexity of this spectrum is at the 
same time an opportunity to identify new patterns, profiles or markers 
associated with certain diseases.  
 
Chapter 2 
68 
As a consequence of the development of this test, the 
opportunity and need arise of intellectually protecting, refining and 
adapting it to the clinical and commercial requirements with the final 
objective to translate the basic research to a useful tool for clinicians 
and patients. With this specific purpose, the spin-off company Biosfer 
Teslab was created as an independent institution to carry out these 
tasks.  
 This section describes the patented technology, the industrial 
development process and the clinical application studies in which the 
PhD candidate, as the scientific responsible and current CEO of the 
company (from 2015), has participated. 
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2.3.1 The technology 
METHOD FOR THE CHARACTERIZATION OF LIPOPROTEINS 
 
 
OBJECT OF THE INVENTION 
The present invention relates to a method for the 
characterization of lipoproteins and is applicable in the field of 
biomedicine. 
 
PRIOR ART 
Lipids are mainly present in the blood in the form of lipoproteins, 
which are particles synthesized in the liver and intestines that transport 
cholesterol, triglycerides and other lipids through the blood stream into 
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peripheral tissues. Abnormal levels of blood lipids may be indicative of 
cardiovascular diseases. To assess cardiovascular risk, a standard lipid 
panel is generally used, which includes the concentration of plasma 
triglycerides, total cholesterol, LDL cholesterol and HDL cholesterol. All 
these parameters are measured experimentally except for the LDL 
cholesterol, which is estimated using the Friedewald formula. A critical 
limitation of this formula is its inaccuracy under certain conditions. Also, 
the measure of the amount of cholesterol in HDL and LDL lipoprotein 
fractions does not suffice to predict cardiovascular risk in every case, 
since also the size and particle number of lipoprotein particles may be 
relevant for a correct diagnosis of lipid-related diseases. Thus, 
lipoprotein particles play a main role in cardiovascular diseases and 
metabolic disorders60,61. 
Lipoproteins are divided into five main fractions or classes 
depending on their size and density: chylomicrons (Q; radii 400-2500 Å), 
very low density lipoproteins (VLDL; radii 150-400 Å), intermediate 
density lipoproteins (IDL; radii 125-175 Å), low density lipoproteins (LDL; 
radii 90-140 Å) and high density lipoproteins (HDL; radii 25-60 Å). These 
main fractions or classes can be further divided into different subclasses 
to obtain a more detailed lipoprotein profile. 
It is generally accepted that the structure of a lipoprotein particle 
is substantially spherical and comprises an inner core and an outer shell, 
wherein non-polar lipids (triacylglycerols and cholesteryl esters) are 
found within the core, while polar lipids (phospholipids and free 
cholesterol) are distributed through a surface monolayer (shell). The 
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protein components of lipoproteins (called apolipoproteins or 
apoproteins) are located on the shell together with the polar lipids. 
Advanced lipoprotein testing (ALT) aims to provide the most 
detailed information on lipoprotein particles. Among the analytical 
techniques for advanced lipoprotein testing currently used the following 
may be mentioned: 
· Density Gradient Ultracentrifugation, which allows measuring 
the relative cholesterol distribution for different lipoprotein 
subclasses (K.R. Kulkarni et al., Quantification of cholesterol in all 
lipoprotein classes by the VAP-II method, Journal of Lipid 
Research 35 (1994) 159–168)11. However, it does not provide 
either the concentration of triglycerides, or the numbers and 
sizes of the lipoprotein particles. 
· Gradient Gel Electrophoresis, which can fractionate LDL and HDL 
subclasses directly from plasma according to their size (G.R. 
Warnick et al., Polyacrylamide gradient gel electrophoresis of 
lipoprotein subclasses, Clinics in Laboratory Medicine 26 (2006) 
803)62. This method requires custom-made gels and strict 
attention to laboratory quality control since small variations in 
gel quality and laboratory conditions may affect accuracy.  
· High Performance Liquid Chromatography measures the 
cholesterol and triglyceride content as well as the size of the 
major lipoproteins and their subclasses (M. Okazaki et al., 
Component analysis of HPLC profiles of unique lipoprotein 
subclass cholesterols for detection of coronary artery disease, 
Clinical Chemistry 52 (2006) 2049–2053)63. 
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· Ion Mobility Analysis relies on differences in electrophoretic 
mobility of gas-phased lipoprotein particles and allows 
measuring the size and concentration of some lipoprotein 
subclasses (M.P. Caulfield et al., Direct determination of 
lipoprotein particle sizes and concentrations by ion mobility 
analysis, Clinical Chemistry 54 (2008) 1307–1316)64. 
· 1H-NMR Spectroscopy for quantifying lipoprotein subclasses 
based on sophisticated line-shape fitting techniques (M. Ala-
Korpela et al., 1H-NMR-based absolute quantification of human 
lipoproteins and their lipid contents directly from plasma, 
Journal of Lipid Research (1994) 2292-2304)46. However, said 
techniques require the use of a library of spectra previously 
characterized and have the disadvantage of extensive 
lipoprotein signal overlap in the analysis of the spectra of 
plasma.  
· Diffusion-Ordered NMR Spectroscopy of lipoprotein fractions, 
which uses the methyl peak of isolated lipoproteins to calculate 
the diffusion coefficient of the lipoproteins and estimate their 
size from this value (R. Mallol et al., Particle size measurement of 
lipoprotein fractions using diffusion ordered NMR spectroscopy, 
Analytical and Bioanalytical Chemistry 402 (2012) 2407–2415)65. 
However, this method requires a previous step of 
ultracentrifugation of the sample in order to obtain the different 
lipoprotein fractions and cannot be used directly in a blood 
serum or blood plasma sample. 
Analytical methods which physically separate the different 
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lipoprotein fractions and subclasses, such as ultracentrifugation, are 
laborious and time-consuming. Moreover, samples suffer a high degree 
of manipulation and they might remain at 4ºC for days. 
Also, ALT methods are not yet ready for routine clinical use, 
some of their limitations being the lack of standardization and the 
varying approaches. Thus, there is a need for a method which allows 
reliable characterization of different lipoprotein fractions and subclasses 
directly from a blood serum or a blood plasma sample, using a single 
analysis and without the processing or destruction of the sample. This 
will be useful for developing and monitoring diet and drug therapies and 
getting insight into the pathophysiology of cardiovascular diseases. 
 
SUMMARY OF THE INVENTION 
The present invention overcomes the above problems by the 
provision of a method according to claim 1. The dependent claims 
define preferred embodiments of the invention.  
Currently, LDL and HDL cholesterol are two factors for 
cardiovascular risk that are routinely used to assess the cardiovascular 
risk of an individual. However, a high percentage of individuals suffering 
a cardiovascular event have normal levels of LDL cholesterol. Patients 
with metabolic disorders such as diabetes tend to have LDL lipoproteins 
which are smaller, poorer in cholesterol content and more atherogenic. 
This smaller size is associated with a greater number of particles, thus 
resulting in a cholesterol concentration similar to that of a pattern with 
a smaller concentration of larger less atherogenic particles. That is the 
reason why there is interest in determining the size and number of LDL 
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lipoprotein particles, beyond their lipid load, to assess cardiovascular 
risk of a patient. Moreover, there are studies which indicate that the 
size and number of HDL particles are better predictors of cardiovascular 
risk than HDL cholesterol. The present invention allows exhaustive 
characterization of lipoprotein particles, providing in a fast and reliable 
way the size and number of particles of the main lipoproteins classes 
and subclasses without physical separation of the different lipoprotein 
fractions and subfractions in the sample. 
The method according to the invention comprises the following 
steps: 
- obtaining a 2D diffusion-ordered 1H-NMR spectrum of a sample; 
- performing a surface fitting of a portion of the spectrum 
corresponding to the methyl signal using a plurality of model 
functions, each model function corresponding to a given particle size 
associated to a lipoprotein fraction and subclass and including at 
least one model parameter to be estimated during the fitting, the 
estimated model parameters being the set of model parameters for 
which the difference between the NMR signal and the model signal 
built as a linear combination of the model functions is minimized, 
wherein each model function is a triplet of lorentzian functions 
having the form: 
 !"#$%&' = ()!%*&+",*-ℎ/', 1' − 13', 4' , 5'6
+ ()!%*&+",*-ℎ8' , 1' , 4' , 5'6
+ ()!%*&+",*-ℎ9' , 1' + 13', 4' , 5'6, 
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where hij(au), fj(ppm), wj(ppm), and Dj(cm2s-1) are the intensities, 
chemical shift, width, and diffusion coefficient, respectively, associated 
to a lipoprotein particle size j. 
The side lorentzian functions are equally spaced in the chemical 
shift axis relative to the central lorentzian function, namely in an 
amount 13. 
The model parameters to be determined for a lipoprotein 
particle size are one or several from: 1, 13, ℎ/, ℎ8, ℎ9, 4 and D. 
Advantageously, the use of triplets of lorentzians as the model 
functions associated to each lipoprotein particle size results in a more 
accurate fitting of the NMR signal, when compared to other methods. 
The sample is preferably a blood plasma sample or a blood 
serum sample, but samples of other biological fluids may be also used, 
such as cerebrospinal fluid, encephalorachidian fluid or amniotic fluid. 
Thus, the NMR methyl signal is decomposed as a number of 
model functions, each model function corresponding to a lipoprotein 
particle size. Each model function is thus associated with a given 
lipoprotein fraction and subclass according to its lipoprotein particle 
size. Not all the model functions included in the fitting will necessarily 
contribute to the model signal built, since not all the lipoprotein particle 
sizes included in the fitting are necessarily present in the sample. 
According to the method of the invention, the lipoproteins 
present in the sample are identified and characterized by determining 
the intensity, chemical shift, width, and diffusion coefficient of the 
associated lipoprotein signals. For further characterization of the 
lipoproteins present in the sample, additional lipoprotein parameters 
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may be determined in subsequent steps based on the model functions 
and on the estimated model parameters. 
Preferably, the lorentzian functions of the triplet associated to 
each lipoprotein particle size j have the form  
()!%*&+",*'-ℎ' , 1' , 4' , 5'6 = ℎ'1 + ;1 − 1'4' <
8 %>?∙AB∙CD 
where k is the Boltzmann constant and G is the gradient strength 
applied (Gauss cm-1). The first quotient part of the lorentzian 
corresponds to a 1D lorentzian, whereas the exponential part includes 
the attenuation effect by means of the diffusion gradient. This preferred 
form of the lorentzian functions is applicable to each embodiment of 
the invention. 
In a preferred embodiment, the method comprises identifying 
the lipoproteins present in the sample as those associated to the model 
functions having a nonzero contribution to the theoretical model signal 
resulting from the fitting and determining at least one and preferably all 
of: average size of lipoprotein particle classes, average size of 
lipoprotein particle subclasses, class and/or subclass lipoprotein particle 
concentration, lipid concentration of at least one lipoprotein particle 
class and/or lipid concentration of at least one lipoprotein particle 
subclass. 
In a preferred embodiment, for the model function associated to 
each lipoprotein particle size j the intensities of the side lorentzian 
functions are made proportional to the intensity of the central 
lorentzian function: 
ℎ/' = E' · ℎ8' , with  /G  ≤ E'  ≤ 9G , and 
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ℎ9' = I' · ℎ8' , with  /G  ≤ I'  ≤ 9G. 
In an embodiment, the proportionality factor E' is made the 
same for all lipoprotein particle sizes and/or the proportionality factor 
I' is made the same for all lipoprotein particle sizes.  
In a preferred embodiment, the intensities of the side lorentzian 
functions are taken to be equal, i.e. ℎ/'= ℎ9' . 
In a preferred embodiment,  
ℎ/ = KD8 , i.e. the intensities of the side lorentzian functions 
are approximately half the intensity of the central lorentzian 
function, and/or 
13 = 0.01 ppm, i.e. the side lorentzian functions are 
spaced approximately 0.01 ppm in the chemical shift axis relative 
to the central lorentzian function. 
In a preferred embodiment, the number of model functions used 
is greater than or equal to 9, each model function corresponding to a 
lipoprotein particle size. 
In a preferred embodiment, the lipoprotein particle sizes used in 
the fitting are defined based on experimental results obtained for 
example by NMR, HPLC, Gradient Gel Eletrophoresis, or Atomic Force 
Microscope. The lipoprotein particle sizes used in the method may be 
selected based on any other technique. 
Preferably, lipoprotein particle sizes corresponding to several 
lipoprotein classes and/or subclasses are used in the method. 
The surface fitting may be performed taking all the model 
parameters as free parameters to be determined during the fitting. 
However, in a preferred embodiment, the surface fitting is performed 
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fixing a number of model parameters and using at least one other model 
parameter as a free parameter to be determined. More preferably, at 
least the signal intensity of the central lorentzian (ℎ8) is used as a free 
parameter and at least one of the chemical shift, width, and diffusion 
coefficient are fixed. 
Where the number of model parameters to be estimated in the 
surface fitting is high, multiple solutions for the fitting appear, many of 
them having no biological meaning. Advantageously, fixing parameters 
by establishing relations between pairs of model parameters allows 
reducing the dimensionality of the problem and avoids the appearance 
of solutions with no biological relevance. 
The shift of the side lorentzian functions relative to the central 
lorentzian function may be estimated during the surface fitting or may 
be taken as a given value. Similarly, the intensities of the side lorentzian 
functions may be estimated during the surface fitting or may be taken 
to be related to the intensity of the central function, preferably to be 
half the intensity of the central lorentzian function. 
In a preferred embodiment, the fixed model parameters used in 
the surface fitting are determined based on the lipoprotein particle size 
and on regression models, the regression models relating pairs of fixed 
model parameters and/or a model parameter and the lipoprotein 
particle size. 
In a preferred embodiment, the regression models used for the 
fixed parameters are obtained from the deconvolution of the methyl 
signal of a plurality of NMR spectra using a plurality of model lorentzian 
functions with the intensity, chemical shift, width, and diffusion 
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coefficient being free model parameters estimated to minimize the 
difference between the NMR methyl signal and the model signal built as 
a linear combination of the model functions, the regression models 
respectively relating at least (i) the chemical shift and the lipoprotein 
particle size, and/or (ii) the width and the lipoprotein particle size.  
In a preferred embodiment, the regression models relating pairs 
of model parameters are built according to the following steps: 
- obtaining a 2D diffusion-ordered 1H-NMR spectrum for a plurality of 
samples; 
- for each sample, performing a surface fitting of a portion of the 
spectrum corresponding to the methyl signal using a plurality of 
model functions, each model function being dependent on the 
model parameters to be fixed, wherein all the model parameters to 
be fixed are estimated during the surface fitting as the set of model 
parameters for which the difference between the NMR signal and 
the model signal built as a linear combination of the model functions 
is minimized, and 
- using the model parameters estimated in the previous step to build 
regression models relating pairs of model parameters. 
Preferably, the regression models respectively relate at least (i) 
the chemical shift and the lipoprotein particle size, and/or (ii) the width 
and the lipoprotein particle size.  
The plurality of samples used to build the regression models 
includes different lipids profiles and the number of samples considered 
is sufficiently high to be statistically meaningful. Preferably, the number 
of samples is equal to or greater than 100 and includes samples taken 
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from healthy subjects and samples corresponding to different profiles of 
atherogenic dyslipidaemia. 
Preferably, the model functions used to build the regression 
models are lorentzian function triplets of the form: 
 !"#$%&' = ()!%*&+",*-ℎ/', 1' − 13', 4' , 5'6
+ ()!%*&+",*-ℎ8' , 1' , 4' , 5'6
+ ()!%*&+",*-ℎ9' , 1' + 13', 4' , 5'6, 
In a preferred embodiment, ℎ/= ℎ9 = ℎ8/2. 
In a preferred embodiment, the triplets of lorentzian functions 
used to build the regression models have the form: 
 !"#$%&' = ()!%*&+",* Oℎ'2 , 1' − 0.01, 4' , 5'P
+ ()!%*&+",*-ℎ' , 1' , 4' , 5'6
+ ()!%*&+",* Oℎ'2 , 1' + 0.01, 4' , 5'P 
Alternatively, the shift (f0) of the side lorentzian functions 
relative to the central lorentzian function may be determined during the 
fitting performed to build the regression models. A single value of the 
shift (f0) may be used for all the lipoprotein sizes. Similarly, the 
intensities of the side lorentzian functions may be estimated during the 
fitting performed to build the regression models. 
In a preferred embodiment, the diffusion coefficient of the 
model functions is estimated from the lipoprotein particle size by means 
of the Einstein Stokes equation  
5 = Q 6STUV 
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k (J K-1) being Boltzmann constant, T (K) temperature, η (Pa s) 
viscosity and RH (Å) the lipoprotein particle size. 
In a preferred embodiment, the method of the invention further 
includes correcting the estimated diffusion coefficients to take into 
account dilution effects, using a relation between the NMR area and the 
diffusion coefficient obtained for several dilutions of a sample wherein 
the sum of the concentration of total cholesterol and triglycerides of 
said sample is higher than 300 mg/dL. Advantageously, using a 
corrected diffusion coefficient to take into account dilution effects 
results in a more accurate surface fitting. 
In a preferred embodiment, the NMR area associated to a 
lipoprotein function is corrected to consider only the contribution of the 
lipids included in the lipoprotein particle core. 
In a preferred embodiment, the corrected NMR area (A’) is 
determined using the following expression: 
W’ = W · (9 · (U − Z)9)[(9 · (U − Z)9) + 6 · # · (U9 − (U − Z)9)]  
with A (au) and R(Å) being respectively the area and lipoprotein 
particle size associated to each model function, s(Å) being the thickness 
of the lipoprotein particle shell and p being the ratio of apoprotein mass 
per unit volume (mg/ml) in the shell of the particle relative to the total 
mass per unit volume (mg/ml) in the particle shell (proteins, free 
cholesterol and phospholipids). The proteins in the shell of the 
lipoprotein particles are called apolipoproteins. The ratio p depends on 
the lipoprotein fraction. For HDL p is approximately 0.5. For other 
lipoprotein fractions p is smaller. Generally, the thickness of the 
lipoprotein particle core is estimated as s = 20 ± 2Å. 
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As used herein, the term “apolipoproteins” or “apoproteins”, i.e. 
proteins in the shell of the lipoprotein particles, refer to proteins that 
bind lipids to form lipoproteins and transport lipids through the 
circulatory system. Apolipoproteins are amphipathic molecules that can 
surround lipids creating the lipoprotein particle that is itself water-
soluble and can thus be carried through water-based circulation (i.e., 
blood). There are six classes of apolipoproteins (A-H) and several 
subclasses; in particular, Apo A-I (or Apo A1) is the major protein 
component of HDL particles wherein Apo A-II (or Apo A2) is also present 
in a minor concentration. Illustrative, non-limitative, methods for 
determination of apolipoprotein concentration include without 
limitation, colorimetric methods, Western blot or ELISA. If 
apolipoprotein concentration is determined in an isolated fraction of 
lipoproteins any method well-known in the art for determining protein 
concentrations may be used such as enzymatic methods, colorimetric 
methods (Biuret, Lowry, Bradford, etc.) or immunochemical techniques 
(Western blot, ELISA, etc.). If apolipoprotein concentration is 
determined in a plasma or serum sample immunochemical techniques 
are used in order to obtain a specific detection of apolipoproteins. 
Illustrative, non-limitative, immunochemical techniques for 
apolipoprotein detection include immunoturbidimetric techniques, 
immunonefelometric techniques, radial immunodiffusion, ELISA, 
electroimmunoanalysis, and radioimmunoanalysis. 
The correction of the area is more important as the lipoprotein 
particle size decreases, i.e. the correction is greater for HDL particles 
than for LDL or VLDL particles, due to the smaller size of HDL particles. 
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In a preferred embodiment, the method additionally comprises 
determining at least one lipoprotein parameter selected from: average 
particle size of lipoprotein fractions, average particle size of lipoprotein 
subclasses, fraction lipoprotein particle concentration, subclass 
lipoprotein particle concentration and lipid concentration of at least one 
lipoprotein particle subclass and/or lipid concentration of at least one 
lipoprotein particle fraction. 
In a preferred embodiment, the average size of a lipoprotein 
particle fraction is determined as: 
^"+% (Å) = ∑ U` · ab`c`d/∑ ab`c`d/ , 
n being the number of lipoprotein particle subclasses included in 
the lipoprotein particle fraction, R(Å) being the lipoprotein particle size 
and PNi being the particle number for said lipoprotein particle size.  
In a preferred embodiment, the particle number (PN) for a 
lipoprotein is determined as: 
ab` ∝ W`U9`  
with A(au) and R(Å) being respectively the area and lipoprotein 
particle size associated to a model function i. Throughout the document 
the size of the lipoprotein particle will be understood as the lipoprotein 
particle radius in Angstroms. The number of lipoprotein particles of a 
specific size is proportional to the ratio of the area associated to the 
model function corresponding to said lipoprotein between the volume 
associated to said lipoprotein, the proportionality factor being a 
calibration parameter of the equipment used. Preferably, in the 
determination of the particle number the area associated to a 
Chapter 2 
84 
lipoprotein function is the area A’ corrected to consider only the 
contribution of the lipids included in the lipoprotein particle core, 
according to an embodiment of the invention. 
The average size of a lipoprotein particle fraction, as used herein, 
refers to the average size of the radius of the lipoproteins forming part 
of a particular lipoprotein particle fraction. 
In a preferred embodiment, the lipoprotein particle 
concentration of a lipoprotein particle fraction is calculated by dividing 
the lipid volumes by the lipoprotein particle volumes. Lipid volumes are 
determined by using common conversion factors to convert 
concentration units into volume units. Total lipoprotein particle 
concentrations of each main lipoprotein particle fraction are obtained 
by summing the concentrations of the corresponding lipoprotein 
particle subclasses. 
In a preferred embodiment, the method comprises determining 
the lipid concentration of at least one lipoprotein particle fraction 
and/or at least one lipoprotein particle subclass. More preferably, the 
determination of the lipid concentration is performed using regression 
models. In a preferred embodiment, the regression models are 
calibrated with lipid concentrations measured in lipoprotein fractions 
obtained by ultracentrifugation in the following regions: from 5.4 to 
5.15 ppm, from 3.28 to 3.14 ppm, from 2.15 to 1.85 ppm, from 1.45 to 1 
ppm and from 1 to 0.7 ppm. Other methods may be used for calibration, 
such as ELISA, chromatography, NMR or enzymatic methods. 
The determination of the lipid concentration of a lipoprotein 
particle fraction or subclass includes the determination of at least one of 
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a lipid selected from triacylglycerols, cholesteryl esters, free cholesterol 
and phospholipids. 
All the features described in this specification (including the 
claims, description and drawings) and/or all the steps of the described 
method can be combined in any combination, with the exception of 
combinations of such mutually exclusive features and/or steps. 
 
BRIEF DESCRIPTION OF (the patent) DRAWINGS  
To better understand the invention, its objects and advantages, 
the following figures are attached to the specification in which the 
following is depicted: 
- Figure 1 shows the deconvolution of a methyl signal according to 
the method of the invention, where the model functions used in the 
fitting are shown in figure 1A and the model functions grouped 
according to their lipoprotein fractions are shown in figure 1B. 
- Figure 2 shows two regression models, respectively relating (a) 
size and chemical shift and (b) width and chemical shift. 
- Figure 3 shows the relation between the NMR area of the methyl 
signal and the diffusion coefficient. 
- Figure 4 shows the regions of the spectrum used in an 
embodiment of the method of the invention to calibrate the regression 
models for the lipid determination. 
- Figure 5 shows the deconvolution of the methyl signal of three 
samples. 
 
 
Chapter 2 
86 
Figure 1. Figure 2. 
  
 
 
Figure 3. 
 
 
 
Chapter 2 
87 
Figure 4. 
 
 
Figure 5. 
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DETAILED DESCRIPTION OF THE INVENTION 
In the in vitro method for the characterization of lipoprotein 
particles according to the invention, the samples are analysed by 2D 
diffusion-ordered 1H-NMR spectroscopy. 
Once the 2D diffusion-ordered 1H-NMR spectrum has been 
obtained, a surface fitting is performed of the portion of the spectrum 
corresponding to the methyl signal. A plurality of model functions is 
used, each model function corresponding to a lipoprotein having a 
specific lipoprotein particle size and including a plurality of model 
parameters to be estimated during the fitting. The model function 
associated to each specific lipoprotein particle size is a triplet of 
lorentzian functions having the form: 
 !"#$%& = ()!%*&+",*(ℎ/, 1 − 13, 4, 5) + ()!%*&+",*(ℎ8, 1, 4, 5)+ ()!%*&+",*(ℎ9, 1 + 13, 4, 5), 
where h(au), f(ppm), w(ppm), and D(cm2s-1) are the model 
parameters to be determined and are respectively the intensity, 
chemical shift, width, and diffusion coefficient associated to a 
lipoprotein signal. 
The model parameters are estimated during the fitting as the set 
of model parameters for which the difference between the 
experimental NMR signal and the model signal built as a linear 
combination of the model functions is minimized. 
Figure 1 shows the part of a spectrum corresponding to the 
methyl signal of a serum sample for a single gradient of a 2D diffusion-
ordered 1H-NMR experiment and its fitting. In this case the fitting for a 
single gradient has been depicted for increased clarity, even if a surface 
fitting is performed for a plurality of diffusion gradients. Figure 1A 
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shows in thin trace a plurality of model functions used to fit an 
experimental NMR spectrum, which is also shown in thick trace. The 
theoretical model signal built from the fitting with model functions is 
depicted in dot line. Each model function can be associated to a given 
lipoprotein particle fraction according to its lipoprotein particle size. In 
Figure 1B thin lines correspond to the sum of the model signals 
associated to each corresponding lipoprotein fraction (in this example 
VLDL, LDL, HDL). 
In this example, the surface fitting is performed fixing all 
parameters (chemical shift, width and diffusion coefficient) except the 
signal intensities, instead of estimating all parameters for each triplet of 
lorentzian functions. The following form is used for the triplet lorentzian 
functions: 
 !"#$%& = ()!%*&+",* fK8 , 1 − 0.01, 4, 5g +
()!%*&+",*(ℎ, 1, 4, 5) + ()!%*&+",* fK8 , 1 + 0.01, 4, 5g, 
the two signals around the central signal being shifted 0.01 ppm 
relative to the central signal. 
In order to fix the chemical shifts and widths associated to each 
model function, 300 spectra were previously deconvoluted using three 
triplet lorentzian functions with all their parameters free. Once the sets 
of parameters which best fit to the 300 experimental spectra have been 
obtained, they were used to fit two regression models to be used as 
predictors of the fixed parameters, a first regression model relating 
chemical shift and size (Figure 2a) and the second regression model 
relating width and chemical shift (Figure 2b). Figures 2a and 2b 
respectively show the chemical shift plotted as a function of size and the 
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width plotted as a function of chemical shift for the estimated 
parameters, from which corresponding relations relating both pair of 
parameters can be determined. Thus, at a fixed lipoprotein particle size, 
its NMR chemical shift and width can be estimated using the built 
regression models. 
A third regression model may be built to relate the diffusion 
coefficient with another parameter. Alternatively, the diffusion 
coefficient may be obtained from the lipoprotein particle size using the 
Einstein Stokes equation: 
h = ijklmno 
Preferably, the lipoprotein particle sizes are selected based on 
experiments and corresponding to a number of different lipoprotein 
particle subclasses, which allows a more complete and reliable 
lipoprotein profile to be achieved.  
Preferably, the determined diffusion coefficients are corrected in 
order to take into account possible dilution effects. To study the degree 
of correction needed, in a preferred embodiment of the invention a 
serum sample having high triglycerides levels (16 mmol/L) and various 
dilutions of the same sample (1:2, 1:4, 1:8 and 1:16) are analyzed 
(Figure 3). Then, the relation between NMR area and diffusion 
coefficient is used to predict the correction needed for each NMR signal: 
hp = hq − irq · s − irt · s 
where D0 is the average diffusion coefficient under dilution 
conditions, D and A(au) are the average diffusion coefficient and the 
total area of the methyl peak, respectively, and kS1, kS2 are the 
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regression coefficients. 
To determine the average diffusion coefficient a number of 
spectra is obtained for each sample, each spectrum being obtained 
under a different gradient strength. The area under the methyl curve 
plotted as a function of the gradient decays exponentially with 
increasing gradients. The average diffusion coefficient is thus 
proportional to the slope of the line obtained when the logarithm of the 
signal attenuation A/A0 is plotted versus the square of the gradient: 
uvw(s/sp) = −ihxt 
where A is the methyl signal area, A0 is the methyl signal area 
with zero gradient, k is a constant parameter and G is the gradient 
strength. 
With the selected lipoprotein particle sizes and the chemical 
shift, width and diffusion coefficient determined for each lipoprotein 
particle size, the signal intensity is determined for each model function 
in order to minimize the difference between the experimental NMR 
signal and the model signal built from the plurality of model signals 
considered.  
The fitting may be made by minimization of the normalized root 
mean squared errors (NRMSE) using the following equation: 
ynzr{ (%) =
}∑ ∑ -r~ − r~6t  · -r~6 − -r~6 · qpp 
where Sexp and Sest are the experimental and estimated surfaces, 
respectively, n is the number of data points considered and m the 
number of gradients used.  
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Once the model parameters have been determined, particle-
weighted lipoprotein sizes can be obtained by dividing the NMR area 
associated to each model function by their associated volume: 
ab` ∝ W`U9` 
where Ai, Ri3 and PNi are the area (au), volume (Å3) and particle 
number (au/Å3) of a given lipoprotein particle i. The proportionality 
factor relating the particle number with the ratio between area and 
volume can be easily obtained by known calibration standards, which 
directly relate the NMR area and the lipid concentration. 
Then a mean particle size can be obtained for each lipoprotein 
particle fraction by multiplying the NMR lipoprotein particle sizes by 
their fractional particle concentration relative to the total particle 
concentration of a given fraction: 
 -Å6 = ∑ n · ydq∑ ydq  
where Z corresponds to mean lipoprotein particle size of a given 
lipoprotein particle fraction. 
PLS regression models were calibrated to predict the cholesterol 
and triglyceride concentration of the main lipoprotein particle fractions 
(VLDL, LDL, and HDL). Regions from 5.4 to 5.15 ppm, from 3.28 to 3.14 
ppm, from 2.15 to 1.85 ppm, from 1.45 to 1 ppm and from 1 to 0.7 ppm 
(shown in Figure 4) were used as X-Block and the cholesterol and 
triglyceride concentrations were used as Y-Block. Both blocks were 
mean-centered. The optimum number of latent variables (LV) and the 
validation performance of the PLS models, were assessed using venetian 
blinds cross-validation splitting the data 10 times. Coefficients of 
Chapter 2 
93 
determination between the predicted and reference concentrations 
ranged from 0.79 to 0.98 in the calibration step. The coefficients of 
determination of the validation step ranged from 0.81 to 0.98. 
The determination of the lipid concentration of a lipoprotein 
particle fraction or subclass includes the determination of at least one of 
a lipid selected from triacylglycerols, cholesteryl esters, free cholesterol 
and phospholipids. 
A triglyceride (or triacylglycerol) is an ester derived 
from glycerol and three fatty acids which can be found in a lipoprotein 
particle. Illustrative, non-limitative, fatty acids that can be found in 
lipoprotein triglycerides are palmitic acid, estearic acid, oleic acid, 
linoleic acid and araquidonic acid. Triglycerides are blood lipids that help 
enable the bidirectional transference of adipose fat and blood glucose 
from the liver. Illustrative, non-limitative, methods for determination of 
triglycerides concentration include enzymatic determination. Enzymatic 
determination of triglycerides is also possible because it is specific and 
sensitive. The principle of reaction is as follows: Triglycerides are 
hydrolyzed by a lipase in glycerol and free fatty acids. In the presence of 
glycerol kinase, glycerol is phosphorylated to glycerol-3-phosphate 
which is then oxidized with a glycerol phosphate oxidase with formation 
of hydrogen peroxide. In the presence of peroxidase, 4-chlorophenol 
and 4-aminoantipyrine with hydrogen peroxide yield a red-colored 
product, quinonimine. The staining intensity is directly proportional to 
the sample concentration of triglycerides. 
Cholesterol is an amphipatic lipid. A cholesteryl ester is 
an ester of cholesterol wherein the ester bond is formed between the 
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carboxylate group of a fatty acid and the hydroxyl group of cholesterol. 
Illustrative, non-limitative, examples of cholesteryl esters present in a 
lipoprotein particle are cholesterylpalmitate, cholesteryl stearate, 
cholesteryloleate, cholesteryllinoleate and cholesterylaraquidonate66. 
Cholesteryl esters have a lower solubility in water than cholesterol and 
are more hydrophobic. Numerous methods are available for 
determination of cholesterol concentration, e.g., gravimetric, 
nephelometric, turbidimetric, or photometric methods, among others. 
Commercially available kits for quantitative colorimetric/fluorimetric 
cholesterol and cholesteryl esters determination may be used. Usually, 
the concentrations of total and free cholesterol (esterified cholesterol 
being previously precipitated by, for example, digitonin) are 
determined, whereas the concentration of cholesteryl esters (esterified 
cholesterol) is calculated from the difference between these two 
concentrations. Enzymatic determination of cholesterol concentration is 
specific and sensitive. The principle of reaction is as follows: Cholesterol 
esterase catalyzes hydrolysis of cholesteryl esters to free cholesterol 
and free fatty acids. In the presence of cholesterol oxidase, cholesterol 
is oxidized to δ-4-cholestanetriol to form hydrogen peroxide. In the 
presence of peroxidase, phenol and 4-aminoantipyrine with hydrogen 
peroxide yield a red-colored product, quinonimine. The staining 
intensity is directly proportional to the sample concentration of total 
cholesterol. 
Phospholipids are a class of lipids that are present in the shell of 
lipoprotein particles and that are a major component of all cell 
membranes as they can form lipid bilayers. Most phospholipids contain 
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a diglyceride, a phosphate group, and a simple organic molecule such as 
choline. The structure of the phospholipid molecule generally consists of 
hydrophobic tails and a hydrophilic head. Illustrative, non-limitative, 
examples of phospholipids present in a lipoprotein particle are 
phosphatidylcholine, sphingophospholipids such as sphingomyelin, 
phosphatidylethanolamine, phosphatidylinositol and 
phosphatidylserine. Illustrative, non-limitative, methods for 
determination of phospholipids concentration, include commercially 
available assay kits for a quantitative colorimetric/fluorimetric 
phospholipid determination. The principle of reaction is as follows: 
phospholipids (such as lecithin, lysolecithin and sphingomyelin) are 
enzymatically hydrolyzed to choline which is determined using choline 
oxidase and a H2O2 specific dye. The optical density of the pink colored 
product at 570 nm or fluorescence intensity (530/585 nm) is directly 
proportional to the phospholipid concentration in the sample. 
Example: 2D diffusion-ordered 1H-NMR spectroscopy (DOSY) 
Serum samples were analysed by NMR spectroscopy, recording 
1H-NMR spectra on a BrukerAvance III spectrometer at 310 K. The 
double stimulated echo (DSTE) pulse program was used with bipolar 
gradient pulses and a longitudinal eddy current delay (LED). The 
relaxation delay was 2 s, the free induction decays were collected into 
64K complex data points and 32 scans were acquired on each sample. 
The gradient pulse strength was increased from 5 to 95% of the 
maximum strength of 53.5 Gauss cm-1 in 32 steps, where the squared 
gradient pulse strength was linearly distributed.  
Surface fitting:  
Chapter 2 
96 
In the present example, the lipoprotein NMR signals were 
modeled as triplets of lorentzian functions, with the two signals around 
the central signal shifted 0.01 ppm: 
ju~ = v~ ;t ,  − p. pq, , h<+ v~(, , , h)
+ v~ ;t ,  + p. pq, , h< 
where h (au), f (ppm), w (ppm), and D (cm2 s-1) are the intensity, 
chemical shift, width, and diffusion coefficient of a given lipoprotein 
signal, each lipoprotein signal corresponding to a lipoprotein particle 
size. 9 lipoprotein particle sizes and consequently also 9 model functions 
were used based on lipoprotein particle sizes obtained by HPLC.  
The 9 model functions were associated with a given lipoprotein 
particle fraction (VLDL, LDL or HDL) according to their NMR size. Thus, 
functions F1-F3 were associated to VLDL, functions F4-F6 to LDL, and 
functions F7-F9 to HDL (Table 1 of the present section). Main lipoprotein 
particle fractions were defined as VLDL (193-409 Å), LDL (74-133 Å) and 
HDL (30-55 Å).  
The surface fitting of the methyl signal was performed using 9 
model functions with all parameters fixed (chemical shift, width and 
diffusion coefficient) except the signal intensity (h). The fitting of each 
sample elapsed 29.47±4.42 seconds on average. The methyl signal was 
thus decomposed into individual lipoprotein signals to obtain the 
contribution of 9 lipoproteins with fixed NMR size. Figures 5A-C show 
the results of the surface fitting for three subjects, which are also 
summarized in Table 1. It must be noted that even using 9 model 
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functions to fit the spectra, not all of them are used to find the final 
solution. Figures 5D-F show the grouping of model functions according 
to their associated lipoprotein particle main fraction. Subject 1 shows a 
prominent HDL area (shown in dark grey in Figure 5D), subject 2 has 
increased LDL area (shown in light grey in Figure 5E), and subject 3 is 
characterized by a very high VLDL area (shown in medium grey in Figure 
5F).  
The uniqueness of the solutions was studied by fitting each 
sample ten times with randomly chosen initial values of the signal 
intensities. Because the dynamic range in signal intensity may be very 
high, the following formula was used to assess the coefficient of 
variation (CV) for each model function and sample across ten different 
fittings: 
 = rh ()z() − z() · qpp (%) 
where h stands for signal intensity of a given model function. 
Maximum (Max), minimum (Min) and standard deviations (SD) values 
where assessed from the ten fittings in each sample. As a result, unique 
solutions were obtained for all samples after 10 runs. 
In this case the coefficient of variation (CV) is determined for the 
signal intensity of the central lorentzian, since the other model 
parameters have been fixed during the fitting. The above expression for 
the calculation of the coefficient of variation may be generalized for the 
case where more than one free model parameters is used in the fitting. 
Normalized root mean squared errors (NRMSE) of the fittings 
were calculated using the following equation 
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ynzr{ (%) =
}∑ ∑ -r~ − r~6t  · -r~6 − -r~6 · qpp 
where Sexp and Sest are the experimental and estimated surfaces, 
respectively, n is the number of data points considered in interval length 
(0.7-1 ppm) and m the number of gradients used. In this example, n and 
m had the same value for each sample. The average NRMSE obtained 
was of less than 1.5%.  
To obtain particle-weighted lipoprotein sizes, we first divided 
each NMR area by their associated volume: 
ab` ∝ W`U9` 
where Ai, Ri3 and PNi are the area (au), volume (Å3) and particle 
number (au/Å3) of a given lipoprotein particle i.  
Then, the mean particle size for each lipoprotein particle fraction 
was obtained multiplying the lipoprotein particle sizes by their fractional 
particle concentration relative to the total particle concentration of a 
given particle fraction: 
h r~ -Å6 = ∑ n · ydq∑ ydq ,  = q, … ,  
h r~ -Å6 = ∑ n · ydq∑ ydq ,  = , … , k 
oh r~ -Å6 = ∑ n · ydq∑ ydq ,  = , … ,  
Particle concentrations of each lipoprotein particle subclass were 
calculated by dividing the lipid volumes by the particle volumes. Lipid 
volumes were determined by using common conversion factors to 
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convert concentration units into volume units. Total particle 
concentrations of each main particle fraction were obtained by 
summing the concentrations of the corresponding particle subclasses. 
Lipid concentration was determined using PLS models calibrated 
in the regions shown in Figure 4, namely: from 5.4 to 5.15 ppm, from 
3.28 to 3.14 ppm, from 2.15 to 1.85 ppm, from 1.45 to 1 ppm and from 
1 to 0.7 ppm. The reference lipids were obtained by sequential 
ultracentrifugation and correspond to cholesterol and triglycerides for 
three lipoprotein particle fractions (VLDL, LDL and HDL). 
The method of the invention allows to obtain an advanced 
lipoprotein profile, as shown in Table 1. The ALT reports for three 
representative subjects from the whole group are summarized in Table 
1 for illustration purposes. Subject 1 was normolipidemic, subject 2 
presented high LDL cholesterol levels (hypercholesterolemic) and 
subject 3 presented high triglycerides and low HDL cholesterol levels 
(atherogenic dyslipidemia). The method of the invention provides total 
cholesterol (C), triglycerides (TG) and particle concentration (P) for the 
main lipoprotein fractions and their subclasses. Additionally, the 
method of the invention provides the size of the main lipoprotein 
fractions. Subject 1 showed normal lipid levels (defined as VLDL-TG<150 
mg/dL, LDL-C<160 mg/dL, and HDL-C>40 mg/dL), subject 2 showed 
elevated LDL-C and normal VLDL-TG and HDL-C levels, and subject 3 
showed elevated VLDL-TG, decreased HDL-C and normal LDL-C levels. It 
should also be pointed out that subject 3 had increased LDL-P despite 
normal LDL-C levels and that its small LDL-P concentration was higher 
than in subject 2. Thus, subjects with elevated triglycerides levels are 
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associated with increased LDL-P values because an increase in 
triglyceride concentration leads to the formation of greater 
concentrations of smaller LDL particles. 
Advanced lipoprotein tests have shown statistical associations 
between these lipoprotein parameters and the risk for cardiovascular 
disease67. For example, in a study, the number of HDL particles (HDL-P), 
but not the high-density lipoprotein cholesterol (HDL-C) concentrations, 
were independently associated with carotid intima-media thickness, 
after adjusting for covariates68. Finally, the use of lipoprotein particle 
subclasses improved NMR-derived risk stratification for subclinical 
atherosclerosis compared with conventional lipid measures in the 
prediction models with risk factors of the Framingham risk score69. 
 
CLAIMS 
1. An in vitro method for the characterization of lipoproteins in a 
sample, comprising the following steps: 
 - obtaining a 2D diffusion-ordered 1H-NMR spectrum of 
the sample; 
 - performing a surface fitting of a portion of the spectrum 
corresponding to the methyl signal using a plurality of model functions, 
each model function corresponding to a given particle size associated to 
a lipoprotein fraction and subclass and including at least one model 
parameter to be estimated during the fitting, the estimated model 
parameters being the set of model parameters for which the difference 
between the NMR signal and the model signal built as a linear 
combination of the model functions is minimized, and  
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 - identifying the lipoproteins present in the sample as 
those associated to the model functions contributing to the theoretical 
model signal resulting from the fitting, 
wherein each model function is a triplet of lorentzian functions 
having the form: 
 !"#$%& = ()!%*&+",*(ℎ/, 1 − 13, 4, 5) + ()!%*&+",*(ℎ8, 1, 4, 5)+ ()!%*&+",*(ℎ9, 1 + 13, 4, 5), 
where h(au), f(ppm), w(ppm), and D(cm2s-1) are, respectively, the 
intensity, chemical shift, width, and diffusion coefficient associated to a 
lipoprotein particle size, wherein the model parameters to be 
determined for each lipoprotein particle size are one or several from: 
1, 13, ℎ/, ℎ8, ℎ9, 4 and D,  
wherein for each model function: 
ℎ/ = E · ℎ8, with  /G  ≤ E ≤ 9G , and 
ℎ9 = I · ℎ8, with  /G  ≤ I ≤ 9G, 
wherein the surface fitting is performed fixing at least one model 
parameter and using at least one other model parameter as a free 
parameter to be determined in the surface fitting, and 
wherein the fixed model parameters are determined based on 
the lipoprotein particle size and on regression models, the regression 
models relating pairs of fixed model parameters and/or a model 
parameter and the lipoprotein particle size.  
2. The in vitro method according to claim 1, wherein the triplets 
of lorentzian functions have the form: 
 !"#$%& = ()!%*&+",*(ℎ/, 1 − 13, 4, 5) + ()!%*&+",*(ℎ8, 1, 4, 5)+ ()!%*&+",*(ℎ/, 1 + 13, 4, 5) 
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3. The in vitro method according to any of the previous claims, 
wherein  
ℎ/ = KD8 , and/or 13 = 0.01 ppm. 
4. The in vitro method according to any of the previous claims, 
wherein the lipoprotein particle sizes are defined based on NMR, HPLC, 
Gradient Gel Electrophoresis or Atomic Force Microscope experiments. 
5. The in vitro method according to any of the previous claims, 
wherein at least one of the chemical shifts, width, and diffusion 
coefficient is fixed and at least the signal intensity of the central 
lorentzian (ℎ8) is used as a free parameter. 
6. The in vitro method according to any of the previous claims, 
wherein the regression models used are obtained from the 
deconvolution of the methyl signal of a plurality of NMR spectra using a 
plurality of model lorentzian functions with the intensity, chemical shift, 
width, and diffusion coefficient being free model parameters estimated 
to minimize the difference between the NMR methyl signal and the 
model signal built as a linear combination of the model functions, the 
regression models respectively relating at least (i) the chemical shift and 
the lipoprotein particle size, and/or (ii) the width and the lipoprotein 
particle size.  
7. The in vitro method according to any of claims 1 to 5, wherein 
the regression models relating pairs of model parameters and/or a 
model parameter and the lipoprotein particle size are built according to 
the following steps: 
- obtaining a 2D diffusion-ordered 1H-NMR spectrum for a plurality of 
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samples; 
- for each sample, performing a surface fitting of a portion of the 
spectrum corresponding to the methyl signal using a plurality of 
model functions, each model function being dependent on the 
model parameters to be fixed, wherein all the model parameters to 
be fixed are estimated during the surface fitting as the set of model 
parameters for which the difference between the NMR signal and 
the model signal built as a linear combination of the model functions 
is minimized, and 
- using the model parameters estimated in the previous step to build 
regression models relating pairs of model parameters and/or a 
model parameter and the lipoprotein particle size, 
wherein the model functions used are preferably lorentzian 
function triplets of the form: 
 !"#$%&' = ()!%*&+",*-ℎ/', 1' − 13', 4' , 5'6
+ ()!%*&+",*-ℎ8' , 1' , 4' , 5'6
+ ()!%*&+",*-ℎ9' , 1' + 13', 4' , 5'6. 
8. The in vitro method according to any of the previous claims, 
wherein the plurality of samples used to build the regression models 
comprise at least 100 samples and a percentage of at least 9% of the 
samples corresponds to individuals having a profile of diabetes mellitus and 
at least 25% of these patients having a profile of atherogenic dyslipidaemia.  
9. The in vitro method according to any of the previous claims, 
wherein the diffusion coefficient of the model functions is estimated from 
the lipoprotein particle size by means of the Einstein Stokes equation  
5 = Q 6ShUV 
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with k (J K-1) being Boltzmann constant, T (K) temperature, η (Pa 
s) viscosity and RH (Å) the lipoprotein particle size. 
10. The in vitro method according to any of the previous claims, the 
method further including correcting the estimated diffusion coefficients to 
take into account dilution effects, based on a relation between the NMR 
area and the diffusion coefficient obtained for several dilutions of a sample 
wherein the sum of the concentration of total cholesterol and triglycerides 
of said sample is higher than 300 mg/dL. 
11. The in vitro method according to any of the previous claims, 
further comprising determining one or more of: average size of 
lipoprotein particle fractions, average size of lipoprotein particle 
subclasses, fraction and/or subclass lipoprotein particle concentration, 
lipid concentration of at least one lipoprotein particle fraction and/or 
lipid concentration of at least one lipoprotein particle subclass. 
12. The in vitro method according to claim 11, wherein the 
average particle size of a lipoprotein particle fraction is determined as: 
^"+% (Å) = ∑ U' ∗ ab'c'd/∑ ab'c'd/ , 
n being the number of lipoprotein particle subclasses included in 
the lipoprotein particle fraction, R(Å) being the lipoprotein particle size 
and PNj being the particle number for said lipoprotein particle size, 
wherein the particle number (PN) for a lipoprotein j is determined as: 
ab' ∝ W'U'9 
with A(au) being the area associated to each model function. 
13. The in vitro method according to any of the previous claims, 
wherein the area associated to a lipoprotein model function is corrected 
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to consider only the contribution of the lipids included in the lipoprotein 
particle core. 
14. The in vitro method according claim 13 wherein the 
corrected area (A’) is determined using the following expression: 
W’ = W · (9 · (U − Z)9)[(9 · (U − Z)9) + 6 · # · (U9 − (U − Z)9)]  
with A (au) and R(Å) being respectively the area and lipoprotein 
particle size associated to each model function, s(Å) being the 
lipoprotein particle shell thickness and p being the ratio of protein mass 
in the shell of the particle relative to the total mass in the particle shell.  
 
Table 1. Summary of lipoprotein parameters using the method of the 
invention. 
  Subject 1 Subject 2 Subject 3 
Lipids (mg/dL) VLDL-TG 13.7 22.6 150.3 
 LDL-C 105.4 161.8 127.0 
 LDL-TG 14.9 20.9 18.4 
 HDL-C 66.5 49.5 34.4 
 HDL-TG 7.1 6.6 11.0 
Particle Concentration* VLDL-P 12.4 22.0 106.3 
 Large VLDL-P 0.2 0.3 5.9 
 Medium VLDL-P 1.0 1.9 21.6 
 Small VLDL-P 11.1 19.7 78.8 
 LDL-P 980.6 1399.1 1230.4 
 Large LDL-P 80.0 184.3 23.7 
 Medium LDL-P 212.4 406.8 310.5 
 Small LDL-P 688.2 808.0 896.1 
 HDL-P 32.2 27.1 25.9 
 Large HDL-P 2.4 1.3 0.3 
 Medium HDL-P 10.0 6.8 3.6 
 Small HDL-P 19.8 19.0 22.0 
Size (nm) VLDL 39.0 38.9 42.2 
 LDL 19.7 20.1 19.5 
 HDL 8.2 8.0 7.8 
*VLDL/LDL: nmol/L; HDL: µmol/L 
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2.3.2 Industrial Development  
As it was mentioned before in the introduction of this section, 
the research group in which the technology was developed was part of 
the Metabolomic Platform (MP), a joint research facility created by URV, 
CIBERDEM and also partners with the IISPV, whose main goal is to offer 
metabolomic services to the biomedical and clinical research groups 
from CIBERDEM and URV. However, the specific industrial development 
of the Liposcale test which includes an optimization of the production 
process and the creation of the proper regulatory environment for 
clinical applications necessary to introduce a competitive test in the 
market was outside of the scope of the MP.  
As a consequence, Biosfer Teslab was created as an independent 
institution to carry out these tasks. Since its creation, Biosfer has 
worked to provide analytical services to study, diagnose and treat 
alterations in lipid metabolism and its associated cardiovascular risk. 
The aim of the company is to become the European benchmark for 
biofluid analysis, by using high performance technologies that allow 
clinicians to provide better tools for diagnosis and treatment of 
metabolic diseases. 
The company's strategy in the medium to long term is based on a 
constant commitment to biomedical research through collaboration 
with different groups and scientific societies at international level and 
participation in different clinical studies, to favor the company’s position 
over potential competitors by distinguishing it with the technological 
know-how in the field of advanced nuclear magnetic resonance tests. 
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To consolidate the strategy, the company initially wagers on a 
mixed business model in which alliances are generated with research 
centres equipped with NMR spectrometers, allowing Biosfer to act as a 
clinical analysis laboratory in both a research and a clinical environment. 
This first stage of market development precedes the association, via the 
licensing of the technology, with specialized laboratories with the 
necessary analytical capacity to deal with large volumes of samples once 
the market has matured. 
In this regard, Biosfer Teslab is currently partner to different 
agreements of clinical and scientific collaboration: with the Spanish 
Nephrology Society and with the Spanish Arteriosclerosis Society to 
generate the scientific-based on evidences to facilitate the introduction 
of the ALT tests to the clinic; and with the Institute of Health Research 
(INCLIVA) and the Principe Felipe Research Institute (CIPF) of Valencia, 
the Andalusian Center for Nomedicine and biotechnology (BIONAND) 
and The  Institute of Physical Chemistry "Rocasolano" (IQFR-CSIC); 
excellence centres for 1H-NMR spectroscopy, with the objective to 
ensure the production capability enabling alternatives NMR facilities.  
Therefore, the cross-validation procedures between laboratories 
for the use of the spectrometers of these institutes for the application 
of the Liposcale test are being successfully developed (See figure below). 
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Figure 1. NMR Cross-validation for Liposcale application. The Figure 
illustrates the status of the cross-validation processes with the different 
centres, spectrometers and dilution protocols. 
As previously said, Biosfer Teslab obtained the advanced 
lipoprotein test based on two-dimensional NMR spectrum for the 
clinical study of lipoproteins created in a pure research framework. To 
adapt the Liposcale test to the needs of the market in terms of 
versatility and price, the company opts for a process of constant 
optimization that began with the migration of the software used in its 
creation (MATLAB) to the free software Phyton. This migration ensured 
the possibility to integrate all the programming routines in a closed and 
automatized software, reduced the computational time and, at the 
same time, diminished dramatically the production costs, since Python 
is a free open source platform. 
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On the other hand, part of the industrial development was 
focused on the scaling process to be able to operate in several NMR 
spectrometers, with different field strength and brands. This step 
guarantees the possibility to collaborate with different laboratories as 
the spectrometers specifications are different in each center. 
Complementary, the sample volume needed to perform the test 
has been reduced from 450 to 100 µL to be able to analyze cohorts in 
which the available volume is limited, as in the case of large cohorts or 
samples from animal models for future commercialization of lipoprotein 
profile in the pre-clinical field studies.  
The following diagram illustrate part of these processes:  
 
Figure 2. Industrial development process. 
During the course of 2015, Biosfer obtained ISO 9001 quality 
certification for the development of in-vitro diagnostic tests and 
advanced NMR analysis services in the field of biomedical research. It 
has also overcome regulatory barriers to achieve the CE certification for 
the current Liposcale lipoprotein test and approval by the Spanish 
Agency of Medicine and Medical Devices (AEMPS) for the manufacture 
of the Liposcale software (2016). The company is also in the process of 
obtaining laboratory authorization for clinical analysis from the 
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Government of Catalonia, and it is expected to be forthcoming in the 
first quarter of 2018 as illustrated below: 
 
Figure 3. Main milestones reached since 2014. 
To be able to execute the industrial development of the Liposcale 
test, as well as to open lines of research for the glycoproteins, low 
molecular weight metabolites (LMWM) and lipidomic characterization by 
using NMR technology that complement it, the company has received 
several public competitive aids detailed in the following figure: 
 
Figure 4. Research lines of Biosfer Teslab. 
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In short, the development of new advanced tests will involve the 
commercialization of new systems for the evaluation of cardiovascular 
problems using a technology (NMR) which is currently not used in this 
field and which represents significant improvements in the results, 
compared to the existing tests on the current market. The development 
of these tests therefore will suppose a qualitative leap for Biosfer that 
will position the company among the leaders in the fields of biofluid 
analysis by high performance technologies, since once the signals 
obtained by NMR are characterized, the tests will combine this 
information with classical values to predict major vascular complications 
such as subclinical atherosclerosis, arterial stiffness, insulin resistance 
and the clinical status of patients. 
Health care system does not offer currently any similar services 
since advanced tests are not included in any clinical guide at national 
level and clinical analyses carried out to evaluate the cardiovascular risk 
include only a basic lipid profile of cholesterol and triglycerides. By 
contrast, American and Canadian endocrinology guidelines are opening 
the door to the incorporation of advanced resonance-based tests, such 
as advanced lipoprotein tests, to include the concentration of LDL 
particles below a limit as a therapeutic target, a parameter obtained 
from tests based on NMR. 
Company’s consolidation will be effective from the time it enters 
the clinical market by licensing of the technology to specialized 
laboratories. To this end, the company is wagering on participation in 
different clinical studies to generate scientific evidence, product 
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attributes for different clinical applications and dissemination to the national 
and international clinical community with the current characterization of 
lipoproteins, as well as complementing the current lipoprotein test with 
other metabolites to be distinguished from the competition. 
 
2.3.3 Clinical applications developed by Biosfer Teslab  
With the ultimate goal of basic research being moved to clinical 
practice, the Biosfer team has promoted scientific-based research studies in 
order to generate more clinical evidence in collaboration with other entities. 
The advanced lipoprotein test, together with the complete molecular 
profiling in which Biosfer is currently working on (i.e. the glycoprotein, the 
low molecular weight metabolite and the lipidic extract characterization by 
NMR), has been applied in different fields of application in a collaborative 
framework, being the PhD candidate an active part of the research groups. 
The following table summarizes these specific collaborations: 
 
Table 1. Research collaboration studies in which the Liposcale test has 
been applied. 
 
Institution Field Liposcale GLYC LMWM Extracts Congresses Articles 
2014 HUJXXIII Head and neck cancer   
     
 
CLINIC DM2   
    
70,71 
2015 HSCSP Nutritional intervention   
     
 
Carlos Haya Obesity   
    
72 
 
HUSJ Preservation studies   
     
 
Carlos Haya LALD   
     
 
VHIR Postprandial response   
 
  
   
 
NC University Nutritional intervention   
    
73,74 
 
HUJXXIII VIH   
     
 
HUJXXIII DM1   
     
 
HUSJ  PCSK9   
    
75,76 
 
INCLIVA CVD 
      
 
HUSJ DM2 – arteriosclerosis   
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HUSJ FAB4   
    
77 
2016 Carlos Haya Obesity   
     
 
VHIR Parkinson   
     
 
VHIR Autoimmune disease     
    
 
HUGTP DM2   
     
 
HUSJ Pneumonia   
     
 
HUSJ Lupus   
     
 
HUJXXIII VIH       
   
 
HUSJ FH kids     
    
 
HUSJ FH adults     
    
 
HUSJ Physiotherapy    
     
 
HUSJ Sudden deafness   
     
 
HUSJ Rheumatoid Arthritis     
    
 
URV NMR T2  
  
  
  
78 
 
HUJXXIII Nephropathy     
    
 
URV Nutritional interventions 
   
  
  
 
Carlos Haya LALD 
      2017 UCM Postprandial response     
 
  
  
 
VHIR Postprandial response 
      
 
CLINIC Fetal development     
    
 
HUSJ Cardiology 
      
 
CLINIC Nutritional Interventions 
      
 
IPM Psychosis     
    
       
Completed Pending 
 
Finally, with the objective to facilitate the clinical interpretation 
of the results of the advanced lipoprotein test and the correct 
evaluation of the patients, we have developed an intuitive clinical report 
that includes the new concept of Lipidic Contour. 
The heterogeneity of the set of variables that contributes to the 
atherosclerotic processes makes the evaluation of the individual risk of 
cardiovascular disease difficult, not only for the complexity involved in 
working with an elevated number of parameters, but also for the 
interaction between them. 
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In this way, the Lipidic Contour was developed to summarize 
complete set of the lipoprotein variables obtained by using DOSY-NMR in 
relation to developing cardiovascular disease in the future. 
The following figure exemplifies the previous concept (considering 
only lipoprotein profile parameters that are clearly associated with 
atherosclerotic processes): the arterial contour represents the patient’s 
profile (orange contour) with respect to mean values from a general 
population, represented by a black circle. The area defined by the patient’s 
arterial contour decreases when its profile is associated with higher 
cardiovascular risk (i.e. values higher than the reference population’s mean 
for VLDL-C, VLDL-TG, VLDL-P, LDL-C, LDL-TG, S-LDL-P, HDL-TG variables; or 
lower than reference population’s mean for LDL-Z, HDL-Z and M-HDL-P 
variables). Variables contributing to a decrease in the arterial contour area 
are marked in red, while variables that contribute to an increase in the 
arterial contour area are marked in green. Variables whose values are close 
to the reference population’s mean appear in yellow.  
 
Figure 5. Example of a Lipidic Contour. 
LDL Cholesterol (LDL-C) 
LDL Triglycerides (LDL-TG) 
Small LDL particles (S-LDL-P) 
LDL particle size (LDL-Ø) 
HDL Cholesterol (HDL-C) 
HDL Triglycerides (HDL-TG) 
Medium HDL particles (M-HDL-P) 
HDL particle size (HDL-Ø) 
VLDL Cholesterol (VLDL-C) 
VLDL Triglycerides (VLDL-TG) 
VLDL particles (VLDL-P) 
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In this section, we present the results of an intervention trial 
designed to evaluate quantitative and qualitative effects of niacin and 
fenofibrate on the HDL fraction in patients with type 2 diabetes. These 
results include the following two original research articles:  
· Amigó, N., Mallol, R., Heras, M., Martínez-Hervás, S., Blanco 
Vaca, F., Escolà-Gil, J. C., Plana, N., Yanes, O., Masana, L. & 
Correig, X. (2016). Lipoprotein hydrophobic core lipids are 
partially extruded to surface in smaller HDL: “Herniated” HDL, a 
common feature in diabetes. Scientific Reports, 6, 19249.  
https://doi.org/10.1038/srep19249 
· Masana, L., Cabré, A., Heras, M., Amigó, N., Correig, X., Martínez-
Hervás, S., Real, J. T., Ascaso, J. F., Quesada, H., Julve, J., Palomer, 
X., Vázquez-Carrera, M., Girona, J., Plana, N. & Blanco-Vaca, F. 
(2015). Remarkable quantitative and qualitative differences in 
HDL after niacin or fenofibrate therapy in type 2 diabetic 
patients. Atherosclerosis, 238(2).  
https://doi.org/10.1016/j.atherosclerosis.2014.12.006 
Both works include the HDL fraction analysis by NMR spectroscopy 
in the framework of a prospective, randomized controlled intervention 
trial entitled LOWHDL: Characterization of High Density Lipoprotein 
(HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment 
(NCT02153879), sponsored by the IISPV and lead by Professor Lluís 
Masana.  
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3.2.1 Abstract  
Recent studies have shown that pharmacological increases in HDL 
cholesterol concentrations do not necessarily translate into clinical 
benefits for patients, raising concerns about its predictive value for 
cardiovascular events. Here we hypothesize that the size-modulated 
lipid distribution within HDL particles is compromised in metabolic 
disorders that have abnormal HDL particle sizes, such as type 2 diabetes 
mellitus (DM2). By using NMR spectroscopy combined with a 
biochemical volumetric model we determined the size and spatial lipid 
distribution of HDL subclasses in a cohort of 26 controls and 29 DM2 
patients before and after two drug treatments, one with niacin plus 
laropiprant and another with fenofibrate as an add-on to simvastatin. 
We further characterized the HDL surface properties using atomic force 
microscopy and fluorescent probes to show an abnormal lipid 
distribution within smaller HDL particles, a subclass particularly enriched 
in the DM2 patients. The reduction in the size, force cholesterol esters 
and triglycerides to emerge from the HDL core to the surface, making 
the outer surface of HDL more hydrophobic. Interestingly, 
pharmacological interventions had no effect on this undesired 
configuration, which may explain the lack of clinical benefits in DM2 
subjects. 
3.2.2 Introduction 
The International Diabetes Federation recently announced that, 
prior to 2014, over 387 million people had been diagnosed with 
diabetes1. Type 2 diabetes mellitus (DM2) accounts for at least 90% of 
the cases of diabetes and it is increasing every year due to genetic 
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factors and changes in lifestyle. A typical feature of DM2 – as well as 
obesity, insulin resistance and the metabolic syndrome – is atherogenic 
dyslipidemia, which has emerged as an important risk factor for 
cardiovascular disease (CVD)2. Atherogenic dyslipidemia consists of a 
triad of increased blood concentrations of small and cholesterol-
depleted low-density lipoprotein (LDL) particles, decreased high-density 
lipoprotein cholesterol (HDL-C) and increased total triglycerides. It 
should be noted that it has become established therapeutic practice to 
increase HDL-C concentrations to decrease cardiovascular risk. 
However, despite the strong inverse association of HDL-C plasma levels 
with coronary heart disease found in epidemiological studies3,4, recent 
evidence has raised serious concerns about the ability of HDL-C 
concentration to assess cardiovascular risk and, hence, whether it 
should be a good target for therapeutic interventions5,6. Indeed, several 
recent clinical trials involving therapeutic elevation of HDL-C were 
prematurely terminated on the basis of futility7-9.  
Recent structure-function studies have suggested that HDL-C is not 
such a good marker of cardiovascular risk because HDL concentration 
does not always reflect HDL function9-11. In some circumstances the 
potentially protective functions of HDL may be compromised despite 
high concentrations of HDL-C 12. This highlights the need to characterize 
lipoprotein particles using a range of additional parameters such as size, 
particle number and chemical composition13, which is expected to 
improve the assessment of CVD risk and guide lipid-lowering 
therapies14.  
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In this context, the structure of lipoproteins has been inferred to 
date from compositional analyses using the classical theoretical 
description of Shen and colleagues15, by which the structure of 
circulating lipoproteins is consistent with a spherical model of radius r in 
which a spherical liquid core of cholesterol esters and triglycerides is 
surrounded by a monolayer of free cholesterol and phospholipids, with 
proteins closely packed with the hydrophilic head groups of 
phospholipids on the outer surface of the particle. On the basis of an 
updated version of the spherical model proposed by Shen et al. and 
experimental data on HDL by 1H-NMR spectroscopy, the theoretical size 
of HDL particles has been estimated and a positive correlation found 
with the HDL-C/ApoA-I ratio16. In this regard, the emergence of 
experimental techniques mainly based on NMR spectroscopy makes it 
possible to characterize the size and particle number of lipoprotein 
particles16,17. This opens up a new scenario for studying lipoprotein 
structure and function. Specific HDL sizes (i.e., subclasses) and, in 
particular, the balance between large and small HDL particles seems to 
be important for evaluating cardiovascular risk13. Recent studies suggest 
that HDL particle number (HDL-P) may be a more suitable and 
independent risk factor than HDL-C18,19 or a combination of both 
parameters, HDL-C/HDL-P, can determine the antiatherogenic function 
of HDLs, rather than either parameter alone20.  
Yet despite these advances, if HDL particle size and number are to 
be used in clinical practice for cardiovascular risk management, the 
ability of existing techniques to estimate consistent HDL size, 
concentration and lipid content needs to be evaluated. Interestingly, the 
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development of these novel techniques has revealed that there is a 
discrepancy between the absolute values of HDL-P obtained by NMR 
and the values generated using the classical model of spherical 
lipoprotein structures proposed by Shen15. In particular, determination 
of HDL-P by NMR gives higher particle numbers than simulations based 
on the Shen model16. This discrepancy between experimental and 
theoretical data has led to modifications being made to the classical 
Shen model21,22. However, none of these studies have investigated the 
clinical implications of changes in the HDL structure.  
Our study aims to gain greater insight into how some of the 
aforementioned HDL parameters are related (for example, the mean 
HDL size and the HDL subclass distribution), and how these parameters 
are affected by the lipid and protein concentrations in the healthy and 
the DM2 pathological state with atherogenic dyslipidemia. For this 
purpose, we used classical biochemical enzymatic techniques and 
advanced 1H-NMR spectroscopy, atomic force microscopy (AFM) and 
fluorescence experiments to model the HDL structure and to 
characterize the size, and the molecular composition and distribution of 
the HDL fraction. We also determined the balance between the three 
main HDL subclasses – namely, large, medium and small HDL – and 
characterized the differences in surface hydrophobicity between them. 
Finally, we performed the same analysis on the DM2 group after two 
pharmacological interventions with fenofibrate and niacin, respectively. 
3.2.3 Results 
HDL fraction analysis: from the biochemical composition and size of 
HDL fractions to the modification of the Shen model 
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The biochemical information of the HDL fractions determined by 
enzymatic assays is described in Table 1. As expected for DM2 patients, 
with the characteristic feature of low HDL cholesterol, all the HDL 
constituent molecules were significantly lower for the DM2 group than 
for the CT group, except triglycerides that were significantly higher. 
Figure 1 illustrates the differences between the mean radius of the HDL 
fractions obtained from DOSY 1H-NMR data (RN) and the mean radius 
derived from the Shen model (RS) for the CT group and the DM2 
patients (see Section 1, SI). We observed that in both groups, RS were 
higher than expected for the mean size of the HDL fractions.  
Table 1. HDL biochemical composition (mg / dl) of CT population and 
DM2 patients.  
 
 CT (26) DM2 (29) p 
T
G  
11.1 [10.2 12.9] 13.1 [11.1 16.9] 0.0
12 
E
C 
28.5 [21.3 32.3] 17.8 [14.6 22.1] <0.
001 
F
C  
10.0 [8.5 12.2] 8.2 [6.2 9.5] 0.0
03 
P
L  
59.7 [49.1 68.9] 45.0 [41.6 50.1] 0.0
02 
P
rot  
113.0 [97.8 127.8] 98.5 [87.0 105.0] 0.0
07 
 
Data are expressed as median ± 25-75. TG: triglycerides, EC: esterified cholesterol, FC: 
free cholesterol, PL: phospholipids, Prot: protein. 
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Figure 1. Differences between the mean HDL radius measured by NMR 
and estimated by the Shen model. The figure illustrates the differences 
between the mean radius obtained from NMR data and the radius 
derived from the Shen model for the CT group (n=26) and the DM2 
patients (n=29). 
 
Considering all the samples together, the mean radius measured by 
NMR was 4.6 [4.4-4.7] nm –expressed as median ± [25-75] – which is 
consistent with previously reported HDL mean sizes considering the 
relative abundances of large, medium and small HDL particles 19,23,24. On 
the other hand, the derived mean radius from the Shen model (see 
Materials and Methods Eq. 2) was 5.0 [4.8-5.1] nm in concordance to a 
distribution of HDL particles centred on large HDL particles. The p value 
between the RN and RS distributions was p<0.001.  
To solve the discrepancies between the biochemical composition 
and the experimental sizes, we newly modified the Shen model, 
increasing the geometrical ratio between surface volume (VShell) and 
core volume (VCore) to obtain a better agreement between the 
biochemical composition and the experimental size, on the basis that 
smaller particles have a higher VShell / VCore than larger particles. This 
modification led to some of the traditionally core lipids were located in 
the lipoprotein shell (see Materials and Methods). Table 2 reports the 
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main parameters obtained when our modified Shen model was used to 
analyse the HDL fractions. In agreement with current knowledge about 
lipoprotein disorders in DM2 patients, we found that the mean radius 
for the CT group determined by NMR was higher than for the DM2 
group (4.7 nm and 4.5 nm, respectively) (p=0.002). Interestingly, our 
modified model detected the presence of hydrophobic core lipids in the 
lipoprotein shell. The percentage of hydrophobic core lipids, basically 
esterified cholesterol (EC) and triglycerides (TG), occupying the external 
shell was 12% for the CT group, significantly less than the 20% found for 
the DM2 group (p=0.016). This redistribution of the core lipids meant 
that 3% and 6% of the volume of the external shell was occupied by 
hydrophobic lipids in the CT and the DM2 groups, respectively 
(p=0.011). In addition, the lipidic core composition was quite different: 
the percentage of the inner core occupied by TG was 30% for the CT 
group, much less than the 43% for the DM2 group (p<0.001). 
 
Table 2. HDL size and HDL lipid distribution between CT population and 
DM2 patients.  
  CT (n=26) DM2 (n=29) P 
Radius (nm) 4.7 [4.6 4.8] 4.5 [4.4 4.6] 0.002 
% Core lipids in the surface  12 [0 20] 20 [13 27] 0.016 
Relative Volume (%)     
Surface volume     
Core lipids 3 [0 6] 6 [4 7] 0.011 
Prot 53 [51 56] 54 [51 56] 0.679 
PL 37 [34 39] 34 [31 37] 0.022 
FC 7 [6 8] 6 [5 7] 0.010 
Internal core     
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TG 30 [26 37] 43 [36 48] <0.0001 
EC 70 [63 74] 57 [52 64] <0.0001 
The table shows the mean HDL radius for the CT and the DM2 groups, the percentage 
(%) of the traditional core lipids (CL) located in the surface shell, and the percentage 
(%) of the surface volume occupied by the CL, the protein, the phospholipids and the 
free cholesterol; and the percentage (%) of the inner core volume occupied by the 
triglycerides and cholesterol. All the results are expressed as medians ± 25-75. Prot: 
protein, PL: phospholipids, FC: free cholesterol, TG: triglycerides, EC: esterified 
cholesterol. 
 
The study design determined the plasma triglycerides levels of the 
DM2 subjects, and hence the HDL triglyceride levels, were significantly 
higher than those of the CT group. Independently, the mean size of the 
DM2 subjects was significantly reduced. Both conditions, high 
triglycerides and reduced size, were associated with a higher percentage 
of the core lipids in the surface, as these variables are correlated (see 
Section 2, SI, Figure S1 and Figure S2). In order to explore whether the 
redistribution of the core lipids in the surface was due to high TG or 
more specific reason for DM2, we analysed separately the association of 
the TG, the size and the percentage of core lipids in the surface for each 
group (see Section 2, SI, Fig S3). This analysis revealed a different 
behavior between the CT and the DM2 groups: while the levels of TG 
were highly associated with the percentage of the core lipids in the 
surface for the CT group (Pearson correlation coefficient r = 0.81) this 
association was lost for the DM2 group (r = 0.35). In the same direction, 
only the CT group presented a clear and inverse association between 
the size and the TG levels (see Section 2, SI, Fig S3). Therefore, the CT 
subjects with high TG levels presented a smaller size and, therefore, an 
increased percentage of core lipids in the surface. Alternatively, the 
levels of TG in the DM2 group were not associated with the size; being 
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possible to find subjects with low TG levels, and a reduced size, 
presenting a high percentage of hydrophobic core lipids in the surface. 
DM2, thus, was a clinical factor that emphasized the percentage of the 
core lipids in the surface independently of the TG levels.  
The above results indicate differences in the composition and 
location of the hydrophobic lipids in the surface shell. The leakage of the 
hydrophobic lipids TG and EC to the surface may contribute to the 
change in polarity of the HDL surface and, in particular, the DM2 group 
should have a more hydrophobic HDL surface than the CT group. In 
order to verify the hypothesis that some of the core lipids are located in 
the surface shell, we carried out some fluorescence experiments to 
evaluate the surface polarity of lipoproteins. The fluorescent membrane 
probes are highly sensitive to the polarity of lipid membranes and lipid 
monolayers. We investigated the surface polarity of a subgroup of 8 CT 
subjects and 4 DM2 patients with three different membrane probes: 
Patman, Prodan and Laurdan. It has been widely reported that the 
fluorescence spectrum of these three probes in lipid membranes and in 
native lipoproteins and lipoprotein models is highly affected by the 
polarity of the microenvironment: a more hydrophobic 
microenvironment produces a blue shift of the emission maximum 
position 25-27. 
The fluorescence spectra of all three probes showed the same 
tendency: the wavelengths of the emission maxima (λem) of the DM2 
group were blue shifted, indicating that the surface microenvironment 
was more hydrophobic than in the CT group (see Section 3, SI Figure S4). 
The Prodan probe exhibited the clearest and best defined spectra, 
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which made it possible to quantify the different behaviour between 
groups. The emission wavelength was λem = 436.1 nm for the CT group 
and λem = 434.1 nm for the DM2 group, (p = 0.02). To evaluate the 
dispersion of the measurements and facilitate the visualization of the 
differences between the CT and the DM2 group, we performed a 
principal component analysis (PCA) of the fluorescence raw data of two 
repetitions per sample (see Section 3, SI Figure S5). 
 
Application of the modified Shen model to the study of the HDL 
subclasses 
To further study the HDL fraction, we extended our modified Shen 
model to the three major HDL subclasses. We used the methylene signal 
of 1D diffusion-edited NMR spectra (LED) to obtain a qualitative picture 
of the distribution of particles in the three HDL subclasses (large, 
medium and small) which contain methylene groups in the constituting 
HDL molecules. The frequency at which the methylene groups of the 
lipids in lipoprotein particles resonate depends on the size of the 
particles that carry them. Larger particles resonate at higher 
frequencies28. We deconvoluted the methylene signal with a lorentzian 
curve for each of the three major HDL subclasses (see Materials and 
Methods) to mathematically reproduce the raw NMR data and compute 
the peak area of the methylene signal. Because the NMR peak areas are 
proportional to the concentration of molecules in solution, the area 
below each lorentzian curve of the methylene peak is proportional to 
the concentration of the methylene groups present in the cholesterol 
and triglyceride molecules carried by each HDL subclass and, hence, 
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proportional to the HDL particles of each subclass. Figure 2 shows that 
the CT group presented a higher percentage of the medium HDL particle 
subclass, than the DM2 group (41% and 34%, respectively) (p=0.014). In 
contrast, the CT group presented a lower percentage of the small HDL 
subclass (42%) than the DM2 group (51%) (p=0.041). The previous 
analysis of the mean sizes of the HDL fraction supported this 
distribution. 
 
Figure 2. Balance between large, medium and small HDL subclasses of 
CT population and DM2 patients. a) The figure illustrates the average of 
the normalised NMR spectra and the means of the three lorentzian 
functions for the CT group (n=26) and the DM2 patients (n=29). The area 
under each curve represents the relative concentration of a particular 
subclass. b) % of integrated area. Data are expressed as medians ± 25-
75. 
 
Since no data were available on the biochemical composition and 
size for each subclass, we used the sizes and the concentrations of the 
molecules constituting each HDL subclasses described in the literature 
for healthy subjects23,29-32. We associated the large HDL subclass to HDL 
2b, the medium HDL subclass to HDL 2a and the small HDL subclass to 
HDL 333,34. The reported particle sizes were 6 nm, 5 nm and 4 nm for 
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large, medium and small HDL respectively, and the molecular 
composition of each subclass is detailed in Table S1 (see Section 4, SI).   
Once the biochemical composition and size had been assigned, our 
modified model was applied to each subclass. As shown in Figure 3, our 
findings revealed that the small HDL subclass is much more affected by 
the space restrictions than the large or medium HDL subclasses. This has 
an effect on the proportion of core lipids in their surface shell. The 
resulting percentage of hydrophobic lipids increases as the size 
decreases: from 3% in the case of large HDL particles and 15% for the 
medium-sized particles, up to 56% for the smallest particles. 
Figure 3. Structural model for different subclasses of HDL particles. The 
figure shows the differences in the amounts of core lipids located in the 
2 nm shell depending on the lipoprotein size. 
 
The mathematical models indicated that there were different 
amounts of hydrophobic lipids in the different HDL subclasses. We used 
Atomic Force Microscopy (AFM) to prove whether the surface polarity 
of lipoproteins depended on size. The size and the hydrophobicity of the 
HDL surface was qualitatively characterized as the adhesion force 
between the tip of the AFM probe (basically hydrophilic) and the 
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lipoprotein surface depends on the hydrophobic or hydrophilic nature of 
the sensed surface 35,36.  
Just as the model did, the AFM experiments showed that smaller 
particles had a more hydrophobic surface. We analyzed three different 
samples, and they all presented the same tendency: the adhesion force 
between the hydrophilic tip and the HDL surface was higher for large 
particles, indicating a more hydrophilic environment. The relation 
between the size and the adhesion force is represented in Figure S6 (see 
Section 5, SI). For the three samples, the correlation coefficients were 
0.34, 0.52 and 0.36 respectively (p values 0.23, 0.01 and 0.19), revealing 
that as larger the particles were, they presented more hydrophilic surface 
(see Section 5, SI, Figure S7). These qualitative results reinforce the 
hypothesis that hydrophobic lipids in small particles rise to the surface.  
 
Characterization of the HDL fraction of DM2 subjects after 
fenofibrate and niacin treatments 
 Finally, we characterized the HDL fraction of the DM2 group 
using two different, commonly used treatments with fenofibrate and 
niacin. As in the case above, we first used our modified Shen model to 
measure the lipid and protein concentrations (see Table 3) and the 
mean HDL size and obtain the fraction of the core lipids located in the 
external shell. Independently, we determined the HDL distribution in 
the large, medium and small subclasses by NMR.  
Table 3. Treatment effects on the HDL biochemical composition (mg/dl) 
of DM2 patients.  
 DM2 FF p1 Ni p2 p3 
TG 13.3 [11.4 17.4] 12.9 [10.0 16.7] 0.149 13.3 [11.4 16.2] 0.192 0.702 
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EC 17.5 [14.6 22.1] 15.5 [13.7 22.0] 0.903 18.7 [14.5 25.3] 0.159 0.050 
FC 8.5 [7.2 9.5] 6.9 [5.6 8.7] 0.027 7.9 [6.0 10.5] 0.931 0.023 
PL 48.1 [42.8 51.9] 41.2 [37.6 53.6] 0.079 40.4 [31.6 56.0] 0.375 0.513 
Prot 99.0 [86.8 112.0] 103.0 [81.8 114.5] 0.867 101.0 [87.8 126.0] 0.651 0.366 
Data are expressed as medians ± 25-75 of the 24 DM2 subjects who finished both 
interventions. Comparative between the basal state and the post fenofibrate state (p1) 
and the post niacin state (p2); comparative between treatments (p3). FF: fenofibrate, 
Ni: niacin, TG: triglycerides, EC: esterified cholesterol, FC: free cholesterol, PL: 
phospholipids, Prot: protein. 
 
 Table 4 shows that neither of the treatments had any significant 
effect on the mean size and percentage (and the composition) of core 
lipids in the external shell, or the subclass distribution of the DM2 
group. However, the effects of the treatments were quite different: the 
fenofibrate treatment tended to decrease the mean HDL size and the 
niacin treatment tended to increase it, leading to a statistically 
significant change in size when both treatments were compared 
(p=0.042). 
Table 4. Treatment effects on the HDL size and HDL lipid distribution of 
DM2 patients.  
 DM2 FF p1 Ni p2 p3 
Radius (nm) 4.5 [4.4 4.6] 4.4 [4.4 4.7] 0.305 4.6 [4.3 4.7] 0.259 0.042 
% Core lipids in the 
surface 
20 [11 28] 22 [16 28] 0.578 15 [9 25] 0.532 0.484 
Relative (%) volume       
 Surface volume       
 Core lipids 5 [4 7] 5 [4 7] 0.958 4 [2 8] 0.689 0.881 
 Prot 53 [50 56] 55 [53 59] 0.205 56 [53 58] 0.170 0.958 
 PL 35 [33 37] 33 [29 37] 0.305 31 [29 38] 0.170 0.434 
 FC 6 [5 7] 5 [4 6] 0.140 6 [6 7] 0.434 0.159 
 Internal core       
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The table shows the treatment effects on the mean HDL radius, the percentage (%) of 
the traditional core lipids (CL) located in the surface shell, and the percentage (%) of 
the surface volume occupied by the CL, the protein, the phospholipids and the free 
cholesterol; and the percentage (%) of the inner core volume occupied by the 
triglycerides and cholesterol.  All the results are expressed as medians ± 25-75 of the 
24 DM2 subjects who finished both interventions. Comparative between the basal 
state and the post fenofibrate state (p1) and the post niacin state (p2); comparative 
between treatments (p3). FF: fenofibrate, Ni: niacin, Prot: protein, PL: phospholipids, 
FC: free cholesterol, TG: triglycerides, EC: esterified cholesterol. 
 
As far as mean size is concerned, Figure 4 shows that the fenofibrate 
treatment tended to increase the relative concentration of the small 
HDL subclass, and that the niacin treatment tended to increase the 
relative concentration of the medium HDL subclass. These different 
effects were statistically significant when both treatments were 
compared (p=0.015). 
 
 
Figure 4. Treatment effects on the balance between large, medium 
and small HDL subclasses of DM2 patients (% integrated area). Data 
are expressed as medians ± 25-75 of the 24 DM2 subjects who finished 
both interventions. FF: fenofibrate, Ni: niacin. 
 
 TG 43 [37 49] 40 [32 48] 0.434 40 [31 48] 0.205 0.217 
 EC 57 [51 63] 60 [52 68] 0.434 60 [52 69] 0.205 0.217 
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3.2.4 Discussion  
The current need to characterize HDL particles using a range of 
additional parameters such us size, particle number, subclass 
distribution and chemical composition increases since HDL-C does not 
always reflect HDL antiatherogenic function. Lipidomic and structural-
function approaches suggest that the alterations of the lipidome37 and 
the negatively charged enrichment of phospholipids38 in the smaller HDL 
subfraction play a crucial role for HDL dysfunctionality.  
Alternatively, the preceding analysis strongly supports the 
hypothesis that HDL functionality may be compromised in a pathological 
state such as DM2. Our results indicate that the HDL of a CT group is 
clearly different from that of a DM2 group, essentially due to the 
differences in HDL particle size and biochemical composition, and the 
implications for lipid relocation.  
A reduction in size has consequences for the lipid distribution of HDL 
particles: Lipoproteins are spheres with a shell thickness of 2 nm that 
define an inner core cavity with a fixed volume. Therefore molecules are 
subject to spatial restrictions. The smaller the particle is, the tighter 
those spatial restrictions are. Thus, providing a lesser volume for 
hydrophobic lipids to rely on. Since volume of a sphere is proportional 
to the third power of its radius, the core volume is extremely sensitive 
to small changes in the radii. Consequently, as the pathological group 
has a smaller size, this phenomenon is emphasized. 
To solve these spatial inconsistencies, we assumed that some of the 
lipids that are traditionally found inside the core (esterified cholesterol 
and triglycerides) have to rise to the lipoprotein surface for volumetric 
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reasons. Other modifications in the spherical model of lipoprotein 
structure have been reported previously: the spherical shape becomes 
more discoidal or cylindrical39, free cholesterol can be found in the inner 
core21,22, and proteins are closely packed on the outer surface of the 
particle15. All these three modifications increase the external shell 
volume and diminish the internal core volume. Consequently, the 
fraction of hydrophobic core lipids outside the lipoprotein shell also 
increases.  
One of the limitations of our model is to consider that the entire 
volume of the apolipoproteins fills the surface shell, independently of 
the curvature radius. Energy derived computational models studying the 
stability of lipoprotein structure identify that the penetration of the 
alpha helixes into the lipoprotein shell is modulated by the curvature 
radius, since they fill the space between the phospholipids head-
groups40,41. The penetration of the amphiphilic helix alpha into the 
lipoprotein shell get higher as the size of the particles get smaller and 
more apolipoproteins are required to fill the gaps between 
phospholipids head-groups. The size-modulated integration of the 
apolipoprotein into the shell in the model would underestimate the 
surface volume of the HDL particles even more, increasing the fraction 
of the hydrophobic core lipids in the surface.  
Another limitation of this study is to not consider the particular 
concentration and composition of the fatty acids (FA) chains 
constituting the TG and CE molecules. Also, hydrophobicity of TG is less 
than that of CE thus TG tends to be more readily exposed to the lipid-
water interface. Furthermore, the TG exposure to the surface is likely to 
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be dependent on its miscibility in the phospholipid monolayer42. For 
that reason, the concentration and, particularly, the composition of the 
FA chains, might have an effect on the whole surface polarity of the HDL 
particles. Therefore, the change on the hydrophobicity of the small HDL 
particles induced by the presence of the core lipids in the surface in the 
DM2 group may be slightly reduced due to the increased concentration 
of TG molecules in the HDL particles.  However, the modifications of the 
polarity due to the composition of the core lipids can be considered as a 
second order effect because CE is the major component for both, the CT 
and the DM2 group.  
Fluorescence studies supported our hypothesis by providing 
experimental evidence that confirms that DM2 HDL particles have a 
different surface polarity. In our opinion, fluorescence is the only 
technique able to distinguish the polarity of the immediate surroundings 
of phospholipids because fluorescence dyes can be found among 
phospholipid molecules. The changes in the probe microenvironment 
are caused by the presence of hydrophobic lipid molecules instead of 
possible protein posttranslational modifications associated with the 
pathological state. 
 Both the high concentration of triglycerides in the HDL of the 
DM2 group and the higher number of small particles – which present 
the most abnormal lipids distribution – may explain the dysfunctional 
behaviour of HDL communicated by several researchers43,44-45. 
Moreover, the lipid composition of the hydrophobic lipids that leaks to 
the surface is significantly different44. The high concentration of 
triglycerides found in the DM2 group could accentuate the changes in 
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the surface polarity even more. The mechanisms behind these HDL 
changes are not well established. We communicated44 that this group of 
diabetic patients have higher cholesterol-ester transfer protein activity, 
what could contribute to HDL smaller size and triglyceride enrichment. 
The hydrophobic and hydrophilic forces regulating the molecular 
interaction between lipoproteins, enzymes and cell membranes, and the 
conformation of apolipoproteins may be compromised 45-47. 
Surprisingly, despite the benefits of the two treatments on the lipid 
content – lower triglyceride count and higher cholesterol – the 
pathological state is not totally reversed after 12 weeks treatment with 
either fenofibrate or niacin, although we cannot exclude a more 
extensive HDL reparation after longer intervention periods. One 
possible reason for this is that the changes in the HDL triglyceride 
concentration and the mean radius that modulates the lipoprotein 
particle distribution are not enough. Instead, they hamper the correct 
distribution of HDL lipids and force them to leak to the external 
lipoprotein shell like a lipidic hernia. 
 
3.2.5 Methods 
Study subjects. A complete description of the population has 
recently been published44. Briefly, 29 type 2 diabetic patients (DM2) 
were recruited: 18 male and 11 female, aged between 30 and 70 years 
old, and with HDL not exceeding 50 mg/dl in men or 60 mg/dl in 
women. The exclusion criteria were as follows: smoker, diagnosed with 
diabetes less than three months before, triglyceride levels above 400 
mg/dl, glycated hemoglobin higher than 9%, albuminuria above 300 
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mg/mg creatinine, chronic kidney disease (estimated glomerular 
filtration rate <30 ml/min/1.73 m2), advanced retinopathy, neuropathy, 
cardiovascular disease in the last three months, chronic liver 
insufficiency, neoplastic disease or any chronic or incapacitating disease. 
The CT group consisted of 26 age- and gender-matched subjects without 
diabetes and with HDL cholesterol higher than 40 mg/dl for men or 50 
mg/dl for women. After a 6-week lipid-lowering drug wash-out, the 
patients with type 2 diabetes were randomly distributed into two 
groups. One group received 20 mg simvastatin plus 145 mg fenofibrate, 
and the other group received 20 mg simvastatin plus 2 g niacin plus 
laropiprant for a 12-week period. After a washout period of 6 weeks, 
they interchanged the treatments for 12 weeks more. At the end of the 
study, 24 DM2 patients finished both treatments after 5 discontinued 
interventions.  
Fasting blood samples were collected in EDTA tubes and centrifuged 
immediately for 15 min at 4°C at 1500 x g at the basal point, after each 
intervention period in the DM2 group, and at the basal point in the CT 
group. Plasma samples were then kept at -80ºC until further analysis.  
The entire study and all related experimental protocols were approved 
by the Ethical Committee of the Sant Joan University Hospital (Reus, 
Spain) and the Ethical Committee of the Clinical University Hospital 
(Valencia, Spain). All subjects provided their written informed consent 
before participating in the study. The study was carried out in 
accordance with the standards set by the Declaration of Helsinki and 
Good Clinical Practice guidelines. 
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Lipoprotein fractionation and HDL analysis. Prior to the NMR 
analysis, total HDL was isolated from plasma using sequential 
preparative ultracentrifugation at 1.21 g/ml density using previously 
described techniques48. Ultracentrifuged HDL (ucHDL) fractions were 
stored at -80°C until the biochemical studies were carried out. In the 
ucHDL fraction, cholesterol, triglycerides, total protein, phospholipids 
and apolipoproteins were quantified using enzymatic and 
nephelometric assays adapted to a COBAS 6000 autoanalyzer (Roche 
Diagnostics, Rotkreuz, Switzerland). 
NMR experiments. 1H-NMR spectra were recorded on a Bruker 
Avance III 600 spectrometer operating at 310 K using two different 
pulses: a 2-D double stimulated echo (DSTE) pulse program with 16 
bipolar gradients to obtain the diffusion coefficients of HDL fraction as 
previously reported49; and a 1D diffusion-edited pulse sequence with 
bipolar gradients and longitudinal eddy-current delay (LED) scheme with 
two spoil gradients to determine the particle distribution between HDL 
subclasses. In both cases, the relaxation delay was 2 seconds and the 
Free Induction Decays (FIDs) were collected into 64 K complex data 
points and 64 scans per sample.  
Radius extraction. DSTE methyl signal was fitted with one lorentzian 
curve to obtain the averaged diffusion coefficient (DCoef) of the 
lipoprotein particles as previously reported50. Then, the hydrodynamic 
radii of the lipoprotein fractions (RH) were extracted from the Stokes-
Einstein equation: 
UV = A ¡¢£    (1) 
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where KB is the Boltzmann constant, T is the temperature (310 K), 
and η is the mean viscosity of the solution (0.75 ± 0.02 mPa·s) measured 
at 310 K with a Cannon-Manning semi-micro capillary viscometer, in 
agreement with previous work49. 
Particle size distribution. To obtain a qualitative picture of the size 
distribution of the HDL lipoproteins, we used the methylene signal from 
the LED NMR experiments. The methylene signal had enough resolution 
to be fitted with three lorentzians, one for each of the three different 
HDL subclasses (large, medium and small HDL). The area below each 
lorentzian curve is proportional to the concentration of particles of this 
particular subclass. Relative concentration of each subclass provides an 
estimation of the size distribution of HDL particles. 
Shen model. We used the classical Shen model of a spherical 
lipoprotein particle as a starting point to estimate the mean HDL sizes 
for each sample. The Shen model describes lipoproteins as spheres with 
a surface shell 2 nm thick consisting of phospholipids (PL), proteins 
(Prot) and free cholesterol (FC) covering a hydrophobic core of esterified 
cholesterol (EC) and triglycerides (TG). Once the concentrations of these 
molecules had been measured (see Table 1), their associated volumes 
could be determined. The ratio between the volume of the surface shell 
and the volume of the internal core is related to the mean lipoprotein 
size as follows:  
 
 
¤¥¦¢§§¤¨¡©¢ =
ª«¬«>ª«(¬>8)«ª«(¬>8)« = ¬
«
(¬>8)« − 1  (2) 
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where the volume of the shell and the core was obtained from the 
concentration and the molecular volumes of each molecule: 
 
 ­®K¯°° = [a(] ∙ ±²³ + [a!)&] ∙ ±²´µ¶ + [¸¹] ∙ ±º»  (3) 
 
 ­»µ´¯ = [¼¹] ∙ ±½» + [ ¾] ∙ ±C   (4) 
 
Modified Shen model. The hypothesized discrepancies between the 
estimated mean sizes using the Shen model and the experimental ones, 
which were in agreement with the literature19,23,24, suggested that the 
lipid distribution within lipoprotein particles is not always well described 
by the Shen model. To solve these discrepancies, and on the basis that 
smaller particles have a higher Vshell / VCore ratio than larger particles, we 
modified the classical spherical model to obtain a ratio for smaller sizes 
in order to some of the traditionally core lipids were located in the 
lipoprotein shell (increasing the Vshell and decreasing the VCore). The 
modified model is described in Equations 5, 6 and 7: 
 
¤¥¦¢§§∗¤¨¡©¢∗ = ¬«(¬>8)« − 1   (5) 
 
­®K¯°°∗ = ­®K¯°° − ­»µ´¯ ∙ E             (6) 
 
­»µ´¯∗ = ­»µ´¯ ∙ (1 − E)       (7) 
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where α is the fraction of core lipids traditionally located in the 
surface shell.  
 Once the mean radii had been measured, α was determined for 
each sample as follows: first, we computed the geometric ratio between 
the volume of the external part (the 2 nm shell) and the internal part 
(the core) using the measured radius in nm; and then, we determined α 
by minimizing the difference between the biochemical ratio (right side 
of the Equation 8) and the geometrical ratio (left side) hence some of 
the core lipids could be located in the surface shell.  
 
¬«(¬>8)« − 1 = ¤¥¦¢§§¿¤¨¡©¢∙À¤¨¡©¢∙(/>À)               (8) 
 
Fluorescence study. Three different fluorescent probes – Prodan, 
Patman and Laurdan – were purchased from SIGMA-ALDRICH and used 
to evaluate the surface properties of lipoproteins. The fluorescent 
probes were introduced into the samples as previously reported27. The 
fluorescence spectra of the probes in native HDL lipoproteins were 
recorded on a luminescence spectrofluorometer AMINCO Bowman 
Series 2 with a Quarzglas cuvette (Hellma), and the excitation 
wavelength was 350 nm. The fluorescence spectra were normalized 
with the maxima intensity equal to one.  
AFM experiments. We used atomic force microscopy to measure the 
adhesion force between the tip of the AFM probe and the surface of the 
HDL particles on the basis of previously reported literature35,36. We 
obtained the topographic images as well as the adhesion force images 
by using the tapping force mode of AFM. The spring constant of the 
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cantilever was 0.31 N/m, the peak force amplitude was 100 nm and the 
peak force frequency was 2 KHz. We observed three samples and about 
15 HDL particles per sample were measured. In order to quantitate the 
particle size and relate it to the adhesion force, the images were initially 
processed with the NanoScope software, Ver. 1.20r1sr3 (Veeco), and 
then exported to MATLAB, Ver. 7.9.0.529 (The MathWorks). 
Statistical analysis. We performed two different statistical tests to 
detect differences between the variables studied: the mean size of the 
HDL fraction; the distribution between large, medium and small 
particles; and the distribution of the lipids traditionally found in the core 
(EC and TG) present in the lipoprotein shell. A statistical Mann-Whitney 
U test (two-tailed) was performed to identify significant differences 
between the CT and DM2 groups. This was followed by a Wilcoxon 
signed-rank test (two-tailed) to evaluate the treatment effects for 
paired samples (n=24). In the fluorescence experiments, a statistical 
Mann-Whitney U test (two-tailed) was performed to identify significant 
differences between the maximum position of the CT and DM2 spectra 
and a principal component analysis (PCA) was carried out using the 
emission spectra of the fluorescent probes as input variables. 
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3.2.7 Supporting information  
S.1 From biochemical data to the analytical expression of the 
lipoprotein radius 
The Shen model describes lipoproteins as spheres with a surface 
shell 2 nm thick consisting of phospholipids (PL), proteins (Prot) and free 
cholesterol (FC) covering a core of esterified cholesterol (EC) and 
triglycerides (TG). We used the Shen model and biochemical 
information to directly determine the theoretical radius of the 
lipoprotein particles as follows: 
First, we computed the geometric ratio between the volume of 
the outside (the 2 nm shell) and the inside (the core). The geometric 
expression for a sphere of known radius is:  
 
 
(1) 
Second, we found that this ratio was equal to the one obtained 
using the biochemical information and the Shen model: 
 
(2) 
where: 
 
(3) 
 
(4) 
 
(5) 
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Finally, rearranging Eq. 2 we found the analytical expression for the 
radius: 
 
(6) 
 
Molecular volumes were 1.058, 1.021, 1.102, 0.984 and 0.738 ml/mg for 
the EC, FC, TG, PL and Prot, respectively. 
 
S.2 Correlation between triglycerides levels, size and 
percentage of core lipids in the surface 
 
Figure S1 Percentage of the core lipids in the surface in relation to the 
size (nm) and the percentage of the triglycerides levels (w/w) of the 
HDL particles. Green circles represent the CT group and red circles the 
DM2 group. 
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Figure S2. a) Percentage of the core lipids vs. Size. b) Percentage of the 
core lipids vs. TG. Green color represents the CT group and red color, 
the DM2 group. R is the Pearson correlation coefficient. 
 
 
Figure S3. Scatter plots of the TG levels (w/w) and Percentage of the 
core lipids in the surface for a) CT group and b) for DM2 group; scatter 
plots of the Size (nm) and the TG levels (w/w) for c) CT group and d) 
for DM2 group. Green color represents the CT group and red, the DM2 
group. R is the Pearson correlation coefficient. 
 


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S.3 Fluorescence analysis 
Fluorescence experiments were performed in a subgroup of the 
samples (CT n=8 and DM2 n=4) in order to observe differences in the 
surface polarity of the two groups. Three different fluorescent probes 
(Prodan, Patman and Laurdan) were used to evaluate the surface 
properties of lipoproteins. 
 
Figure S4. Fluorescence spectra of Prodan, Patman and Laurdan. 
  
The fluorescence spectra of all three probes showed the same 
tendency: the wavelengths of the emission maxima (λem) of the DM2 
group were blue shifted (towards shorter wavelengths), indicating a 
more hydrophobic surface microenvironment than the CT group. 
 
To evaluate the dispersion of the measurements and display the 
differences between the CT and the DM2 group, we performed a 
principal component analysis (PCA) of the fluorescence intensity 
between 350 and 600 nm of two repetitions per sample. 
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Figure S5. Principal component analysis of the fluorescence raw data 
of two repetitions per sample. Red triangles represent the DM2 group 
and black circles, the CT group.  
 
S.4 HDL subclass analysis 
The biochemical composition of each subclass was calculated 
considering the molecular weight of FC, CE, PL and TG was 387, 650, 787 
and 885, respectively.  
Table S1: Chemical composition of lipids and protein of each HDL 
subclass.  
 Large HDL Medium HDL Small HDL 
FC 7 4 3 
CE 22 19 20 
PL 30 30 20 
TG 4 3 3 
Prot 37 44 54 
Data are expressed as w/w. TG: triglycerides, CE: cholesteryl esters, FC: free 
cholesterol, PL: phospholipids, Prot: protein.  
 
S.5 Atomic force microscopy experiments 
We used atomic force microscopy to measure the adhesion force 
between the tip of the AFM probe and the surface of the HDL. We 
obtained topographic images and their adhesion force map. The 
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adhesion force between the tip of the AFM probe and the sensed 
surface is inversely associated with the surface hydrophobicity. 
Topographic image   Adhesion map 
Figure S6. AFM topographic image and adhesion map of HDL particles. 
Lipoproteins of different size (red squares on the topographic image) 
interacted with the AFM tip. The adhesion map shows the adhesion 
force between the tip and the lipoprotein surface for each lipoprotein 
particle (green squares on the adhesion map). 
 
 
 
Figure S7. Scatter plots of HDL size by the tip adhesion force.
  
 
 
 
  
 
 
 
 
 
 
 
3.3 Remarkable quantitative and qualitative 
differences in HDL after niacin or fenofibrate 
therapy in type 2 diabetic patients  
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3.3.1 Abstract  
HDL-increasing drugs such as fenoﬁbrate and niacin have failed to 
decrease the cardiovascular risk in patients with type 2 diabetes. Drug-
mediated quantitative and qualitative HDL modiﬁcations could be 
involved in these negative results. To evaluate the quantitative and 
qualitative effects of niacin and fenoﬁbrate on HDL in patients with type 
2 diabetes, a prospective, randomised controlled intervention trial was 
conducted. Thirty type 2 diabetic patients with low HDL were 
randomised to receive either fenoﬁbrate (FFB) or niacin þ laropiprant 
(ERN/LPR) as an add-on to simvastatin treatment for 12 weeks 
according to a crossover design. At the basal point and after each 
intervention period, physical examinations and comprehensive standard 
biochemical determinations and HDL metabolomics were performed. 
Thirty nondiabetic patients with normal HDL were used as a basal 
control group. ERN/LRP, but not FFB, signiﬁcantly increased HDL 
cholesterol. Neither ERN/LRP nor FFB reversed the HDL particle size or 
particle number to normal. ERN/LRP increased apoA-I but not apoA-II, 
whereas FFB produced the opposite effect. FFB signiﬁcantly increased 
preβ1-HDL, whereas ERN/LRP tended to lower preβ1-HDL. CETP and 
LCAT activities were signiﬁcantly decreased only by ERN/LRP. PAF-AH 
activity in HDL and plasma decreased with the use of both agents. 
Despite their different actions on antioxidant parameters, none of the 
treatments induced detectable antioxidant improvements. 
ERN/LRP and FFB had strikingly different effects on HDL quantity and 
quality, as well as on HDL cholesterol concentrations. When prescribing 
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HDL cholesterol increasing drugs, this differential action should be 
considered. 
3.3.2 Introduction 
Cardiovascular (CV) diseases are responsible for approximately 50% 
of deaths in patients with type 2 diabetes1. In the presence of additional 
CV risk factors, achieving a low density lipoprotein (LDL) concentration 
below 70 mg/dl is recommended2. Even if the LDL target is achieved, an 
important residual risk remains. A portion of this residual risk has been 
attributed to lipid proﬁle alterations, as well as plasma LDL 
concentrations3. Patients with type 2 diabetes usually have profound 
lipid metabolism derangement, which is characterized by low high 
density lipoprotein (HDL) and high triglyceride concentrations. This lipid 
pattern is referred to as atherogenic dyslipidemia because of its high 
vascular damaging capacity. The inverse association between circulating 
HDL cholesterol concentrations and CV disease risk is unquestionable4. 
In many epidemiological studies, HDL cholesterol below 40 mg/dl in 
men and 45 mg/dl in women has been associated with an increased CV 
disease risk2. Recent data from the “Emerging Risk Factors 
Collaboration” conﬁrmed that HDL cholesterol is inversely associated to 
coronary heart disease after adjusting for lipid and non-lipid risk 
factors5. 
Despite this strong epidemiological association, increasing HDL 
cholesterol by medications has not produced a beneﬁcial impact on CV 
disease risk. In recent years, clinical outcome intervention trials using 
ﬁbrates, niacin and cholesteryl ester transfer protein (CETP) inhibitors 
have had negative results6. Among the ﬁbrate intervention trials, only 
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the VA-HIT study using gemﬁbrozil showed a 22% relative CV disease 
risk reduction associated with a 6% increase in HDL cholesterol7. More 
recent studies using fenoﬁbrate (FIELD and ACCORD)6,8 did not show a 
beneﬁcial effect, albeit post hoc analyses suggested a marginal beneﬁt 
in the atherogenic dyslipidemia subgroup. Similarly, two studies that 
used niacin as an add-on to statin treatment, AIM-HIGH and HPS2-
THRIVE, were prematurely stopped due to a lack of efﬁcacy9,10. In all of 
these trials, the effect on HDL cholesterol concentrations was relatively 
poor, with mean increases ranging from 0% to 6%. The failure of the 
ﬁbrate and niacin trials has been attributed to a lack of effect on lipid 
parameters or a poor study design, among other reasons. Beyond these 
circumstances, the complex composition and metabolism of HDL 
particles must be considered. Data from proteomic and lipidomic 
studies have shown the heterogeneity of this lipoprotein family, which is 
involved in many biological functions11–15. Moreover, HDL has 
considerable plasticity and is capable of changing its composition 
according to the environmental needs. Although reverse cholesterol 
transport is considered to be the key HDL antiatherogenic function, 
other biological effects of HDL are equally important, including its anti-
inﬂammatory, endothelial protective, and antioxidant capacities16. The 
cholesterol content in HDL is only a subrogated marker of the HDL 
particle concentration and has a weak correlation with HDL functions17. 
The anti-inﬂammatory, antioxidant, and endothelial protective or 
antiapoptotic effects of HDL seem to be more related to the HDL 
particle shape, size, number and composition. All of these 
characteristics are altered by pathological conditions such as type 2 
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diabetes mellitus (T2DM)18. Many efforts have been made to evaluate 
the clinical impact of HDL function rather than HDL cholesterol 
concentrations. Recently, the HDL cholesterol efﬂux capacity was 
observed to be a better indicator of HDL CV protection than HDL 
cholesterol19. Despite this evidence, HDL cholesterol concentrations 
remain the primary treatment determinant, and the efﬁcacy of 
medication is assessed by its capacity to increase HDL cholesterol. 
In this study, we hypothesized that global HDL particle alterations of 
T2DM patients are reversed by neither ERN/LRP nor FFB despite their 
HDL cholesterol increasing effect and that both drugs impact differently 
in HDL particle size distribution, composition and HDL metabolic 
determinants in these patients. 
3.3.3 Patients and methods 
Subjects and design of the study. Thirty type 2 diabetic patients, 19 
male and 11 female, ranging in age from 30 to 70 years old and with 
HDL not exceeding 50 mg/dl in men or 60 mg/dl in women were 
recruited. This HDL cut off points were selected to avoid the impact of 
genetic factors associated to high HDL values. The exclusion criteria 
were as follows: smoker, diagnosed with diabetes less than three 
months before, triglyceride levels above 400 mg/dl, glycated 
haemoglobin higher than 9%, albuminuria above 300 mg/mg creatinine, 
chronic kidney disease (estimated glomerular ﬁltration rate <30 
ml/min/1.73 m2), advanced retinopathy, neuropathy, cardiovascular 
disease in the last three months, chronic liver insufﬁciency, neoplastic 
disease or any chronic or incapacitating disease. The control group 
consisted of 30 age and gender-matched subjects without diabetes and 
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with HDL cholesterol higher than 40 mg/dl for men or 50 mg/dl for 
women. After a 6-week lipid-lowering drug wash-out, the patients with 
type 2 diabetes were randomly distributed into two groups. One group 
received 20 mg simvastatin plus 145 mg fenoﬁbrate, and the other 
group received 20 mg simvastatin plus 2 g niacin plus laropiprant for a 
12-week period. After this intervention period, the patients followed a 
new 6-week lipid-lowering drug wash-out; subsequently, they were 
shifted to the other lipid-lowering drug, in a crossover design, for a 12-
week period (Figure 1). Physical examinations, anthropometry and 
blood extraction for standard biochemical and metabolic tests were 
obtained at the basal point and after each intervention period in the 
type 2 diabetes group and at the basal point in the control group. All of 
the study investigations were conducted according to the principles 
expressed in the Declaration of Helsinki. The study was approved by the 
Ethic Committees of the recruiting hospitals. All of the subjects provided 
their written informed consent before participating in the study.  
Sample collection and storage. At the time points indicated in the 
ﬂow chart (Figure 1), fasting blood samples were collected in serum 
tubes with EDTA and were centrifuged immediately at 1500 g for 15 min 
at 4 °C. Aliquots of plasma and serum were stored at -80 °C until the 
analyses were performed (except for preβ1-HDL).  
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Figure 1. Flow chart of participant enrolment, randomisation and 
analysis. 
 
Standard lipid analyses. Biochemical parameters, lipids, 
apolipoproteins, fructosamine and homocysteine were measured using 
colourimetric, enzymatic and immunoturbidimetric assays (Spinreact, 
SA, Spain; Wako Chemicals GmbH, Germany; Polymedco, NY) adapted 
to a Cobas Mira Plus autoanalyser (Roche Diagnostics, Spain)20–22. 
Enzymes and protein concentrations are outlined in the supplemental 
materials.  
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Preβ1-HDL measurements. To determine preβ1-HDL measurements, 
plasma samples were immediately placed on ice in a 50% sucrose 
solution. Preβ1-HDL was analysed using a quantitative ELISA (Daichii, 
Japan). 
HDL isolation using ultracentrifugation. Total HDL was isolated from 
plasma using sequential preparative ultracentrifugation (uc) at 1.21 
mg/dl density according to previously described techniques23. 
Ultracentrifuged HDL (ucHDL) fractions were stored at 80 °C until 
biochemical studies were performed.  
Plasma and HDL oxidation status. The OxyStat (Biomedica, Wien) 
colorimetric assay was used for the quantitative determination of lipid 
peroxides in apoB-depleted plasma after the precipitation of b-
lipoproteins using phosphotungstic acid and magnesium ions (Roche 
Diagnostics). The results are expressed as µmol/L lipoperoxides/mg 
apoA-I. Serum paraoxonase 1 (PON1) and paraoxonase 3 (PON3) 
concentrations were determined using an in-house ELISA and rabbit 
polyclonal antibodies generated against synthetic peptides with 
sequences speciﬁc for mature PONs. The employed peptides were 
CRNHQSSYQTRLNALREVQ (speciﬁc for PON1) and CRVNASQEVEPVEPEN 
(speciﬁc for PON3). The details of these methods have been previously 
reported24. Serum PON1 lactonase activity was analysed by measuring 
5-thiobutyl butyrolactone (TBBL) hydrolysis, as previously described25,26.  
HDL antioxidant activity was determined by conjugated diene 
formation by incubating the patient's HDL (0.1 mg/ml apoA-I) with 
human LDL (0.1 mg/ml apoB, obtained from a pool of normolipidemic 
individuals) in the presence of 2.5 µmol/L CuSO4. Continuous monitoring 
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at an absorbance of 234 nm was performed in a microplate reader 
(BioTek Synergy, Winooski, VT, USA) at 37 ºC for 4 h. The kinetics of LDL 
in the LDL+ HDL incubations were calculated by subtracting the kinetics 
of HDL incubated without LDL; the lag phase was calculated as 
previously described27. 
HDL composition analyses. In the ucHDL fraction, cholesterol, 
triglyceride, total protein, phospholipid, apolipoprotein AI (apoA-I) 
(Roche Diagnostics), apolipoprotein A-II (apoA-II), apolipoprotein E 
(apoE), apolipoprotein CII (apoC-II), and apolipoprotein CIII (apoC-III) 
(Kamiya Biomedical Company) contents were quantiﬁed using 
enzymatic and nephelometric assays adapted to a BM/HITACHI 911 
autoanalyser (Spinreact S.A.U., Spain).  
HDL analyses by 2D diffusion-ordered 1H-NMR spectroscopy 
(DOSY). The ucHDL fraction samples were analysed using nuclear 
magnetic resonance (NMR) spectroscopy and a modiﬁed existing 
protocol28. The 1H-NMR spectra were recorded using a BrukerAvance III 
spectrometer at 310 K. We used the double stimulated echo (DSTE) 
pulse program with bipolar gradient pulses and a longitudinal eddy 
current delay (LED). The DSTE methyl signal was ﬁtted with one 
lorentzian function to obtain the averaged diffusion coefﬁcient of the 
lipoprotein particles. The hydrodynamic radii of the lipoprotein fractions 
were extracted from the Stokes-Einstein equation. Further details about 
the ucHDL NMR feature extraction and HDL particle size distribution and 
number calculations are outlined in the supplemental material.  
Statistical analysis: Normal distributed data are shown as the mean 
± SD values, and non-normal distributed data are shown as the median 
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(interquartile range). We performed two different statistical tests to 
detect differences between the studied variables. A statistical Mann-
Whitney U test was performed to identify signiﬁcant differences 
between the control group and the group comprising patients with type 
2 diabetes, followed by a Wilcoxon signed-rank test to evaluate the 
treatment effects for paired samples. We performed alpha corrections 
due to multiple testing by multiplying the p value by the number of 
related variables tested (lipids, enzymes, oxidation, HDL subclasses). We 
excluded any carryover effect by the Fleiss method. There were no 
signiﬁcant differences (by t test) in the results obtained in any of the 
variables after the same treatment, regardless of the intervention 
order29. Subsequently, the data of the two sequences were combined 
and analysed as described in the design section. The analyses were 
performed using SPSS software (IBM SPSS Statistics, version 20). P < 
0.05 was considered to be statistically signiﬁcant. 
3.3.4 Results  
Baseline differences. The anthropometric and clinical characteristics 
of these groups are presented in Supplemental Table 1S. In Table 1, we 
show the lipid metabolism and oxidation parameters and HDL subclass 
distribution in both T2DM patients and controls. As expected, the 
patients with T2DM had lower HDL cholesterol and apoA-I. The total 
number of HDL particles was lower in T2DM patients (P = 0.009). The 
difference was primarily due to the medium-sized HDL particles (P = 
0.004) (Table 1). They had higher preβ1-HDL and CETP activity and lower 
PON1. HDL from T2DM patients had less cholesterol and apoE and more 
triglycerides and apoC-III (Supplemental Table 2S). Because of the side 
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effects of the medications, one patient withdrew from the study during 
the fenoﬁbrate treatment, and four patients withdrew during the niacin 
treatment. The anthropometric and clinical characteristics of these 
groups are presented in Supplemental Table 3S.  
Table 1. Biochemical characteristics of control population and T2DM 
patients. 
  
Control 
(n=30) 
T2DM 
(n=30) 
P 
Lipoproteins    
Cholesterol (mmol/L) 5.42 ± 0.99 6.14 ± 1.24 0.030 
Triglycerides (mmol/L) 0.95 (0.73-1.20) 2.39 (1.63-3.49) <0.001 
HDL-C (mmol/L)  1.51 ± 0.36 1.05 ± 0.28 <0.001 
ApoA-I (g/L) 149 ± 15 132 ± 15 <0.001 
ApoA-II (g/L) 30.3 ± 3.9 28.6 ± 4.8 0.095 
ApoB-100 (g/L) 96 ± 22 121 ± 26 0.001 
Pre 1-HDL (µg/ml) 17.8 (11.6-22.6) 22.8 (15.5-27.7) 0.027a 
Enzymes    
CETP mass (µg/ml) 2.5 ± 0.7 2.5 ± 0.7 0.906 
CETP activity (pmol/h*µl) 7.2 ± 2.0 9.2 ± 2.9 0.006 
LCAT mass (µg/ml) 9.6 ± 1.4 10.7 ± 1.9 0.006 
LCAT activity (FER) 6.28 ± 4.6 11.3 ± 10.6 0.152 
PAF-AH (µmol/min*ml) 19.7 ± 5.1 22.7 ± 7.5 0.101 
PAF-AH in HDL 
(µmol/min*ml) 
11.9 ± 4.9 12.6 ± 5.8 0.644 
Oxidation    
PON1 (mg/L) 78.6 ± 23.9 62.0 ± 23.4 0.007 
PON3 (mg/L) 1.4 ± 0.5 1.6 ± 0.5 0.255 
Lactonase activity (U/L) 6.4 ± 2.9 7.6 ± 2.1 0.021a 
Paraoxonase activity 
(U/L) 
269.2 ± 101.9 320.2 ± 146.4 0.193 
LOOH in HDL (µmol/mg) 0.15 ± 0.10 0.19 ± 0.10 0.044a 
Antioxidant capacity (% 
dienes) 
100.1 ± 21.7 91.6 ± 25.9 0.208 
HDL subclass particle 
concentration (µmol/L) 
   
Large HDL  0.6 (0.4-0.8) 0.5 (0.4-0.7) 0.196 
Medium HDL 3.9 (2.9-5.3) 2.9 (1.8-4.2) 0.004 
Small HDL 7.8 (6.1-9.7) 7.8 (6.2-10.2) 1 
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Total HDL 13.6 (11.0-15.2) 10.8 (10.0-12.6) 0.009 
Normal distributed data are given as mean ± SD and non-normal distributed data as 
the median (interquartile range). The control population and T2DM patients were 
analysed using the Mann–Whitney U test. Bold signifies P value. a Results lost 
statistical significance at P ≤ after we adjusted for inflation caused by multiple testing. 
Changes induced by fenoﬁbrate. Despite a signiﬁcant decrease in 
plasma TG, FFB did not increase HDL cholesterol or apoA-I (Table 2). 
Conversely, it increased apoA-II and preβ1-HDL (Table 2) and decreased 
HDL apoC-III whereas HDL apoE remained unchanged (Supplemental 
Table 4S). LCAT and CETP activities did not vary with treatment. FFB 
decreased the number of medium size HDL particles (Table 2 and Figure 
2). Regarding oxidative parameters, FFB decreased both paraoxonase 
and PAF-AH activities without signiﬁcant changes in LOOH and 
antioxidant capacity (Table 2). 
Changes induced by niacin. ERN/LRP signiﬁcantly increased HDL 
cholesterol and apoA-I, and showed a tendency to decrease preβ1-HDL 
(Table 2). CETP and LCAT mass and activity were decreased after 
treatment. ERN/LRP did not show any effect on HDL subclass distribution 
(Table 2 and Figure 2). Regarding oxidation, PAF-AH and paraoxonase 
activities were signiﬁcantly decreased by ERN/LRP (Table 2).  
Comparison between treatments. Although ERN/LRP signiﬁcantly 
increased HDL cholesterol, the total HDL particle number was not 
signiﬁcantly modiﬁed by any of the treatments (Table 2). 
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Figure 2. Percentage of change between baseline and post-FFB and 
post-ERN/LRP of HDL lipids, apolipoproteins and enzymes. The data 
represent the mean ± SD values; n = 26. The effect of treatment was 
analysed using the paired sample Wilcoxon signed rank test, *P < 0.05. 
 
The HDL spectra of medium and large HDL particles were different 
between controls and T2DM and were not reversed to normal after any 
treatment (Figure 3A). No differences in the NMR spectrum of small HDL 
were observed. Figure 3B shows the average HDL particle sizes, 
conﬁrming that the HDL from T2DM patients is smaller than that of 
controls, and neither FFB nor ERN/LRP fully correct this alteration. The 
mean radius for the healthy group (4.7 nm) was higher than that of the 
T2DM group (4.5 nm) (P = 0.002). FFB tended to shift the distribution 
towards smaller particles, whereas RN/LRP treatment increased the 
relative concentration of the medium HDL subclass, which 
consequently, although not signiﬁcantly, approached the healthy state. 
The effects of different treatments on the mean HDL radius were 
signiﬁcantly different (P = 0.042).  
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Figure 3. HDL particle size distribution in controls and T2DM patients 
before and after ERN/LRP and FFB treatments. A) The coloured curves 
are the means of the three normalised functions for each group. The 
area under each curve represents the relative lipid concentration of a 
particular subclass. B) The mean HDL radius in controls and T2DM 
patients before and after ERN/LRP and FFB treatments. 
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3.3.5 Discussion 
Three essential messages are obtained from our study. The ﬁrst 
message is that pharmacological intervention with ERN/LRP and FFB in 
T2DM patients leads to important HDL particle modiﬁcations, beyond 
HDL cholesterol concentrations. The second message is that these 
composition changes differ according to the HDL cholesterol-increasing 
medication used. The third message is that neither ERN/LRP nor FFB 
reverses diabetic HDL alterations ad integrum. These differences could, 
in part, be explained by the mechanisms of action of both medications. 
FFB is a PPARα agonist that increases proteins associated with lipolysis 
activity, whereas niacin, among other mechanisms, reduces adipose 
tissue lipolysis30,31. The post-treatment HDL particles differ depending 
on the medication used, and they also differ from normal; therefore, the 
expected effect on cardiovascular risk should be unequal. HDL 
cholesterol, which is the primary variable that is expected to be 
modiﬁed by ERN/LRP and FFB, increases in different proportions. 
Although niacin produced a mean 18% increase, FFB did not signiﬁcantly 
modify HDL cholesterol. These results are in concordance with previous 
publications that show similar effects of niacin and FFB6,8–10. Niacin was 
also the only medication that produced a signiﬁcant increase in apoA-I. 
However, consistent with previous observations, only FFB induced a 
signiﬁcant 15% increase in apoA-II32. Patients with T2DM had 
signiﬁcantly higher preβ1- HDL particles, which were further increased 
by FFB, whereas niacin tended to decrease the levels of preβ1-HDL. The 
clinical repercussion of this fact is not clear. Both high and low levels of 
preβ1-HDL have been associated with cardiovascular risk and the 
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presence of cardiovascular risk factors33,34. These discrepancies can be 
explained by different mechanisms, including increased synthesis, 
decreased maturation, or both, that can be involved in the origin of 
preβ1-HDL plasma accumulation. Patients with T2DM had higher CETP 
activity, which tended to be reduced by both treatments, although only 
after ERN/LRP, this tendency was statistically signiﬁcant, which suggests 
that partial inhibition of CETP could be a mechanism that explains the 
effects of both ERN/LRP and FFB on HDL cholesterol concentrations. 
T2DM patients had a high LCAT mass, but no signiﬁcant differences in 
activity were observed. ERN/LRP signiﬁcantly reduced LCAT activity in 
T2DM patients. Despite a different marginal effect on PAF-AH and PON 
1 mass and activity, neither fenoﬁbrate nor niacin treatment was 
associated with better oxidation proﬁle markers according to the 
lipoperoxide concentration in apoB-lipoprotein-containing depleted 
plasma, which is an indirect index of HDL oxidation, and the capability of 
HDL to protect against LDL oxidation. Diabetic patients had an HDL 
fraction with increased proportions of apoA-II and C-III and half the 
concentration of apoE. Although FFB increased apoA-II, niacin reduced 
its concentration. FFB reduced apoC-III; however, neither FFB nor 
ERN/LRP modiﬁed the proportion of apoE. The biological impact of 
these differences is not known (Supplemental Tables 3S and 4S). We 
speculate that the increased apoA-II after FFB treatment may modify 
apolipoprotein exchange between HDL and triglyceride-rich particles, 
thus decreasing lipoprotein lipase activity and inﬂuencing both 
triglyceride and HDL cholesterol concentrations35. 
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The NMR results reinforced that HDL from T2DM patients is clearly 
different from the healthy group in terms of particle size and number. T2DM 
patients had fewer HDL particles, and the HDL particles from T2DM patients 
had smaller radii. These alterations were not reversed by ERN/LRP or FFB.  
Some limitations of our study are that the intervention period of the 
study was only 12 weeks; therefore, our results cannot be extrapolated 
over a longer period of time. The sample size is small due to the 
comprehensive analyses performed, including metabolomics 
techniques. This rather small sample size allows only the detection of 
large effects; however, it does warrant enough power for the main 
results of the study. The ERN preparation was associated with LRP, so 
we cannot exclude the lipid effects associated with this product, 
although if they exist, they seem to be very light.  
ERL/LRP has been withdrawn from the market, although other 
niacin-based pills are available in different countries, and FFB is widely 
available. The overall conclusions of our work are that neither ERN/LPP 
nor FFB reverse HDL particle abnormalities associated to T2DM. 
Moreover, these two drugs act differently on HDL. Our results should 
contribute to a better understanding of the negative results observed in 
randomized controlled trials using niacin or fenoﬁbrate. In our hands 
these two drugs don't improve HDL particle composition, size and 
metabolism, despite a marginal impact on HDL cholesterol 
concentrations. Clinicians prescribing these drugs must be aware of 
their overall impact on HDL particles and lipoprotein metabolism. 
Supplementary data related to this article can be found at 
http://dx.doi.org/10.1016/j.atherosclerosis.2014.12.006. 
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Nutritional interventions and dietary habits assessment are the 
perfect study examples where the use of NMR derived lipoprotein 
characterization can provide information about pathophysiological 
mechanisms involving atherosclerosis and CVD and external agents such 
as long chain omega-3 fatty acids.  
The present chapter describes how nutrition and, in particular the n-
3 fatty acids modulate the lipoprotein profile in an epidemiological 
association study and two nutritional interventions. Firstly, we present 
an epidemiological study involving more than 26,000 apparently healthy 
women to evaluate the associations between the fish consumption and 
n-3, and the lipoprotein profile determined by NMR by using the 
technology commercialized by Liposcience. This original research 
resulted from the doctoral stay at the unit of preventive medicine 
(Brigham and Women’s Hospital) under the supervision of Dr. Samia 
Mora. Currently, after the internal review which includes an external 
data check of all the developed software code for statistical analysis and 
the results, the document is being prepared for submission as an 
original article as follows: 
· Amigó N., Akinkuolie, A.O., Chiuve, S.E., Correig, X., Cook, NR & 
Mora, S. Fish consumption omega-3 fatty acids and NMR 
lipoprotein subfractions in 26.034 apparently healthy women.   
 
Complementary, we wanted to present in the same section two 
published works of an intervention trial designed to evaluate the effect 
of diets enriched with either SFA or n-6 PUFA, and supplemented with 
LCn-3PUFA on the lipoprotein profile by using the Liposcale test.  
· Dias, C. B., Amigó, N., Wood, L. G., Mallol, R., Correig, X., & Garg, 
M. L. (2016). Improvement of the omega 3 index of healthy 
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subjects does not alter the effects of dietary saturated fats or n-
6PUFA on LDL profiles. Metabolism: Clinical and Experimental, 
68. 
https://doi.org/10.1016/j.metabol.2016.11.014 
 
· Dias, C. B., Amigo, N., Wood, L. G., Correig, X., & Garg, M. L. 
(2017). Effect of diets rich in either saturated fat or n-6 
polyunsaturated fatty acids and supplemented with long-chain 
n-3 polyunsaturated fatty acids on plasma lipoprotein profiles. 
European Journal of Clinical Nutrition.  
https://doi.org/10.1038/ejcn.2017.56 
 
These two works are the result of an international collaboration with 
the Dra. Cintia Botelho Dias during her visit to Biosfer Teslab during 
August 2015. The three works demonstrate how lipoprotein 
characterization by NMR can be an evaluation tool for diet and 
nutritional interventions. 
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4.3.1 Abstract  
Dietary fat composition is known to modulate circulating lipid 
and lipoprotein levels. Although supplementation with long chain 
omega-3 polyunsaturated fatty acids (LCn-3PUFA) has been shown to 
reduce plasma triglyceride levels, the effect of the interactions between 
LCn-3PUFA and the major dietary fats consumed has not been 
previously investigated.  
In a randomized controlled parallel design clinical intervention, 
we examined the effect of diets rich in either saturated fatty acids (SFA) 
or omega-6 polyunsaturated fatty acids (n-6PUFA) on plasma lipid levels 
and lipoprotein profiles (lipoprotein size, concentration and distribution 
in subclasses) in subjects with an adequate omega 3 index. Twenty six 
healthy subjects went through a four-week pre-supplementation period 
with LCn-3PUFA and were then randomized to diets rich in either n-
6PUFA or SFA both supplemented with LCn-3PUFA. 
The diet rich in n-6PUFA decreased low density lipoprotein (LDL) 
particle concentration (-8%, p=0.013) and LDL cholesterol (LDL-C) level  
(-8%, p=0.021), while the saturated fat rich diet did not affect LDL 
particle number or LDL-C levels significantly. Nevertheless, dietary 
saturated fatty acids increased LCn-3PUFA in plasma and tissue lipids 
compared with n-6PUFA, potentially reducing other cardiovascular risk 
factors such as inflammation and clotting tendency.  
Improvement on the omega 3 index of healthy subjects did not 
alter the known effects of dietary saturated fats and n-6PUFA on LDL 
profiles. 
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4.3.2 Introduction  
Incorporation of long chain omega 3 polyunsaturated fatty acids 
(LCn-3PUFA) into cell membranes, in particular docosahexaenoic acid 
(DHA, 22:6n-3), modulate biophysical properties and functionality of the 
cell membranes1,2. Dietary supplementation with LCn-3PUFA have been 
shown to reduce the risk of cardiovascular disease (CVD) and other 
chronic diseases, by reducing blood triglycerides and inflammation and 
increasing high density lipoprotein cholesterol, among other 
mechanisms3,4, although some controversy is still observed in the 
literature5. Thus, an optimal omega-3 index [eicosapentaenoic acid 
(EPA, 20:5n-3) plus 22:6n-3 in erythrocytes] of 8% or greater has been 
suggested for the prevention of chronic diseases and for health 
promotion6. 
Other dietary fatty acids, such as omega 6 polyunsaturated fatty 
acids (n-6PUFA) from vegetable oils and saturated fatty acids (SFA) from 
animal or plant sources, may influence LCn-3PUFA absorption and 
incorporation into plasma and tissue lipids7,8. Our group has previously 
demonstrated that a diet enriched with saturated fatty acids and 
supplemented with LCn-3PUFA was more efficient in improving the 
incorporation of LCn-3PUFA into plasma and tissue lipids than a diet 
enriched with n-6PUFA, although an increase in low density lipoprotein 
cholesterol (LDL-C) was also observed with the SFA enriched diet8. 
Due to their capacity to modulate membrane composition and 
function, LCn-3PUFA may also influence the efficacy of other dietary 
fatty acids to alter blood lipid levels and lipoprotein profiles. In spite of 
the association between SFA and CVD and elevated blood lipid levels4, 
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studies in animal9 and human10 models have demonstrated that SFA 
increase plasma triglyceride level only when the diet is deficient in n-
3PUFA. Therefore, we aimed to determine if an improvement in the 
omega-3 index of healthy subjects would modulate the effect of the 
dietary SFA and n-6PUFA on plasma lipid levels [total cholesterol, LDL-C, 
high density lipoprotein cholesterol (HDL-C) and triglycerides] and 
lipoprotein profiles (lipoprotein size, concentration and distribution in 
subclasses). Furthermore, we hypothesize that a saturated fat rich diet 
does not adversely affect lipid and lipoprotein profiles compared to a 
diet rich in n-6PUFA in the context of an adequate omega-3 index.  
 
4.3.3 Material and Methods  
Study Population. Twenty nine healthy adults (16 females and 
13 males) aged between 21 and 65 years were recruited. Subject’s 
exclusion criteria were: use of lipid-lowering drugs (e.g. statins); regular 
consumption of fish oil supplements within the past month; regular 
consumption of 2 or more fish meals a week over the past month; any 
history of congestive heart failure, stroke, myocardial infarction, 
coronary artery bypass graft, or atherosclerotic CVD; history of diabetes, 
renal disease, gastrointestinal disorder or liver disease. Smokers and 
pregnant or breast feeding women were also excluded. 
Study design. In this randomized controlled, parallel, dietary 
intervention trial design, subjects consumed 4x1g fish oil capsules  
[100 mg 20:5n-3: 500 mg 22:6n-3 each (EPAX 1050TG, Norway)] for 4 
weeks. Subjects were then randomized to a diet rich in either saturated 
fatty acids (SFA+LCn-3PUFA diet) or n-6PUFA (n-6PUFA+LCn-3PUFA diet) 
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for a further ten-day period, while continuing fish oil supplementation 
(Figure 1). Subjects on the SFA+LCn-3PUFA diet group consumed daily 
24g of butter, 40g of white chocolate (providing 30g total fat, 20.9g 
saturated fat) and 4x1g fish oil capsules; they were also advised on how 
to use more foods containing SFA for cooking, while reducing n-6PUFA 
intake. Subjects on the n-6PUFA+LCn-3PUFA diet consumed daily 20g of 
margarine (Flora original), 42g of sunflower seeds (providing 30g total 
fat, 20g n-6PUFA) and 4x1g fish oil capsules; they were also advised on 
how to use more foods and oils containing n-6PUFA for cooking, while 
reducing SFA intake. Following an overnight fast, subjects visited the 
Nutraceuticals Research Clinic facility at the University of Newcastle on 
three occasions; before LCn-3PUFA supplementation, after 4 weeks of 
supplementation and after the dietary intervention with the SFA+LCn-
3PUFA and the n-6PUFA+LCn-3PUFA diets. All subjects were advised not 
to change their physical activity status or any other aspect of their 
habitual diet. After pre-supplementation with LCn-3PUFA, subjects were 
allocated to one of the 2 diets using computer generated random tables 
(www.randomization.com, seed 7027 for males and seed 4586 for 
females). Nutrient intake prior and during the intervention period was 
assessed using a three-day food record (2 week days and one weekend 
day) and the software FoodWorks 7 Professional (Xyris software). At 
each visit, blood samples and anthropometric measurements were 
collected following an overnight fast (10 hours) and 24 hours refrain 
from strenuous exercise and alcohol consumption. Blood samples were 
assessed for plasma lipid levels, lipoprotein profiles and fatty acid 
composition of plasma and erythrocyte lipids. Physical activity 
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(International Physical Activity Questionnaire long form), medical 
history and consumption of medications, supplements and alcohol were 
also assessed at each visit. This study was conducted according to the 
guidelines laid down in the Declaration of Helsinki, all procedures 
involving human subjects were approved by the University of Newcastle 
Human Research Ethics Committee (protocol H-2012-0117), and the 
study was registered with the Australia New Zealand Trial registry 
(registration identification number ACTRN12614001051639, 
http://www.anzctr.org.au/). All subjects gave their written informed 
consent before participation. 
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Figure 1. Schematic representation of the study schedule. 
 
Compliance was monitored by count back of fish oil capsules and 
other food products provided, interview with volunteers about their 
food consumption at the end of the trial, evaluation of their dietary 
records, and analysis of plasma fatty acid composition. No subject 
showed any signs of intolerance to the supplements provided. 
Chapter 4 
244  
Plasma and erythrocyte sample preparation. Fasting blood 
samples were collected in EDTA vacutainer. Plasma was immediately 
separated from erythrocytes by centrifugation (1000 g x 15 minutes at 
4oC) and both fractions were stored at -80oC until analyzed. 
Plasma and erythrocyte fatty acid composition. Incorporation of 
fatty acids in plasma and erythrocytes was determined using gas 
chromatography following trans-esterification as described previously8. 
Plasma lipoprotein profiles. Frozen plasma samples (500μl) were 
shipped on dry ice to Biosfer Teslab (Reus, Spain) for the analysis of 
lipoprotein profiles by nuclear magnetic resonance (NMR). The 
determination of lipoprotein size, concentration and lipoprotein 
subclasses distribution have been previously reported by Mallol and 
colleagues11. Briefly, particle concentration and diffusion coefficients 
were obtained from the measured amplitudes and attenuation of the 
particles’ spectroscopically distinct lipid methyl group NMR signals, 
using the 2D diffusion-ordered 1H-NMR spectroscopy (DSTE) pulse. The 
methyl signal was surface fitted with 9 lorentzian functions associated 
with each lipoprotein subclass of the main lipoprotein groups (VLDL, LDL 
and HDL). The area of each lorentzian function was related to the lipid 
concentration of each lipoprotein subclass, and the size of each subclass 
was calculated from their diffusion coefficient. The concentration of 
each lipoprotein subclass was calculated by dividing the lipid volume by 
the particle volume of a given class. Lipid volumes were determined by 
using common conversion factors to convert concentration units into 
volume units12. The different lipoprotein subclasses correspond to the 
following diameter size ranges: large VLDL, 68.5 to 95.9 nm, medium 
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VLDL, 47 to 68.5 nm, small VLDL, 32.5 to 47 nm, very large LDL, 24 to 
32.5 nm, medium-large LDL, 20.5 to 24 nm, small LDL, 17.5 to 20.5 nm, 
very large HDL, 10.5 to 13.5 nm, medium-large HDL, 8.5 to 10.5 nm and 
small HDL, 7.5 to 8.5 nm. 
Plasma lipid profile, glucose and high sensitivity C-reactive 
protein. Blood samples were collected in lithium heparin vacutainers. 
Plasma was immediately separated from erythrocytes by centrifugation 
(3000 g x 10 min at 4oC) and analyzed for total cholesterol, triglycerides, 
glucose and C-reactive protein by the accredited Hunter New England 
Area Pathology Service. 
Statistical analysis. Sample size calculation was based on an 
anticipated 30% (0.45 mmol/L) change in plasma triglycerides (primary 
outcome) with triglyceride standard deviation 0.387 mmol/L, level of 
significance 0.05 and 80% power13. Thirteen subjects were then 
recruited in each group. 
All data are presented as median and interquartile range (IQR). 
Kruskal-Wallis test was used for comparing the randomized groups 
before dietary intervention. Pre-supplementation period data were 
compared using Wilcoxon signed-rank test. Data obtained before and 
after dietary intervention were compared within group using Wilcoxon 
signed-rank test and data on change were compared between groups 
using Kruskal-Wallis test. For all tests a p-value lower than 0.05 was 
considered statistically significant. Mat Lab R2010a (MathWorks) was 
used to perform the statistical analysis. 
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4.3.4 Results  
From the 29 subjects recruited (15 on the SFA+LCn-3PUFA diet 
and 14 on the n-6PUFA+LCn-3PUFA diet), 2 dropped from the study, 1 
did not comply with the study protocol and 1 had lipoprotein profiles 
data missing. Therefore, 3 subjects (2 on the SFA+LCn-3PUFA diet and 1 
on the n-6PUFA+LCn-3PUFA diet) were excluded from all data analysis 
and one subject was excluded only from the lipoprotein profiles 
analysis. Twenty six subjects were then included in the statistical 
analysis, 13 on the SFA+LCn-3PUFA diet (5 males and 8 females) and 13 
on the n-6PUFA+LCn-3PUFA diet (6 males and 7 females).  
The pre-supplementation period efficiently increased the 
consumption of LCn-3PUFA and their incorporation into blood lipids. 
Percentage of 20:5n-3 and 22:6n-3 increased in plasma and erythrocyte 
lipids at the expense of monounsaturated fatty acids and n-6PUFA as 
expected, indicating compliance with the study protocol. The LCn-
3PUFA supplements consumed have been previously characterized8. 
During pre-supplementation, there was an increase in body mass index 
(BMI) and percentage body fat. There was also a significant decrease in 
total triglycerides consistent with a decrease in the concentration of 
total, large, medium and small VLDL particles. Very large and medium-
large LDL particle concentration increased, without significant change to 
LDL-C. Very large HDL particle concentration decreased, while medium-
large HDL particle concentration, HDL average size and HDL-C increased 
(Tables A.1 to A.5 in the supplementary appendix). 
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Table 1. Subjects characteristics at randomization. 
 SFA+LCn3PUFA n-6PUFA+LCn3PUFA P 
Age (years) 32.0 (29.0) 28.0 (37.8) 0.777 
BMI (Kg/m2) 24.4 (4.5) 23.5 (4.4) 0.758 
Body fat (%) 27.0 (20.7) 22.6 (16.7) 0.758 
Glucose (mmol/L) 5.10 (0.45) 5.00 (0.83) 1.000 
Triglycerides (mmol/L) 0.76 (0.55) 0.86 (0.56) 0.489 
Total cholesterol (mmol/L) 4.80 (1.53) 5.40 (1.25) 0.719 
LDL-C (mmol/L) 2.31 (0.98) 2.65 (0.73) 0.807 
HDL-C (mmol/L) 1.46 (0.38) 1.26 (0.32) 0.370 
hsCRP (mmol/L) 1.00 (1.60) 0.90 (1.80) 0.699 
Plasma LCn-3PUFA (%) 7.98 (2.63) 8.01 (1.51) 0.412 
Omega 3 index  
(20:5n-3+22:6n-3)  
10.45 (1.86) 10.77 (1.77) 0.356 
Data presented as median (interquartile range - IQR). P, p-value for comparison 
between groups; BMI, body mass index; LDL-C, low density lipoprotein cholesterol; 
HDL-C, high density lipoprotein cholesterol; hsCRP, high sensitivity C-reactive protein; 
LCn-3PUFA, long chain omega-3 polyunsaturated fatty acids [eicosapentaenoic acid 
(20:5n-3) + docosapentaenoic acid (22:5n-3) + docosahexaenoic acid (22:6n-3)]. 
 
At randomization, both groups were of similar age, body mass 
index, percentage body fat, plasma lipid levels, lipoprotein profiles and 
plasma and erythrocyte fatty acid composition, except for 
docosapentaenoic acid (22:5n-3) percentage (Tables 1 and A.2 to A.5). 
Subjects in both groups also had similar energy and nutrient 
consumption, except for the percentage energy from total fat. During 
the dietary intervention, subjects on the n-6PUFA+LCn3PUFA diet 
reduced their carbohydrate consumption while increasing total fat 
consumption compared to subjects on the SFA+LCn3PUFA diet, despite 
subjects in both groups being advised not to change the consumption of 
nutrients other than the fat type. Subjects on the SFA+LCn3PUFA diet 
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increased their saturated fat consumption and reduced their linoleic 
acid consumption in contrast with subjects in the n-6PUFA+LCn3PUFA 
diet (Table A.1). 
After the n-6PUFA+LCn3PUFA diet, the percentage of plasma 
linoleic acid increased and the LCn-3PUFA (20:5n-3, 22:5n-3 and 22:6n-
3) decreased, compared to the SFA+LCn3PUFA diet (Figure 2). A similar 
pattern was observed in erythrocyte lipids with an increase in percent 
linoleic acid and a decrease in percent 20:5n-3 in the n-
6PUFA+LCn3PUFA group compared to the SFA+LCn3PUFA group (Figure 
3). After the n-6PUFA+LCn3PUFA diet there was a decrease in total 
cholesterol and LDL-C, as well as a decrease in LDL triglycerides and 
total, very large, medium-large and small LDL particle concentration 
compared to the SFA+LCn3PUFA diet (Figures 4 and 5). However, the 
concentration of small LDL was not increased significantly after 
consumption of the SFA+LCn3PUFA diet. There were no further changes 
in body composition or other lipoprotein profiles (Tables A.2 to A.5). 
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Figure 2. Change in plasma linoleic acid (18:2n-6) and long chain 
omega-3 polyunsaturated fatty acids (20:5n-3, 22:5n-3, 22:6n-3) (% 
from total fatty acids detected). Data presented as median 
(interquartile range - IQR). Different lower case letters represent 
significant difference (p<0.05) between changes caused by dietary 
intervention with either (■) SFA+LCn-3PUFA (n=12, 5 males and 7 
females) or (■) n-6PUFA+LCn-3PUFA (n=13, 6 males and 7 females). 
Dots represent outliers.  
 
Figure 3. Change in erythrocyte linoleic acid and eicosapentaenoic acid 
(20:5n-3) (% from total fatty acids detected). Data presented as median 
(interquartile range - IQR). Different lower case letters represent 
significant difference (p<0.05) between changes caused by dietary 
intervention with either (■) SFA+LCn-3PUFA (n=12, 5 males and 7 
females) or (■) n-6PUFA+LCn-3PUFA (n=13, 6 males and 7 females). 
Dots represent outliers. 
 
 
Figure 4. Change in plasma total cholesterol (mmol/L) and triglycerides 
(mmol/L). Data presented as median (interquartile range - IQR). 
Different lower case letters represent significant difference (p<0.05) 
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between changes caused by dietary intervention with either (■) 
SFA+LCn-3PUFA (n=12, 5 males and 7 females) or (■) n-6PUFA+LCn-
3PUFA (n=13, 6 males and 7 females). Dots represent outliers.  
 
Figure 5. Change in lipoprotein profiles. Data presented as median 
(interquartile range - IQR). LDL, low density lipoprotein; C, cholesterol 
(mmol/L); TG, triglycerides (mmol/L); P, particle (nmol/L). Different 
lower case letters represent significant difference (p<0.05) between 
changes caused by dietary intervention with either (■) SFA+LCn-3PUFA 
(n=12, 5 males and 7 females) or (■) n-6PUFA+LCn-3PUFA (n=13, 6 
males and 7 females). Dots represent outliers. 
 
4.3.5 Discussion  
This clinical intervention was designed to determine if improving 
the LCn-3PUFA status by prior dietary supplementation with fish oil 
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would modulate the effect of the major dietary fats (SFA versus n-
6PUFA) on lipoprotein profiles and plasma lipid levels. A diet rich in 
saturated fatty acids raised LDL-C compared to a diet rich in n-6PUFA 
despite LCn-3PUFA supplementation. However, the increase in LDL-C 
was primarily due to an increase in very large and medium-large LDL 
particles that are known to be less atherogenic than small LDL 
particles14-16, which were not significantly elevated by saturated fat 
consumption. 
The n-6PUFA+LCn3PUFA diet caused a decrease in total, very 
large, medium-large and small LDL particles as well as a decrease in LDL-
C and LDL-triglycerides (LDL-TG) compared to the SFA+LCn3PUFA diet. 
Similar effects have been observed previously in a study assessing the 
effects of a diet enriched with n-6PUFA17. Additionally, an 
epidemiological study has demonstrated an inverse association between 
serum n-6PUFA and the concentration of total and small LDL particles 
and a positive association with large LDL18. Indeed, n-6PUFA have been 
demonstrated to increase LDL-r transcription and synthesis19, improving 
the transfer of LDL particles from the bloodstream to the liver. N-6PUFA 
also increase the catabolism of Apolipoprotein B-100, impairing the 
formation of new LDL particles20. In contrast most dietary saturated 
fatty acids reduce the expression of hepatic LDL-r21, impairing the 
capitation of LDL particles, and consequently LDL-C, by the liver. Dietary 
saturated fatty acids have also been associated with an increase in the 
concentration of large LDL particles in healthy22 and obese23 men. In the 
present intervention an SFA rich diet supplemented with LCn-3PUFA 
increased the concentration of very large and medium-large LDL 
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particles, without a significant increase to the total concentration of LDL 
particles. In epidemiological studies, total LDL particle concentration 
and small LDL particle concentration were inversely associated with CVD 
risk independently of the LDL-C level, while large LDL particles were not 
associated with increased risk14,16. Therefore, the higher LDL-C levels 
observed after consumption of the SFA rich diet compared to the n-
6PUFA rich diet may not necessarily heighten the CVD risk, particularly 
when LCn-3PUFA intake is adequate. 
Interestingly, saturated fat consumption for 10 days resulted in 
further increase in erythrocyte 20:5n-3 and 22:6n-3 percentage whereas 
n-6PUFA diet induced a significant decline in the percentage of all LCn-
3PUFA in plasma and a non-significant reduction in erythrocyte 20:5n-3 
percentage despite an increase in 22:6n-3 percentage. These results are 
in agreement with our previous observations that saturated fat 
enhances incorporation of LCn-3PUFA into plasma and tissue lipids, 
while n-6PUFA and LCn-3PUFA compete for incorporation8,9. These 
results may have important implications when considering the health 
effects of LCn-3PUFA. Despite the negative effects of SFA on cholesterol 
levels, greater incorporation of LCn-3PUFA following supplementation 
with a background diet rich in saturated fats has the potential to result 
into greater anti-inflammatory and anti-aggregatory effects. The 
importance of background dietary fat on the health effects of LCn-
3PUFA supplementation therefore merits further exploration. 
Furthermore, animal studies have demonstrated that diets rich 
in n-6PUFA compared to diets rich in SFA, promote a shift of the 
cholesterol and triglyceride pools from the circulation into tissue lipids, 
Chapter 4 
253 
especially the liver, despite supplementation with plant or marine n-
3PUFA24,25. Fat accumulation in the liver may promote increased 
systemic inflammation, atherosclerosis and metabolic syndromes26, 
being potentially more detrimental in the long term than elevated 
plasma cholesterol. Therefore, further studies are warranted to 
understand the effect of the background diet on inflammation, fat 
accumulation in the tissues and other risk factors in subjects consuming 
an adequate amount of LCn-3PUFA. 
Among the study strengths are its unique design, the addition of 
a pre-supplementation period to eliminate bias due to difference in 
omega-3 index, the high compliance with the study diets and 
supplementation (over 80% compliance) and the monitoring of the 
participants' life-style (physical activity and general health) throughout 
the trial. 
Some limitations of this study should be considered. The mixed 
population recruited for the intervention may have been a confounder, 
as sex and age dependent effects were not accounted for. The decrease 
in carbohydrate intake during the n-6PUFA-LCn-3PUFA diet, not 
observed during the SFA-LCn-3PUFA diet, may have been another 
confounder. Although previous studies demonstrate that high fat diets 
cause changes in plasma lipids in 8 days or less27,28, the short duration of 
the dietary intervention may also have been a limiting factor, as longer 
intervention periods are likely to show greater changes in lipoprotein 
profiles. In longer term dietary interventions, saturated fatty acids do 
not seem to be associated with cardiovascular disease risk factors29. 
Moreover, the sample size may have been small to assess differences in 
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the profile of some lipoproteins, as the changes in the short term may 
be small in magnitude, especially for HDL profiles. 
In conclusion, improvement in the LCn-3PUFA status in the pre-
supplementation period modulated the effect of SFA and n-6PUFA on 
most lipoprotein profiles. Nevertheless, a diet enriched with n-6PUFA 
still decreased LDL particle and cholesterol concentration. The 
cholesterol-raising effects of dietary saturated fats were accompanied 
by a greater increase in the proportion of plasma and tissue LCn-3PUFA, 
which may potentially reduce other cardiovascular risk factors such as 
inflammation and clotting tendency. This study sheds further light on 
the effect of the various classes of fatty acids. Furthermore, future 
intervention studies must consider LCn-3PUFA status as a confounding 
factor in the determination of the health effects of the main dietary fats. 
Supplementary data to this article can be found online at: 
http://dx.doi.org/10.1016/j.metabol.2016.11.014. 
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4.4.1 Abstract  
Abnormalities in lipoprotein profiles (size, distribution and 
concentration) play an important role in the pathobiology of 
atherosclerosis and coronary artery disease. Dietary fat, among other 
factors, has been demonstrated to modulate lipoprotein profiles. We 
aimed to investigate if background dietary fat (saturated, SFA versus 
omega-6 polyunsaturated fatty acids, n-6PUFA) was a determinant of 
the effects of LCn-3PUFA supplementation, on lipoprotein profiles.  
A randomized controlled clinical intervention trial in a parallel 
design was conducted. Healthy subjects (n=26) were supplemented with 
400 mg eicosapentaenoic acid plus 2,000 mg docosahexaenoic acid) 
daily and randomised to consume diets rich in either SFA or n-6PUFA for 
a period of 6 weeks. Blood samples, collected at baseline and after six 
weeks of intervention, were assessed for plasma lipoprotein profiles 
(lipoprotein size, concentration and distribution in subclasses) 
determined using nuclear magnetic resonance spectroscopy (NMR). 
Study participants receiving the SFA or the n-6PUFA enriched 
diets consumed similar percentage energy from fat (41% and 42% 
respectively, p=0.681). However, subjects on the SFA diet consumed 
50% more energy as saturated fat and 77% less as linoleic acid than 
those consuming the n-6PUFA diet (p<0.001). The diets rich in SFA and 
n-6PUFA reduced the concentration of total very low density lipoprotein 
(VLDL) particles (p<0.001, both) and their subclasses and increased VLDL 
(p=0.042 and p=0.007, respectively) and LDL (p=0.030 and 0.027, 
respectively) particle size. In addition, plasma triglyceride concentration 
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was significantly reduced by LCn-3PUFA supplementation irrespective of 
the dietary fat. 
LCn-3PUFA modulated lipoprotein profiles in a similar fashion 
when supplemented in diets rich in either SFA or n-6PUFA. 
 
4.4.2 Introduction 
Abnormalities in lipoprotein profiles have been associated with 
coronary heart disease (CHD) risk in men1 and women2-5. Evidence 
suggests that CHD risk is increased by larger very low density lipoprotein 
(VLDL) particle sizes, smaller high density lipoprotein (HDL) and low 
density lipoprotein (LDL) particle sizes and increased concentration of 
small LDL and large VLDL particles; although the ideal lipoprotein 
profiles for the prevention of CHD may vary according to age, gender 
and health status1,6. A variety of factors can modulate lipoprotein 
profiles, including dietary habits7 or physical activity8. 
Long chain omega-3 polyunsaturated fatty acids (LCn-3PUFA), 
despite some controversy9, are well known for their health benefits, 
particularly in the prevention of CHD, due to their capacity to help 
manage hyperlipidaemia10, inflammation11 and platelet aggregation11,12 
as well as their potential to modulate lipoprotein profiles. Dietary 
supplementation with LCn-3PUFA has been shown to decrease the 
concentration of small HDL particles13 and increase the concentration of 
large HDL particles13-15 and the average HDL particle size16, although 
change in HDL particle size has not been observed in all studies15,17. LCn-
3PUFA supplementation has also been shown to decrease VLDL particle 
size15,18 and large and medium VLDL particle concentration14. However, 
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the effect of LCn-3PUFA supplementation on the LDL profile is 
heterogeneous. Some authors suggest an increase in LDL particle 
size15,19,20, while others have not observed change in LDL size17,21-23 or 
have even observed a decrease in particle size13. The literature also 
suggests an increase in the concentration of medium and large LDL 
particles and a decrease in small particles, despite no change in the 
average size of the particles14,15,22. 
In all the above mentioned studies involving LCn-3PUFA 
supplementation and lipoprotein profiles, little attention has been given 
to the other components of the diet, especially the amount and type of 
the fats consumed. The human diet comprises a mixture of fats and 
even after supplementation and increase in seafood consumption, LCn-
3PUFA remains a minor proportion of the total fat consumed. We have 
recently demonstrated that LCn-3PUFA are incorporated in plasma and 
erythrocytes to a greater extent when consumed with a diet rich in 
saturated fats compared to a diet rich in n-6PUFA24. The aim of this 
study was to examine whether the background dietary fat induced 
changes in lipoprotein concentration, size and subclass distribution are 
modulated by co-supplementation with LCn-3PUFA. 
 
4.4.3 Material, Subjects and Methods  
Subjects. Healthy adults aged between 18 and 65 years were 
recruited. Subjects were excluded if they were using lipid-lowering 
drugs (e.g. statins) or fish oil supplements; regularly consuming 2 or 
more fish meals per week; had any history of stroke, congestive heart 
failure, coronary artery bypass graft (CABG), myocardial infarction, or 
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atherosclerotic CVD; had diabetes, liver or gastrointestinal disease; were 
smokers; were pregnant or breast-feeding. 
Study design. This randomized, parallel design, dietary 
intervention trial has been previously described24. In summary, subjects 
were randomized using computer generated random tables to diets 
supplemented with LCn-3PUFA and either enriched with saturated fatty 
acids (SFA+LCn-3PUFA diet) or n-6PUFA (n-6PUFA+LCn-3PUFA diet). 
Subjects in the SFA+LCn-3PUFA diet group consumed daily 24g of 
butter, 40g of white chocolate (30g fat, 20.9g saturated fat) and 4x1g 
fish oil capsules [100mg eicosapentaenoic acid (EPA) and 500mg 
docosahexaenoic acid (DHA) each (EPAX 1050TG, Norway)]. Participants 
were also encouraged to consume foods containing SFA, while reducing 
n-6PUFA intake. Subjects on the n-6PUFA+LCn-3PUFA diet received 20g 
of margarine, 42g of sunflower seeds (30g fat, 20g n-6PUFA) daily and 
4x1g fish oil capsules. They were also guided on how to increase 
consumption of foods containing n-6PUFA while reducing SFA intake. All 
subjects were advised to maintain other aspect of their habitual diet 
and their usual physical activity status. Before starting and on their last 
week on the intervention, subjects completed a three day food record 
(2 week days and 1 weekend day), a physical activity questionnaire and 
a medical questionnaire, which included current medications and 
supplements, illnesses and alcohol consumption. FoodWorks 7 
Professional (Xyris software) was used to assess the food records. A 
fasting blood sample was collected in EDTA vacutainers at baseline and 
following 6 weeks of dietary supplementation and plasma lipoprotein 
profiles were determined. Blood samples were also analysed for fatty 
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acids as previously reported24. Subjects were asked to refrain from 
vigorous exercise and alcohol consumption for 24 hours prior to the 
study day and fasted for at least 10 hours prior to each blood collection. 
The study was carried out in accordance with the guidelines provided in 
the Declaration of Helsinki. The study protocol was approved by the 
University of Newcastle’s Human Research Ethics Committee (protocol 
H-2012-0117) and registered with the Australia New Zealand Trial 
registry (identification number ACTRN12613000962730, 
http://www.anzctr.org.au/). All participants gave written consent prior 
to participation. 
Adherence to the dietary supplementation was determined by 
counting the left-over LCn-3PUFA capsules and interventional food 
products provided (butter, white chocolate, margarine and sunflower 
seeds), querying subjects about their food intake, assessing subjects’ 
dietary records, and analysis of plasma fatty acid composition. None of 
the participants reported any signs of intolerance to the supplements or 
the study foods. 
Plasma Lipoprotein profiles. Blood samples were centrifuged 
(1000 g x 15 minutes at 4oC) immediately after collection to separate 
plasma from erythrocytes and the fractions were stored at -80oC until 
analysed. 
Plasma samples were analysed for lipoprotein profiles using 
nuclear magnetic resonance spectroscopy (NMR) at Biosfer Teslab 
(Reus, Spain). The detailed methods for the determination of lipoprotein 
profiles (size, concentration and subclass distribution) has been 
reported previously25. Lipid volumes were calculated by using common 
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conversion factors to convert concentration units into volume units26. 
The size range for different lipoprotein subclasses corresponded to: 
large VLDL, 68.5-95.9 nm; medium VLDL, 47-68.5 nm; small VLDL, 32.5-
47 nm; very large LDL, 24-32.5 nm; medium-large LDL, 20.5-24 nm; small 
LDL, 17.5-20.5 nm; very large HDL, 10.5-13.5 nm; medium-large HDL, 
8.5-10.5 nm; and small HDL, 7.5-8.5 nm. 
Statistical analysis. This study was primarily designed to assess 
blood lipid levels, discussed in Dias et al24. Thirteen subjects were 
necessary to cause a 30% (0.45mmol/L) decrease in fasting plasma 
triglycerides with 0.387 mmol/L of standard deviation, 0.05 of 
significance level and 80% power.  
All data are presented as median and interquartile range (IQR) 
and non-parametric statistical tests were employed on the analysis. 
Kruskal-Wallis test was used for baseline comparisons. Data at baseline 
and 6 weeks were compared within groups using Wilcoxon signed-rank 
test and data on change was compared between groups using Kruskal-
Wallis test. Statistical analysis were performed using Mat Lab R2010a 
(MathWorks) and p-values lower than 0.05 were considered statistically 
significant.  
 
4.4.4 Results  
 From the 33 subjects who completed the intervention period (18 
on the SFA+LCn-3PUFA diet and 15 on the n-6PUFA+LCn-3PUFA diet), 7 
failed to adhere to the intervention diets or the supplementation 
(compliance lower than 80%) and were, therefore, excluded from the 
data analysis (Figure 1). Twenty six healthy subjects were then included 
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in the statistical analysis, 14 subjects on the SFA+LCn-3PUFA diet (3 
males and 11 females) and 12 on the n-6PUFA+LCn-3PUFA diet (3 males 
and 9 females).  
The concentration of LC-n-3PUFA in the fish oil capsules 
supplemented, measured using gas chromatography27, was more than 
70% total LCn-3PUFA [14.3% EPA and 58.8% DHA] as previously 
described24. 
Subjects’ general characteristics, dietary intake and plasma and 
erythrocyte fatty acid composition have been discussed previously, the 
full discussion and other supporting materials are available in Dias et 
al24. Summary tables are also available in the supplementary material 
(Tables SM.1 to SM.3). In summary, subjects on the SFA+LCn-3PUFA and 
the n-6PUFA+LCn-3PUFA did not differ significantly in age [40.0 (15.0) 
and 43.5 (27.5), respectively], body mass index [22.2 (4.9) and 22.7 
(4.3), respectively], percentage body fat [26.2 (18.5) and 26.4 (10.6), 
respectively] and blood lipids at baseline. As expected participants 
randomized to the SFA+LCn-3PUFA diet increased saturated fat and 
decreased linoleic acid intake (p<0.01, both), while participants 
randomized to the n-6PUFA+LCn-3PUFA diet increased linoleic acid (LA) 
and decreased saturated fat intake (p<0.01, both) compared to baseline 
values.  
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Figure 1. Enrolment schedule for the interventional trial. 
 
Changes in dietary protein, total fat, carbohydrates and 
cholesterol did not differ significantly between dietary groups. There 
were no significant differences in plasma fatty acids between the two 
groups at baseline, except for percentage DHA which was significantly 
greater in the plasma of subjects randomized to the SFA+LCn-3PUFA 
diet. Changes in dietary patterns and plasma fatty acids suggest that 
participants complied with the study protocol. Change in plasma LCn-
3PUFA [including EPA, docosapentaenoic acid and DHA] was significantly 
greater (p<0.05) after the consumption of the SFA+LCn-3PUFA diet 
compared to the n-6PUFA+LCn-3PUFA diet. There was also a significant 
Chapter 4 
268  
increase in percentage LA and a concomitant decrease in percentage 
arachidonic acid (AA) after the consumption of n-6PUFA+LCn-3PUFA 
diet, while no significant change in LA and AA was observed after the 
SFA+LCn-3PUFA diet. 
Lipoprotein profiles at baseline were not significantly different 
between groups (Tables 1 and 2). Both diets decreased cholesterol and 
triglyceride concentrations in VLDL particles (n-SFA+LCn-3PUFA diet, 
p<0.001, n-6PUFA+LCn-3PUFA diet p=0.002 and p<0.001, respectively). 
After the n-6PUFA+LCn-3PUFA diet, there was a significant decrease in 
cholesterol and triglyceride levels in intermediate density lipoprotein 
(IDL) particles (p=0.001 for both). After the SFA+LCn-3PUFA there was a 
significant increase in the concentration of LDL triglycerides (p=0.002). 
Additionally, subjects on the SFA+LCn-3PUFA diet presented significantly 
higher triglyceride levels in IDL and LDL particles after intervention than 
subjects on the n-6PUFA+LCn-3PUFA. There was also an increase in 
cholesterol levels in HDL particles after consumption of both diets, 
although this increase was significant only for subjects consuming the n-
6PUFA-LCn-3PUFA diet (p=0.012) (Table 1). 
 
Table 1. Plasma lipid concentrations of subjects at pre and post 
intervention, measured using nuclear magnetic resonance 
spectroscopy. 
mmol/l  Pre-
intervention 
Post-
intervention 
Δ Change P-value
a
 
VLDL-C SFA+LCn-3PUFA 0.12 (0.12) 0.02 (0.02) − 0.05 (0.08)
b
 0.129 
 n-6PUFA+LCn-3PUFA 0.14 (0.15) 0.02 (0.07) − 0.11 (0.15)
b
 
 
IDL-C SFA+LCn-3PUFA 0.09 (0.06) 0.09 (0.06) − 0.01 (0.06) 0.076 
 n-6PUFA+LCn-3PUFA 0.09 (0.07) 0.04 (0.07) − 0.04 (0.08)
b
 
 
LDL-C SFA+LCn-3PUFA 2.70 (0.51) 2.71 (0.59) 0.13 (0.57) 0.425 
 n-6PUFA+LCn-3PUFA 2.50 (0.72) 2.43 (0.29) 0.01 (0.47)  
HDL-C SFA+LCn-3PUFA 1.39 (0.40) 1.55 (0.23) 0.07 (0.32) 0.857 
 n-6PUFA+LCn-3PUFA 1.24 (0.45) 1.27 (0.58) 0.08 (0.17)
b
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Total C SFA+LCn-3PUFA 4.23 (0.78) 4.57 (1.09) 0.13 (0.67) 0.355 
 n-6PUFA+LCn-3PUFA 4.01 (0.93) 3.99 (0.57) − 0.06 (0.49)  
VLDL-TG SFA+LCn-3PUFA 0.44 (0.30) 0.29 (0.27) − 0.17 (0.18)
b
 0.857 
 n-6PUFA+LCn-3PUFA 0.46 (0.11) 0.29 (0.15) − 0.20 (0.18)
b
 
 
IDL-TG SFA+LCn-3PUFA 0.06 (0.02) 0.05 (0.02) − 0.00 (0.02) 0.033 
 n-6PUFA+LCn-3PUFA 0.06 (0.02) 0.06 (0.02) − 0.02 (0.02)
b
 
 
LDL-TG SFA+LCn-3PUFA 0.12 (0.15) 0.12 (0.09) 0.02 (0.02)b 0.042 
 n-6PUFA+LCn-3PUFA 0.10 (0.06) 0.11 (0.03) − 0.01 (0.04)  
HDL-TG SFA+LCn-3PUFA 0.04 (0.08) 0.05 (0.05) 0.01 (0.03) 0.117 
 n-6PUFA+LCn-3PUFA 0.06 (0.05) 0.05 (0.04) − 0.01 (0.03)  
Total TG SFA+LCn-3PUFA 0.70 (0.20) 0.54 (0.24) − 0.16 (0.24)
b
 0.503 
 n-6PUFA+LCn-3PUFA 0.67 (0.18) 0.49 (0.15) − 0.19 (0.28)
b
 
 
Abbreviations: C, cholesterol; HDL, high-density lipoprotein; IDL, intermediate-
density lipoprotein; LCn-3PUFA, long-chain omega-3 polyunsaturated fatty acids; 
LDL, low density lipoprotein; n-6PUFA, omega-6 polyunsaturated fatty acid; SFA, 
saturated fatty acid; TG, triglycerides; VLDL, very-low-density lipoprotein. aP-values 
for  comparison  of change values between  diets.  bSigniﬁcant difference  between 
pre  and  post intervention  (P<0.05). Data presented  as median  (interquartile range) 
for the SFA+LCn-3PUFA diet (n = 14; 3 males and 11 females) and the n-6PUFA+LCn-
3PUFA diet (n = 12; 3 males and 9 females). Bold values in the delta- change 
column indicate signiﬁcant difference between pre and post intervention (P<0.05). 
Bold values in the P-value column indicate P<0.05. 
 
Total, large, medium and small VLDL particles were decreased 
after the consumption of both diets (n-SFA+LCn-3PUFA diet, p<0.001, 
p=0.025, p<0.001 and p<0.001; n-6PUFA+LCn-3PUFA diet p<0.001, 
respectively). A decrease was also observed in very large HDL particles 
after both diets (n-SFA+LCn-3PUFA diet, p=0.01; n-6PUFA+LCn-3PUFA 
diet, p<0.001, respectively), with no change in total HDL particle 
concentration and a tendency for increase in medium-large HDL 
particles after the SFA+LCn-3PUFA (p=0.058) and the n-6PUFA+LCn-
3PUFA (p=0.064) diet. After the SFA+LCn-3PUFA there was a significant 
increase in the concentration of medium-large LDL particles (p=0.011). 
However, change in medium-large LDL was not significantly different 
between the two diets. Increases in VLDL and LDL particle size were not 
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significantly different between both diets (Table 2). For all other 
parameters there was no significant difference between diets. 
 
Table 2. Lipoprotein profiles (distribution in subclasses, 
concentration and size) of subjects at pre at pre and post 
intervention. 
    Pre-
intervention 
Post-
intervention 
Δ Change P-valuea P-valueb 
Particle concentrations 
 
    
VLDL-P (nmol/L) SFA+LCn-3PUFA 23.93 (17.27) 13.85 (16.28) -10.85 (9.53) <0.001 0,939 
n-6PUFA+LCn-3PUFA 26.03 (8.76) 13.63 (9.09) -13.34 (12.53) <0.001 
Large VLDL-P 
(nmol/L) 
SFA+LCn-3PUFA 0.73 (0.26) 0.55 (0.45) -0.20 (0.33) 0,025 0,625 
n-6PUFA+LCn-3PUFA 0.77 (0.31) 0.57 (0.25) -0.21 (0.24) <0.001 
Medium VLDL-P 
(nmol/L) 
SFA+LCn-3PUFA 3.77 (2.36) 2.32 (1.90) -1.44 (1.74) <0.001 0,979 
n-6PUFA+LCn-3PUFA 4.01 (1.19) 2.40 (1.09) -1.80 (1.58) <0.001 
Small VLDL-P 
(nmol/L) 
SFA+LCn-3PUFA 19.35 (14.74) 10.77 (14.01) -9.33 (7.91) <0.001 0,898 
n-6PUFA+LCn-3PUFA 20.96 (7.46) 10.45 (6.67) -11.28 (10.65) <0.001 
LDL-P (nmol/L) SFA+LCn-3PUFA 725.9 (126.2) 739.0 (189.5) 39.6 (159.4) 0,173 0,292 
n-6PUFA+LCn-3PUFA 682.6 (210.3) 667.7 (79.5) 2.5 (146.5) 0,91 
       
Very large LDL-P 
(nmol/L) 
SFA+LCn-3PUFA 107.9 (29.0) 108.7 (39.0) 7.1 (20.7) 0,119 0,341 
n-6PUFA+LCn-3PUFA 99.9 (27.2) 100.1 (15.6) 1.5 (14.1) 0,301 
Medium-large 
LDL-P (nmol/L) 
SFA+LCn-3PUFA 243.4 (54.7) 249.2 (72.7) 21.5 (47.6) 0,011 0,173 
n-6PUFA+LCn-3PUFA 229.3 (66.9) 235.7 (42.6) 3.85 (32.9) 0,519 
Small LDL-P 
(nmol/L) 
SFA+LCn-3PUFA 380.2 (88.8) 388.2 (100.5) 6.5 (88.0) 0,426 0,341 
n-6PUFA+LCn-3PUFA 353.0 (105.2) 328.8 (46.4) -5.3 (90.2) 0,519 
HDL-P (μmol/L) SFA+LCn-3PUFA 24.44 (6.79) 27.13 (3.99) 1.40 (4.35) 0,173 1,000 
n-6PUFA+LCn-3PUFA 23.10 (6.43) 23.32 (9.35) 0.60 (1.97) 0,077 
Very large HDL-
P (μmol/L) 
SFA+LCn-3PUFA 0.10 (0.07) 0.06 (0.06) -0.04 (0.05) 0,011 0,738 
n-6PUFA+LCn-3PUFA 0.10 (0.05) 0.06 (0.05) -0.05 (0.05) <0.001 
Medium-large 
HDL-P (μmol/L) 
SFA+LCn-3PUFA 8.11 (1.36) 8.95 (1.41) 0.56 (1.63) 0,058 1,000 
n-6PUFA+LCn-3PUFA 7.03 (2.52) 7.54 (3.71) 0.65 (1.06) 0,064 
Small HDL-P 
(μmol/L) 
SFA+LCn-3PUFA 16.53 (4.03) 18.00 (2.21) 0.95 (3.30) 0,217 0,817 
n-6PUFA+LCn-3PUFA 15.96 (4.26) 15.83 (6.21) 0.06 (1.26) 0,519 
Lipoprotein particle size (nm) 
 
    
VLDL-Z SFA+LCn-3PUFA 42.17 (0.53) 42.48 (0.67) 0.27 (0.45) 0,042 0,662 
n-6PUFA+LCn-3PUFA 42.22 (0.62) 42.46 (0.80) 0.37 (0.46) 0,007 
LDL-Z SFA+LCn-3PUFA 21.11 (0.10) 21.16 (0.15) 0.04 (0.08) 0,030 0,341 
n-6PUFA+LCn-3PUFA 21.11 (0.08) 21.16 (0.12) 0.06 (0.10) 0,027 
HDL-Z SFA+LCn-3PUFA 8.23 (0.03) 8.24 (0.05) 0.00 (0.04) 0,670 0,662 
n-6PUFA+LCn-3PUFA 8.23 (0.01) 8.22 (0.04) -0.01 (0.05) 0,970 
Abbreviations: HDL, high-density lipoprotein; IDL, intermediate-density 
lipoprotein; LCn-3PUFA, long-chain omega-3 polyunsaturated fatty acids; LDL, low 
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density lipoprotein; n-6PUFA, omega-6 polyunsaturated fatty acid; P, particle; SFA, 
saturated fatty acid; VLDL, very-low-density lipoprotein; Z, size (diameter in 
nm).aP-values for  comparison  for comparison between pre and post intervention.  
b
 
P-values for comparison of change values between diets.  
Data presented  as median  (interquartile range) for the SFA+LCn-3PUFA diet (n = 14; 
3 males and 11 females) and the n-6PUFA+LCn-3PUFA diet (n = 12; 3 males and 9 
females). Bold values in the delta-change and P-value (a) indicate signiﬁcant 
difference for comparison between pre and post intervention (P<0.05). Bold 
value (b) column represent significant difference for comparison of values between 
diets. 
 
4.4.5 Discussion  
The present intervention trial was designed to evaluate the 
effect of diets enriched with either SFA or n-6PUFA and supplemented 
with LCn-3PUFA, on lipoprotein profiles as a secondary outcome. Both 
diets produced similar changes in lipoprotein profiles, suggesting that 
neither SFA nor n-6PUFA modulate LCn-3PUFA induced changes in 
lipoprotein profiles. Additionally, both diets increased LDL particle size, 
profile that has been associated with a reduced risk for atherosclerosis 
in epidemiological studies. 
Subjects consuming either of the diets presented comparable 
reductions in total, large, medium and small VLDL particle 
concentrations, as well as in VLDL triglycerides, consistent with the 
decrease in total triglycerides and VLDL particle concentration following 
LCn-3PUFA supplementation observed in other studies23,28,29. Decrease 
in plasma triglycerides and VLDL particles have been associated with a 
protective profile against atherosclerosis and CVD risk6,30. 
Supplementation with n-3PUFA has been shown to inhibit VLDL 
synthesis31 and secretion by the liver32, improve VLDL clearance33 and 
enhance VLDL conversion to LDL29. One of the mechanisms by which 
LCn-3PUFA may act is the stimulation of lipoprotein lipase expression; 
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resulting in triglyceride hydrolysis in chylomicrons and VLDL particles, 
forming lipoprotein remnants (small VLDL and IDL particles). Lipoprotein 
remnants have more affinity to the LDL receptor (LDL-r) 28,34, and 
compete with LDL particles for clearance35,36. Additionally, both LCn-
3PUFA and SFA decrease expression of hepatic LDL-r33,37, also explaining 
the increase in large LDL particle concentration after consumption of 
the SFA+LCn-3PUFA diet. N-6PUFA are also known to reduce circulating 
VLDL particle concentration, by increasing VLDL uptake and lipolysis38. 
The n-6PUFA lipolysis effect in VLDL may also explain the reduction in 
triglycerides in IDL particles that occurred after the consumption of the 
n-6PUFA+LCn-3PUFA diet, but not after the SFA+LCn-3PUFA diet. 
Despite the VLDL lowering ability of both n-6 and LCn-3PUFA, the n-
6PUFA+LCn-3PUFA diet did not affect VLDL particle concentration and 
subclass distribution differently than the SFA+LCn-3PUFA diet, 
suggesting no increased benefit obtained in VLDL particle modulation by 
combining n-6 and LCn-3PUFA. 
N-6PUFA have also been demonstrated to reduce plasma LDL 
particle concentration by increasing the fractional catabolism of apoB-
10039, the main apolipoprotein in VLDL and LDL particles, and by 
increasing LDL-r transcription and synthesis35,40. However, no significant 
change was observed in LDL particle concentration or distribution after 
the consumption of the n-6PUFA+LCn-3PUFA diet in our study, 
suggesting that LCn-3PUFA may have neutralized the LDL lowering effect 
of n-6PUFA. 
The size of VLDL particles increased in both groups, conflicting 
with findings from Mostad et al21 and Maki et al41, who observed a 
Chapter 4 
273 
decrease in VLDL particle size in type 2 diabetes and 
hypercholesteraemic patients, respectively, after supplementation with 
LCn-3PUFA compared to placebo (corn oil and soya oil, respectively). 
This may suggest that either both background dietary fats (n-6PUFA and 
SFA) suppress the ability of LCn-3PUFA to reduce VLDL size or LCn-
3PUFA modulate VLDL size differently in healthy subjects.  
After the consumption of both diets, there was an increase in 
LDL size and medium-large LDL particle concentration. Epidemiological 
studies suggest that serum LCn-3PUFA level is positively correlated with 
LDL particle size7,42. Furthermore, intervention trials suggested an 
increase in LDL particle size43, especially when DHA is supplemented in 
the diet13. The increase in medium-large LDL particle concentration is 
also consistent with previously published studies14,22. 
No change in total HDL particle concentration was observed, 
despite a decrease in very large HDL particle concentration. Indeed, 
there was a trend for an increase in medium-large HDL particle 
concentration after both diets, which counter-balanced the decrease of 
very large HDL particles. This is consistent with previous epidemiological 
and interventional studies. In epidemiological studies a positive 
correlation between dietary LCn-3PUFA and serum large HDL particle 
concentration was observed7,44. In interventional trials, an increase in 
large HDL particle concentration was observed in the plasma of mildly 
and hypercholesterolemic subjects during a DHA supplementation 
trial13,14; and no change in plasma small, medium or large HDL particles 
after supplementation with EPA17. The very large HDL particles (10.5-
13.5nm) in the present intervention are just a small proportion of the 
Chapter 4 
274  
total HDL particles and even a small change in magnitude may result in a 
significant change. Nevertheless, medium-large HDL particles (8.5-
10.5nm) represent mature HDL particles and therefore active in the 
reverse transport of cholesterol, conferring a profile protective against 
atherosclerosis risk.   
The decrease in very large HDL particles after consumption of 
both diets is consistent with an increase in the activity of cholesteryl 
ester transfer protein (CETP) caused by LCn-3PUFA supplementation, 
especially DHA37. An increase in CETP activity consequently increases 
the exchange of cholesterol from HDL particles for triglycerides from 
VLDL particles, improving the reverse cholesterol transport and 
facilitating the conversion of VLDL to LDL. This mechanism may also be 
responsible for the concomitant decrease in VLDL particles and increase 
in LDL triglycerides. Triglyceride-rich HDL particles have their 
triglycerides hydrolysed by hepatic lipase, which may explain the shift in 
the subclass distribution of HDL particles45.  
Comparison between the different studies performed on 
lipoprotein profiles is limited by the lack of standardization between the 
different analytical methods used for the determination of lipoprotein 
profiles46, although the gap between methods has been closing with 
recent studies47. Furthermore, the literature on the classification of 
lipoprotein subclasses according to their diameter and density is 
heterogeneous. The method used was limited by the fact that 
intermediate density particles were not measured separately25, but 
were combined with very large LDL particles. However, large and small 
LDL subclasses and VLDL particles seem to be of more importance to 
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atherosclerosis management1. Another limitation in the discussion 
about the effect of LCn-3PUFA on lipoprotein profiles is the difference in 
composition and dose of LCn-3PUFA used across different studies, as 
well as the lack of dietary information. Additionally, sample size and 
power were calculated for determining change in plasma triglycerides 
and not specifically for determining changes in lipoprotein profiles. 
Thus, the sample size may have been small to assess differences in 
lipoprotein profiles, as the changes are small in magnitude, especially 
for HDL profile. The results may also have been confounded by sex and 
age dependent effects, as a mixed population was assessed. Moreover, 
it is possible that a small increase in LCn-3PUFA in tissues may produce a 
desirable effect on lipoprotein profiles that is not improved with a 
further increase in LCn-3PUFA. In which case, the high LCn-3PUFA dose 
may have masked the effects of the background dietary fat consumed. 
In conclusion, a background diet rich in saturated fatty acids 
versus n-6PUFA did not modulate the effect of LCn-3PUFA on 
lipoprotein profiles, despite the enhanced LCn-3PUFA incorporation into 
plasma and erythrocyte lipids with consumption of a diet rich in 
saturated fatty acids compared to n-6PUFA24. Further investigation of 
the interaction of LCn-3PUFA with saturated fats is warranted, in order 
to clarify the role of LCn-3PUFA status in modulating dietary SFA-
induced changes in circulating lipoproteins. However, the changes to 
lipoprotein profiles observed suggest an improvement towards a less 
atherogenic profile after intervention with both diets, supporting the 
hypothesis that a diet rich in saturated fatty acids does not modulate 
cardiovascular risk factors differently than a diet rich in n-6PUFA when 
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an adequate amount of LCn-3PUFA is consumed. Furthermore, sex 
differences, as well as age, dose and intervention length, should be 
considered in future studies. 
Supplementary Information accompanies this paper on 
European Journal of Clinical Nutrition website 
(http://www.nature.com/ejcn). 
 
4.4.6 References  
1. Carmena, R., Duriez, P. & Fruchart, J.-C. Atherogenic Lipoprotein 
Particles in Atherosclerosis. Circulation 109, III-2-III-7 (2004). 
2. Mackey RH, McTigue KM, Chang YF, Barinas-Mitchell E, Evans 
RW, Tinker LF,  et al. Lipoprotein particles and size, total and high 
molecular weight adiponectin, and leptin in relation to incident 
coronary heart disease among severely obese postmenopausal women: 
The Women’s Health Initiative Observational Study. BBA Clin. 3, 243–
250 (2015). 
3. Akinkuolie, A. O., Paynter, N. P., Padmanabhan, L. & Mora, S. 
High-density lipoprotein particle subclass heterogeneity and incident 
coronary heart disease. Circ. Cardiovasc. Qual. Outcomes 7, 55–63 
(2014). 
4. Mora, S. et al. Lipoprotein Particle Profiles by Nuclear Magnetic 
Resonance Compared With Standard Lipids and Apolipoproteins in 
Predicting Incident Cardiovascular Disease in Women. Circulation 119, 
931–939 (2009). 
5. Mackey RH, Kuller LH, Sutton-Tyrrell K, Evans RW, Holubkov R, 
M. K. Lipoprotein subclasses and coronary artery calcium in 
postmenopausal women from the healthy women study. Am. J. Cardiol. 
90, 71–76 (2002). 
6. Cromwell, W. C. et al. LDL particle number and risk of future 
cardiovascular disease in the Framingham Offspring Study—Implications 
for LDL management. J. Clin. Lipidol. 1, 583–592 (2007). 
Chapter 4 
277 
7. Bogl, L. H. et al. Association between habitual dietary intake and 
lipoprotein subclass profile in healthy young adults. Nutr. Metab. 
Cardiovasc. Dis. 23, 1071–8 (2013). 
8. Ahmed, H. M., Blaha, M. J., Nasir, K., Rivera, J. J. & Blumenthal, R. 
S. Effects of Physical Activity on Cardiovascular Disease. Am. J. Cardiol. 
109, 288–295 (2012). 
9. Rizos, E. C., Ntzani, E. E., Bika, E., Kostapanos, M. S. & Elisaf, M. S. 
Association between omega-3 fatty acid supplementation and risk of 
major cardiovascular disease events: a systematic review and meta-
analysis. JAMA 308, 1024–33 (2012). 
10. Eslick, G. D., Howe, P. R. C., Smith, C., Priest, R. & Bensoussan, A. 
Benefits of fish oil supplementation in hyperlipidemia: a systematic 
review and meta-analysis. Int. J. Cardiol. 136, 4–16 (2009). 
11. Russo, G. L. Dietary n−6 and n−3 polyunsaturated fatty acids: 
From biochemistry to clinical implications in cardiovascular prevention. 
Biochemical Pharmacology 77, 937–946 (2009). 
12. Phang, M., Lincz, L. F. & Garg, M. L. Eicosapentaenoic and 
Docosahexaenoic Acid Supplementations Reduce Platelet Aggregation 
and Hemostatic Markers Differentially in Men and Women. J. Nutr. 143, 
457–463 (2013). 
13. Mori, T. A. et al. Purified eicosapentaenoic and docosahexaenoic 
acids have differential effects on serum lipids and lipoproteins, LDL 
particle size, glucose, and insulin in mildly hyperlipidemic men. Am. J. 
Clin. Nutr. 71, 1085–94 (2000). 
14. Neff, L. M. et al. Algal docosahexaenoic acid affects plasma 
lipoprotein particle size distribution in overweight and obese adults. J. 
Nutr. 141, 207–13 (2011). 
15. Kelley, D. S., Siegel, D., Vemuri, M. & Mackey, B. E. 
Docosahexaenoic acid supplementation improves fasting and 
postprandial lipid profiles in hypertriglyceridemic men. Am. J. Clin. Nutr. 
86, 324–33 (2007). 
16. Erkkilä, A. et al. Effect of fatty and lean fish intake on lipoprotein 
subclasses in subjects with coronary heart disease: A controlled trial. J. 
Clin. Lipidol. 8, 126–133 (2014). 
Chapter 4 
278  
17. Bays, H. et al. Icosapent ethyl, a pure EPA omega-3 fatty acid: 
Effects on lipoprotein particle concentration and size in patients with 
very high triglyceride levels (the MARINE study). J. Clin. Lipidol. 6, 565–
572 (2012). 
18. Mostad, I. L., Bjerve, K. S., Lydersen, S. & Grill, V. Effects of 
marine n-3 fatty acid supplementation on lipoprotein subclasses 
measured by nuclear magnetic resonance in subjects with type II 
diabetes. Eur. J. Clin. Nutr. 62, 419–429 (2008). 
19. Satoh, N. et al. Purified eicosapentaenoic acid reduces small 
dense LDL, remnant lipoprotein particles, and C-reactive protein in 
metabolic syndrome. Diabetes Care 30, 144–6 (2007). 
20. Shigemasa Tani, MD; Ken Nagao, MD; Michiaki Matsumoto, MD; 
Atsushi Hirayama, M. Highly Purified Eicosapentaenoic Acid May 
Increase Low-Density Lipoprotein Particle Size by Improving Triglyceride 
Metabolism in Patients With Hypertriglyceridemia. Circ. J. 77, 2349– 
2357 (2013). 
21. Mostad, I L; Bjerve, K S; Lydersen, S; Grill, V. Effects of marine n-3 
fatty acid supplementation on lipoprotein subclasses measured by 
nuclear magnetic resonance in subjects with type II diabetes - ProQuest. 
Eur. J. Clin. Nutr. 62, 419–29 (2007). 
22. Oelrich, B., Dewell, A. & Gardner, C. D. Effect of fish oil 
supplementation on serum triglycerides, LDL cholesterol and LDL 
subfractions in hypertriglyceridemic adults. Nutr. Metab. Cardiovasc. 
Dis. 23, 350–7 (2013). 
23. Rivellese, A. A. et al. Effects of dietary saturated, 
monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size 
and post-prandial lipid metabolism in healthy subjects. Atherosclerosis 
167, 149–158 (2003). 
24. Dias, C., Wood, L. & Garg, M. Effects of dietary saturated and n - 
6 polyunsaturated fatty acids on the incorporation of long - chain n - 3 
polyunsaturated fatty acids into blood lipids. Eur. J. Clin. Nutr. Adv. 
online Publ. 13, (2016). 
Chapter 4 
279 
25. Mallol, R. et al. Liposcale: a novel advanced lipoprotein test 
based on 2D diffusion-ordered 1H NMR spectroscopy. J. Lipid Res. 56, 
737–746 (2015). 
26. Jeyarajah, E. J., Cromwell, W. C., Otvos, J. D. & al.,  et. 
Lipoprotein particle analysis by nuclear magnetic resonance 
spectroscopy. Clin. Lab. Med. 26, 847–70 (2006). 
27. Wood, L. G., Fitzgerald, D. A., Gibson, P. G., Cooper, D. M. & 
Garg, M. L. Increased plasma fatty acid concentrations after respiratory 
exacerbations are associated with elevated oxidative stress in cystic 
fibrosis patients. Am. J. Clin. Nutr. 75, 668–75 (2002). 
28. Mori, T. A. et al. Effects of varying dietary fat, fish, and fish oils 
on blood lipids in a randomized controlled trial in men at risk of heart 
disease. Am. J. Clin. Nutr. 59, 1060–8 (1994). 
29. Chan, D. C. et al. Randomized controlled trial of the effect of n–3 
fatty acid supplementation on the metabolism of apolipoprotein B-100 
and chylomicron remnants in men with visceral obesity. Am. J. Clin. 
Nutr. 77, 300–307 (2003). 
30. Nordestgaard, B. & Varbo, A. Triglycerides and cardiovascular 
disease. Lancet 384, 626–635 (2014). 
31. Schoonjans, K., Staels, B. & Auwerx, J. Role of the peroxisome 
proliferator-activated receptor (PPAR) in mediating the effects of 
fibrates and fatty acids on gene expression. J. Lipid Res. 37, 907–25 
(1996). 
32. López-Soldado, I., Avella, M. & Botham, K. M. Suppression of 
VLDL secretion by cultured hepatocytes incubated with chylomicron 
remnants enriched in n−3 polyunsaturated fatty acids is regulated by 
hepatic nuclear factor-4α. Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 
1791, 1181–1189 (2009). 
33. Fernandez, M. L. & West, K. L. Mechanisms by which dietary fatty 
acids modulate plasma lipids. J. Nutr. 135, 2075–8 (2005). 
34. Griffin, B. A. The effect of n−3 fatty acids on low density 
lipoprotein subfractions. Lipids 36, S91–S97 (2001). 
Chapter 4 
280  
35. Jackson, K. G., Maitin, V., Leake, D. S., Yaqoob, P. & Williams, C. 
M. Saturated fat-induced changes in Sf 60-400 particle composition 
reduces uptake of LDL by HepG2 cells. J. Lipid Res. 47, 393–403 (2006). 
36. Olano-Martin E, Anil E, Caslake MJ, Packard CJ, Bedford D, 
Stewart G,  et al. Contribution of apolipoprotein E genotype and 
docosahexaenoic acid to the LDL-cholesterol response to fish oil. 
Atherosclerosis 209, 104–110 (2010). 
37. Ishida T, Ohta M, Nakakuki M, Kami H, Uchiyama R, Kawano H,  
et al. Distinct regulation of plasma LDL cholesterol by eicosapentaenoic 
acid and docosahexaenoic acid in high fat diet-fed hamsters: 
Participation of cholesterol ester transfer protein and LDL receptor. 
Prostaglandins, Leukot. Essent. Fat. Acids 88, 281–288 (2013). 
38. van Schalkwijk, D. B. et al. Dietary Medium Chain Fatty Acid 
Supplementation Leads to Reduced VLDL Lipolysis and Uptake Rates in 
Comparison to Linoleic Acid Supplementation. PLoS One 9, e100376 
(2014). 
39. Ooi, E., Watts, G., Ng, T. & Barrett, P. Effect of Dietary Fatty Acids 
on Human Lipoprotein Metabolism: A Comprehensive Update. Nutrients 
7, 4416–4425 (2015). 
40. Mustad, V. A., Ellsworth, J. L., Cooper, A. D., Kris-Etherton, P. M. 
& Etherton, T. D. Dietary linoleic acid increases and palmitic acid 
decreases hepatic LDL receptor protein and mRNA abundance in young 
pigs. J. Lipid Res. 37, 2310–23 (1996). 
41. Maki, K. C. et al. Effects of Prescription Omega-3-Acid Ethyl 
Esters on Fasting Lipid Profile in Subjects With Primary 
Hypercholesterolemia. J. Cardiovasc. Pharmacol. 57, 489–494 (2011). 
42. Mäntyselkä, P. et al. Cross-sectional and longitudinal associations 
of circulating omega-3 and omega-6 fatty acids with lipoprotein particle 
concentrations and sizes: population-based cohort study with 6-year 
follow-up. Lipids Health Dis. 13, 28 (2014). 
43. Lee, M. W. et al. Beneficial Effects of Omega-3 Fatty Acids on 
Low Density Lipoprotein Particle Size in Patients with Type 2 Diabetes 
Already under Statin Therapy. Diabetes Metab. J. 37, 207 (2013). 
Chapter 4 
281 
44. Annuzzi, G. et al. Lipoprotein subfractions and dietary intake of 
n-3 fatty acid: the Genetics of Coronary Artery Disease in Alaska Natives 
study. Am. J. Clin. Nutr. 95, 1315–1322 (2012). 
45. Kuang, Y.-L., Eric Paulson, K., Lichtenstein, A. H. & Lamon-Fava, S. 
Regulation of the expression of key genes involved in HDL metabolism 
by unsaturated fatty acids. Br. J. Nutr. 108, 1351–1359 (2012). 
46. Ensign, W. et al. Disparate LDL phenotypic classification among 4 
different methods assessing LDL particle characteristics. Clin. Chem. 52, 
1722–7 (2006). 
47. Sninsky, J. J., Rowland, C. M., Baca, A. M., Caulfield, M. P. & 
Superko, H. R. Classification of LDL phenotypes by 4 methods of 
determining lipoprotein particle size. J. Investig. Med. 61, 942–9 (2013). 
 
  
 
 
 
 
 
 
 
Chapter 5: Discussion and conclusions 
 
 
  
  
 
Chapter 5 
284 
Perspectives on NMR-based advanced lipoprotein tests (ALTs) 
into clinical practice 
The exhaustive characterization of the lipoprotein profile is 
anything but trivial. The main reason for this is that the chemical 
compositions, density and size of lipoproteins vary greatly, limiting the 
possibility of clearly establishing the relationships amongst these three 
fundamental properties. The wide variety of methodologies used, the 
non-uniform definitions or descriptions of lipoprotein subfractions and 
the heterogeneity limit the comparability among and within analytical 
techniques.  
Due to its inherent quantitative nature and sensitivity to size and 
density, NMR spectroscopy has increasingly gained attention as a 
valuable method for lipoproteins measurement, attracting several 
research groups to test and apply the methodology. However, so far, 
the applications with coherent NMR and reference data (e.g. UC) have 
been limited to relatively small cohorts, and the lack of appropriate 
standards both for the UC measurements and the NMR measurements 
have made meta-studies extremely difficult if not impossible. Several 
commercial companies are now offering lipoprotein analysis through 
NMR spectroscopy, but there is still some controversy about the 
introduction of NMR-based ALTs into clinical practice, partly because 
current methods do not provide a direct measure of lipoprotein sizes. 
Currently, most NMR-based molecular profiles base the results 
on empirical models developed by correlation between the crude NMR 
spectrum and laboratory biochemical measurements of lipid 
concentrations, which make the scientific and clinical community 
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somewhat distrustful, taking into account that the size of the particles is 
the most relevant parameter to estimate the particle number. In this 
context, the approximation proposed by the research group for the 
lipoprotein characterization, the Liposcale test, using two-dimensional 
NMR experiments, whose signal is modulated by the diffusion of the 
particles in the mixture (DOSY-NMR), allows the hydrodynamic 
characteristics of the molecules, such as the size, to be included in the 
obtained information.  
On the other hand, for the introduction of the NMR-based tests 
for the lipoprotein characterization, it is not only necessary to create 
trust and understanding in relation to a particular technology, but also 
attention should be given to the standardization between the different 
NMR platforms and approaches. 
Current efforts towards extreme standardization of NMR 
measurements of blood samples and similar efforts on standardization 
of the reference methods will become game changers that will 
revolutionize the field of lipoprotein profiling. In particular, the 
development of NMR-specific standard operation procedures will allow 
the comparison of different cohorts and will generate new knowledge 
on the lipoprotein particle distribution with the possibility of turning it 
into a biomarker of lifestyle, diseases and healthiness. 
The long-term application of NMR-based lipoprotein analysis in 
medical research is obviously an encouraging example of the 
epidemiological and clinical prospects of NMR-based technologies. 
In the present thesis, it has been demonstrated that 1H-NMR 
spectroscopy is a suitable technique for the characterization of 
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lipoprotein particles and related parameters, reflecting its function and 
the cardio-metabolic health. We have tested this hypothesis within 
different contexts and approximations, from the analysis of lipoprotein 
fractions previously isolated using ultracentrifugation to the analysis of 
serum/plasma samples without the need for separation protocols and 
with minimal sample manipulation by using 1 and 2-dimensional NMR 
approaches in pharmacological, nutritional and epidemiological studies.  
In Chapter 2, we presented our patented methodology for the 
lipoprotein characterization based on the DOSY NMR experiments, the 
Liposcale test, as well as the industrial development carried out by the 
spin off company Biosfer Teslab.  
The Liposcale test1 was created in a pure research framework, 
and therefore, with some limitations to coexist in the market with other 
NMR based on technologies for lipoprotein characterization. Thus, an 
industrial development and regulatory requirements for clinical 
applications were needed to become competitive enough. In this 
regard, Section 2.3.2 offers an overview of the industrial development 
and milestones achieved by the spin off company Biosfer Teslab in order 
to introduce the advance lipoprotein test Liposcale in the market for its 
distribution and commercialization from its constitution.  
During the industrial development of the Liposcale test, with the 
objective to favor the introduction of the NMR based on tests for 
lipoprotein characterization into the clinical practice, the research group 
has been involved in multiple and diverse research studies in 
collaboration with different national and international entities in which 
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the Liposcale test has been applied to characterize the lipoprotein 
profile in different pathologies, interventions and population studies.  
Importantly, the main difference between our 2D NMR approach 
and current 1D NMR methods is that the addition of a second dimension 
in the NMR spectrum by means of a diffusion experiment allows the 
separation of the lipoprotein subclasses according to their diffusion 
coefficient, and with the use of the Stokes-Einstein equation2, DOSY 
NMR yields an objective separation of lipoprotein subclasses based on 
their size and favors the uniqueness of mathematical solutions 
compared to 1D NMR, and therefore is a potentially useful alternative 
to other available approaches for measuring lipoprotein fraction particle 
sizes or discrete size distributions for an arbitrary number of NMR-
derived lipoprotein subclasses due to its inherent robustness and 
minimal sample manipulation3, ready to be used in the clinical routine 
to determine whether there are progressive changes in lipoproteins and 
to identify certain subgroups of individuals with lipoprotein 
abnormalities contributing to the understanding of the physiopathology 
of lipid-mediated cardiometabolic disorders.  
 
Lipoproteins, beyond the lipidic content 
NMR has successfully been applied to identify the presence of 
pro-atherogenic particles, particularly smaller and dense LDL particles, 
reflecting a higher risk for the development of atherosclerosis and 
therefore the possibility of developing cardiovascular disease1.  
On the other hand, the HDL hypothesis considers that a low level 
of cholesterol carried by this fraction accelerates also the development 
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of atherosclerosis. However, the development of drugs that increase its 
concentration, although increasing the level of HDL cholesterol, has 
been unsuccessful due to the lack of efficacy or increasing 
cardiovascular risk4. 
The NMR derived results, presented in Chapter 3 Section 3.2, 
introduce a radically new attempt to explain the above facts, 
considering that HDL undergo alterations in their size that determine its 
structure and composition. 
Since the 1970s, it has been known that the cholesterol 
concentration of the HDL fraction of lipoproteins (HDL-C) is inversely 
related to cardiovascular risk4. The protective function of HDL is 
characterized by its anti-inflammatory and anti-oxidant properties and 
reverse cholesterol transport (CRT)5, that is, the uptake of cholesterol 
from peripheral tissue cells and its transport to the liver for its 
subsequent elimination. Clinical trials with treatments which tend to 
increase HDL cholesterol concentration have revealed that increasing 
cholesterol from pharmacological interventions does not necessarily 
translate into a benefit for the patient as it does naturally. The 
mechanisms affecting the functionality of the HDL particles are 
unknown. As a consequence, the validity of HDL-C as a marker of 
cardiovascular risk protection is questioned. There is currently no 
procedure to evaluate the functionality of HDL in clinical practice and 
therefore no HDL-associated biomarker, alternative to HDL cholesterol, 
has been found which can be used universally to estimate 
cardiovascular risk. 
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Currently the HDL functionality is evaluated from in-vitro 
experiments in which the cholesterol reverse transport efficiency of HDL 
particles is calculated from measurement of the incorporation of 
radioactive isotope-labeled cholesterol molecules5 or fluorescent labels6 
from macrophages. However, these tests are slow, tedious and poorly 
reproducible. Therefore, they can only be carried out in the framework 
of research studies. In addition, they do not generate information about 
the structure and composition of HDL. Some studies of lipidomics and 
proteomics7,8 have also been carried out, although the results have not 
been validated, and they not reveal structural information on HDL 
particles. Other studies indicate that the distribution of HDL's in their 
various subfractions, as well as the quantification of the number of 
particles of each subfraction, may be more informative parameters in 
relation to the cardiovascular protection function9. However, there is no 
consensus on which parameters are optimal and there is no clear 
correlation between these and their functionality / efficacy10. Direct 
measurement of the number of HDL (HDL-P) particles in serum / plasma 
can only be done by nuclear magnetic resonance (NMR)11. 
The group of Samia Mora and colleagues published a relevant 
study comparing the number of HDL particles measured by NMR and 
those obtained with the HDL-C / ApoA-112 ratio and demonstrated a 
clear discrepancy between them in the Women’s health study, the same 
study cohort that has been presented in Chapter 4 in the present thesis. 
In this study, they estimated the particle number considering the classic 
model of Shen13, valid for all fractions of lipoproteins and considered to 
be spherical. Its radius was calculated from lipid and protein volume 
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distribution criteria, taking into account that the surface layer measures 
2 nm and that proteins (basically ApoA-I, ApoA-II) together with free 
cholesterol and phospholipids are on the surface and the esterified 
cholesterol and the triglycerides in the nucleus. 
The reason for the discrepancy is based on the fact that the NMR 
technique measures smaller sizes than those calculated using the Shen 
model. This discrepancy has not been solved by the scientific 
community before the results presented in this thesis, in which we 
performed a preliminary experiment with a small number of control 
samples and patients with type 2 diabetic patients (DM2), reproducing 
the methodology of the mentioned article, although measuring the size 
of isolated HDL by means of ultracentrifugation by NMR with a method 
developed by the group14, seeing that our results15 exhibited 
qualitatively similar discrepancy to that reported in the previously 
mentioned article. 
Our hypothesis considers that the size of the HDL measured 
experimentally is correct and questions the validity of the classic model 
of HDL, proposed by Shen in 197713  and universally accepted by the 
scientific community without providing significant modifications to the 
original proposal. Our model update implies that the lipid distribution in 
HDL is not that predicted by the theory, in the sense that some of the 
hydrophobic lipids (triglycerides and esters of Cholesterol) that 
theoretically occupy the interior of the HDL particles must necessarily, 
by restriction of space, emerge towards the surface of the particles, and 
possibly modify its functionality.  
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The existence of surface hydrophobic lipids would change the 
hydrophobicity of HDL, modify the conformation of the proteins found 
on the surface (basically Apo A-1 and Apo A-2) and therefore affect its 
functionality.  
The results presented in this thesis open the door to the 
development of new procedures to directly identify and distinguish 
lipoprotein abnormalities in this specific fraction, in which the ratio 
surface/volume is crucial due to the particular small size. The novelty of 
the proposal resides in the application, for the first time, of the most 
modern biophysical techniques to the study of lipoproteins combining 
atomic force microscopy (AFM), microscopy equipment and classic 
fluorimetric scattering to analyze the polarity of the surface of the HDL 
particles as well as their viscoelastic properties from the 
electromechanical interactions of the microscope sensor complemented 
by the visualization of lipoproteins with NMR, a technique capable to 
provide the hydrodynamic size information of the particles.  
 
Lipoprotein profile characterization as an evaluation tool for 
nutritional habits and nutritional interventions 
Finally, in Chapter 4, we have applied two different approaches 
for the lipoprotein characterization, the Liposcale test1 and the 
Lipoprofile test developed by Otvos et al.11, demonstrating the utility of 
the lipoprotein NMR characterization for the assessment of the 
nutritional habits and evaluation of nutritional interventions affecting 
the lipoprotein profile opening the fundamental application of NMR 
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spectroscopy to the study of the non-pharmacologically modulation of 
the lipoprotein profile. 
In the first study presented in Section 4.2, with a large cohort of 
26,034 female healthcare professionals, we found that higher intake of 
fish and n-3 were significantly associated with lower triglycerides and 
larger VLDL particles. On the other hand, there was a positive 
association between the intake of fish and n-3 fatty acids and the LDL 
size, consistent with increased levels of large LDL particles. Total n-3, 
DHA and ALA intake were associated with larger HDL size and elevated 
levels of large HDL particles, factors that may be associated with lower 
CVD risk.  
Importantly, we report for the first time that higher habitual fish 
consumption and higher levels of dietary derived n-3 fatty acid intake 
were both found to be associated with much larger magnitudes of 
association with lipoproteins fractions than the corresponding 
magnitudes of associations observed with traditional lipids. This finding 
suggests that dietary derived n-3 fatty acids influence CVD risk through 
lipid and lipoprotein metabolism perhaps more than previously 
appreciated, given that lipoprotein particles, particularly LDL and HDL 
particles concentration or number, have both been shown to perform 
better than their respective major lipid components for assessing CVD 
risk16–18.  
In the same direction, the two intervention trials presented in 
Section 4.319 and Section 4.420, designed to evaluate the effect of diets 
enriched with either SFA or n-6PUFA, and supplemented with LCn-
3PUFA, produced similar changes in lipoprotein profiles. Both diets 
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increased the LDL particle size, a parameter that has been associated 
with a reduced risk for atherosclerosis in epidemiological studies. In 
addition, they produced a reduction in total, large, medium and small 
VLDL particle concentrations, as well as in VLDL triglycerides, consistent 
with the decrease in total triglycerides and VLDL particle concentration, 
in agreement with the previous association study.  
Altogether, the results presented in this thesis demonstrate that 
the use of NMR is ideal for the routine characterization of lipoproteins 
in the research, the clinical and the epidemiological frameworks, due to 
the simplicity of the preparation of the sample, the reliability and the 
robustness of the 1H-NMR spectroscopy and the possibility of 
automatization; and could be the basis for a revolution in clinical lipid 
analysis, which would provide invaluable help in the evaluation of the 
lipid-mediated cardiovascular risk as well as the development and 
evaluation of new drugs and diet intervention to combat dyslipidemia 
and metabolic disorders. 
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